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Abstract 
There has been a significant increase in the number of people diagnosed with 
diabetes from 1980 to 2016, rising from 108 million to approximately 420 million 
people worldwide, and is predicted to rise to above 640 million by the year 2040 and 
type II diabetes is seen in 90-95% of those diagnosed. Many treatments currently 
exist to treat type II diabetes, although there are considerable adverse health effects 
associated with these drugs including a risk of hypoglycaemia. Accordingly, there is 
a swift need for a new, effective treatment that has little to no side effect for those 
suffering from T2D. β-D-Glucopyranosyl derivatives are known to inhibit glycogen 
phosphorylase, which is a valid target for controlling hyperglycaemia in type 2 
diabetes. Computational methods, such as molecular docking with Glide and GOLD 
as well as post-docking free energy calculations using MM-GBSA calculations were 
used to screen a library of β-D-glucopyranosyl analogues and we, for the first time, 
have derived computational models of MMGBSA for the GPb catalytic site have 
revealed excellent predictive potential based on a thorough statistical analysis. 
Using these models, correlations between predicted and experimental inhibitory 
potential as high as 0.95 – 0.97 were obtained for a training set of ligands. These 
methods have substantial potential for discovery of new effective compounds in the 
treatment of T2D as thousands of potential ligands could in the future be screened. 
Previous computational screening of 5,7-dihydroxyflavone analogues which have 
been predicted to bind at the caffeine binding site have been performed and a 
number of these analogues have been synthesized and will undergo kinetic 
experiments which will give insight into the effectiveness of 5’,7’-dihydroxyflavone 
derivatives so that a wider library of similar compounds could be tested that displays 
biological activity towards glycogen phosphorylase. 
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Chapter 1 – Introduction. 
1.1 Introduction to Diabetes 
 
1.1.1 Prevalence of Diabetes 
 
 
Figure 1.1 - Map showing the number of those diagnosed with diabetes in 2015, and the 
respective predicted amount in 2040.[2] 
There has been a significant increase in the number of people diagnosed with 
diabetes from 1980 to 2016, rising from 108 million to approximately 420 million 
people worldwide, and is predicted to rise to above 640 million by the year 2040 at 
the current rate. (Figure 1.1) [3] Each year, 7 million people develop diabetes and the 
most dramatic increases in type 2 Diabetes (T2D) have occurred in populations 
where there have been rapid and major changes in lifestyle, demonstrating the 
important role played by lifestyle factors with respect to diabetes.[4] Over the past 
decade, diabetes has risen substantially in countries at all income levels, mirroring 
the global increase in the number of people who are overweight or obese, but has 
risen faster in low- and middle-income countries. The global prevalence of diabetes 
has grown from 4.7% in 1980 to 8.5% in 2014.[5] 
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1.1.2 Type I Diabetes 
Type I diabetes (T1D) or diabetes mellitus is characterized by the absence of insulin 
production within the pancreas. The onset of T1D usually begins in childhood or 
adolescence and is classified as an autoimmune disease. In T1D, beta cells (β-cells) 
in the pancreas that produce insulin are gradually destroyed. Eventually, insulin 
deficiency is absolute. Without insulin (to move glucose into cells) blood glucose 
levels become excessively high, a condition known as hyperglycaemia. Because the 
body cannot utilize the sugar, it persists in the blood stream before entering into the 
urine (glycosuria), where it is lost.[6] T1D is less common than T2D and consists of 
only 5-10% of cases of diabetes with both males and females being of equal risk. 
T1D can occur at any age but usually between infancy and the late 30s. A few risk 
factors that increase the likelihood of developing the disease are; being ill in early 
infancy, having a parent with T1D, having an older mother and having other 
autoimmune disorders for example.[6] The symptoms associated with T1D can take 
some time to show as β-cell insulin production can still occur. At the point of no 
insulin production, the symptoms progress rapidly. Frequent urination, unusual 
thirst, extreme hunger, weight loss, weakness, fatigue, changes in eyesight are all 
associated with T1D (Table 1.1.) 
1.1.3 Type II Diabetes. 
Type II diabetes or non-insulin dependent diabetes mellitus is the most common 
form of diabetes and is seen in 90-95% of those diagnosed. There are several 
factors that can increase the risk of developing type 2 diabetes. Obesity, unhealthy 
diet, physical inactivity, smoking, having a first-degree relative with T2D and being 
of South Asian and African-Caribbean descent are examples of factors that can 
increase the likelihood of developing T2D (Table 1.1.)[7] Too much glucose left to 
circulate in the blood (hyperglycaemia) can cause tissue damage whereas too little 
glucose (hypoglycaemia) can lead to tiredness, shaking and loss of consciousness, 
demonstrating the importance of insulin in blood glucose level regulation. As well as 
the translocation of glucose into cells,[8] insulin also regulates the breakdown of 
glycogen to glucose (glycogenolysis) and also the production of glucose from 
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pyruvate and other non-carbohydrate substances (gluconeogenesis). T2D is 
characterised by three factors; (1) some resistance of insulin action on glucose 
uptake in tissues such as adipocytes, liver tissue and skeletal muscle tissues. (2) A 
relatively low production of insulin from the β-cells of the pancreas and (3) an 
impaired insulin action to inhibit the hepatic glucose production. [9] The T2D form of 
diabetes frequently goes undiagnosed for many years because the hyperglycaemia 
develops gradually and is less severe at earlier stages.[10] 
Table 1.1 – Differences of Type I and Type II diabetes[11] 
 Type I Type II 
Onset Acute; severe Mild-severe; often insidious 
Insulin Secretion None Variable 
Insulin Sensitivity Normal Decreased 
Insulin 
Dependence 
Permanent Temporary; may occur later 
Racial/ethnic 
groups at 
increased risk 
All (low in Asians) African Americans, 
Hispanics, Native 
Americans, Asian/Pacific 
Islanders. 
Association: 
Obesity 
No Strong 
Autoimmune 
etiology 
Yes No 
 
1.1.4 Gestational Diabetes. 
Gestational diabetes (GD) is a temporary disease that can affect pregnant women 
and arises typically in the second or third trimester and this usually dissipates after 
the pregnancy. During the later stages of pregnancy as the foetus develops, there 
is an increased need for insulin by up to two to three times that of normal levels. If 
the body cannot make the required amount of insulin, glucose will remain in the 
blood stream and cause hyperglycaemia.[12] Most women suffering from GD will not 
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require insulin and instead blood sugar levels can be reduced through changes in 
diet and exercise. Although the majority of women with GD will experience a normal 
pregnancy and give birth to healthy babies, GD can cause problems such as: 
polyhydramnios – an excess of amniotic fluid, which can cause premature labour, 
the baby growing larger than usual – possibly leading to difficulties during delivery 
and pre-eclampsia – a condition that causes high blood pressure during pregnancy 
which can lead to pregnancy complications if not treated. GD will usually disappear 
after pregnancy but women who have suffered from this are more likely to develop 
T2D in the future.[13] 
1.2 Symptoms of Diabetes. 
The symptoms of diabetes are caused as a result of glucose remaining in the blood 
rather than entering the cells for glucose metabolism. The symptoms are seen in 
both T1D and T2D and develop quickly in T1D often over a few weeks but these 
symptoms can take longer to manifest in T2D and typically develop over a few years 
- often going undiagnosed. Symptoms such as more frequent urination, particularly 
at night, increased thirst, tiredness, and unexplained weight loss, slow healing and 
blurred vision are all associated with diabetes. Hyperglycaemia causes the main 
symptoms of diabetes and can occur from ineffective diabetes medication, eating 
too much of the wrong foods or being unwell.[14] 
1.3  Long-Term Diabetes Complications 
There are many possible long term complications associated with diabetes usually 
effecting the eyes (retinopathy), heart (cardiovascular disease), kidneys 
(nephropathy), and nerves and feet (neuropathy). The eyes are particularly at high 
risk of damage with those who suffer from diabetes. Diabetes is associated with 
damage to the tiny blood vessels in the retina leading to diabetic retinopathy (DR). 
Untreated, DR can cause blood vessels in the retina to leak fluid or haemorrhage 
(bleed), distorting vision. In its most advanced stage, new abnormal blood vessels 
proliferate on the surface of the retina, leading to cell loss of the area.[15] People with 
diabetes are also at a much greater risk of developing problems with their feet, due 
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to the damage caused by raised blood sugar relating to sensation and reduced 
circulation. Untreated, these problems can cause foot ulcers, infections and may 
possibly lead to amputation.[16] Those with diabetes are twice as likely as non-
sufferers to have heart disease or a stroke, and those same people tend to develop 
heart disease or have strokes at an earlier age than other people. Over time, high 
blood glucose levels can lead to increased deposits of fatty materials on blood 
vessel walls. These deposits may affect blood flow, increasing the chance of 
clogging and hardening of blood vessels (atherosclerosis).[17] Kidney disease 
develops very slowly in people who have diabetes for over a period of about 20 
years. About one in three people with diabetes will develop kidney disease, this is 
decreasing as treatments improve. Hyperglycaemia causes damage to small blood 
vessels. This damage can cause the kidneys to work less efficiently. Keeping a 
normal blood glucose levels can greatly reduce the risk of kidney disease.[16]   
1.4  Current Treatment 
Each sufferer of diabetes requires individualized treatment. Those with T1D will 
always require insulin as well as diet and exercise changes. T2D may require insulin 
or oral hypoglycaemic agents (medication that results in lower blood sugar), if diet 
and exercise alone fail to lower blood glucose levels. 
1.4.1 Lifestyle Changes 
It should not be understated that lifestyle changes can cause serious improvements 
in health of those who suffer from diabetes. Dietary changes can be powerful in 
preventing and reversing diabetes. Diabetic experts have taken care to limit fats – 
especially saturated fats that can raise cholesterol levels, and to limit protein for 
those with impaired kidney function. Fat is a problem for people with diabetes as 
increased fat in the diet reduces the efficacy of insulin to get glucose into cells. It is 
advised that patients eat unlimited amounts of grains, fruits and vegetables. Modest 
amounts of non-fat condiments, alcohol and caffeine containing beverages are fine. 
High blood pressure is often associated with diabetes and as a result, patients are 
advised to limit the amount of salt in the diet.[18] A study found that patients taking 
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oral medications and patients on insulin were able to get off their medications after 
some days on a near-vegetarian diet and exercise program.[19] Regular physical 
activity helps the body cells take up glucose for metabolism and this lowers blood 
glucose levels. Regular exercise also helps weight loss as well as controlling blood 
cholesterol and blood pressure both of which can be caused as a result of diabetes. 
The benefits of a regular aerobic exercise program in diabetes management include 
decreased need for insulin, decreased risk of obesity, and decreased risk of heart 
disease.[18] 
1.4.2 Oral Hypoglycaemic Agents. 
As T2D is a progressive disease, lifestyle changes alone may not be enough to 
control elevated blood glucose levels and a patient may also need to take 
medication. Oral hypoglycaemic agents (OHA) are an example of such drugs and 
are all similar in that they reduce blood glucose levels. 
1.4.3 Biguanides 
 
 
Figure 1.2 Metformin. The Most common Biguanide. 
Metformin is the most common OHA prescribed for the treatment of T2D (Figure 
1.2), being prescribed to at least 120 million people worldwide. The main effect of 
this drug from the biguanide family is to acutely decrease hepatic glucose 
production, mostly through a mild and transient inhibition of the mitochondrial 
respiratory-chain complex 1. The resulting decrease in hepatic energy activates the 
AMP-activate protein kinase (AMPK), a cellular metabolic sensor, providing a 
generally accepted mechanism for metformin action on hepatic gluconeogenesis.[20] 
In addition, there is evidence for other beneficial effects, including a reduction in 
cardiovascular disease[21] as well as being an effective ovulation induction agent for 
7 | P a g e  
non-obese women for polycystic ovary syndrome (PCOS)[22] Metformin does not 
have many significant adverse effects but could possibly cause lactic acidosis, 
causing dizziness, severe drowsiness, muscle pain, tiredness, chills, blue/cold skin 
and stomach pains. Metformin isn’t particularly known for causing hypoglycaemia; 
however, low blood glucose levels may occur if this drug is used with other anti-
diabetic drugs. Hypoglycaemia is more likely to occur with heavy exercise, drinking 
large amounts of alcohol, or not consuming enough calories from food.[23] 
1.4.4 Sulphonylureas 
 
Figure 1.3 - Typical Sulphonylurea structure. 
Sulphonylureas can be used to treat T2D as they are able to stimulate insulin 
secretion from pancreatic β-cells (Figure 1.3). The principle target of these drug is 
the inhibition of adenosine triphosphate (ATP)-sensitive potassium (KATP) channel, 
which plays a major role in controlling the β-cell membrane potential. The KATP 
channel consists of an inwardly rectifying K+ channel and a sulphonylurea receptor. 
Binding of either ATP or a sulphonylurea to the intracellular domains of the subunit 
produces channel inhibition.[24] Inhibition of KATP channels causes depolarization of 
the β-cell membrane; in turn, this triggers the opening of the voltage-gates Ca2+ 
channels, eliciting Ca2+ influx and a rise in intracellular Ca2+ which stimulates the 
exocytosis of insulin containing secretory granules.[25] Although Sulphonylureas are 
usually well tolerated, the most common side effect is hypoglycaemia which is more 
common with long-acting sulphonylureas such as chlorpropamide and 
glibenclamide.[26] 
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1.4.5 α-Glucosidase inhibitors 
n 
Figure 1.4 - Acarbose, an example of an α-Glucosidase inhibitor. 
An effective management of T2D to decrease hyperglycaemia is to retard the 
absorption of glucose by inhibition of carbohydrate hydrolysing enzymes, such as α-
glucosidase (Figure 1.4). α-Glucosidase is the key enzyme in catalysing the final 
step in the digestive process of carbohydrates. Therefore, α-glucosidase inhibitors 
(ADI) can retard the liberation of D-glucose from dietary complex carbohydrates and 
delay glucose absorption.[27] Examples of ADI’s include: acarbose, miglitol and 
voglibose. Typical side effects of ADI’s concern gastrointestinal problems such as: 
flatulence and diarrhoea. 
1.4.6 Meglitinides 
Meglitinides work in a similar way to sulphonylureas in that they stimulate insulin 
secretion from the pancreas (Figure 1.5). Meglitinides bind to a different part of the 
sulphonylurea receptor than sulphonylurea drugs, which may mean less effect on 
ischemic preconditioning, but have the same effect on increasing β-cell apoptosis.[28] 
Meglitinides have very few side effects and those caused are often caused by wrong 
dosage causing hypoglycaemia. 
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Figure 1.5 - The structure of Meglitinide. 
1.4.7 Thiazolidinediones 
Thiazolidinediones (TZDs) have various effects that help to control hyperglycaemia, 
but their primary mechanism of action is to improve insulin sensitivity. A common 
TZD, pioglitazone, stimulates the peroxisome proliferator-activated receptor 
gamma, which alters key transcription genes responsible for carbohydrate and lipid 
metabolism.[29] The side effects associated with TZDs are more notable than other 
OHAs and include edema, weight gain, macular edema and heart failure.[30] 
1.4.8 Insulin Therapy 
Insulin therapy is recommended for patients with T2D with initial A1C levels (test 
measuring the glucose blood levels by assessing the amount of glycated 
haemoglobin) greater than 9 percent or if the diabetes is uncontrolled despite 
receiving OHAs.[31] Numerous studies have shown that patients with experienced 
physicians can achieve excellent glycaemic control with insulin therapy and will 
experience very few adverse health effects.[32] Weight gain is very common in 
patients undergoing insulin therapy as there is reduced glycosuria and an increase 
of glucose uptake in cells and it is therefore suggested that dietary and exercise 
modifications would be beneficial.[33]  Another common side effect of insulin therapy 
is hypoglycaemia, especially if used in combination therapy with other OHAs. There 
are a few possible ways a patient may administer insulin to the body, the most 
common of which is insulin injections where the insulin is injected into a muscle. 
Long term insulin injections can cause localized lipoatrophy at the injection site, 
considered to be an adverse immunological side effect of insulin therapy. [34] Another 
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popular method is to use an insulin pen which use replaceable cartridges containing 
an insulin reservoir. Continuous Subcutaneous Insulin Infusion (CSII) devices or 
insulin pumps are a modern form of insulin delivery and are programmed to deliver 
insulin under the skin. These devices are sometimes fitted with internal blood 
glucose monitors and are sometimes able to automatically deliver insulin when 
needed. 
1.5 Synopsis 
Type II diabetes mellitus is becoming increasingly common due to the changing 
lifestyles and affects approximately 420 million people worldwide, and is predicted 
to rise to above 640 million by the year 2040 at the current rate.[3] This thesis 
investigates the prospect of targeting glycogen phosphorylase (GP) as a potential 
treatment of T2D and in particular, in silico screening of β-D-glucopyranosyl 
derivatives with different 5-membered heterocyclic linkers targeting the catalytic site 
and synthesis of flavonoid analogues as inhibitors of the caffeine binding site. Liver 
GP is an important target for the treatment of T2D due to the fact that that this 
enzyme catalyses the breakdown of glycogen to glucose, therefore inhibition can 
reduce hyperglycaemia.  
In this project, by exploiting docking and post-docking computational methods of β-
D-glucopyranosyl derivatives using different parameters, effective statistical models 
can be created and then used to predict potential candidates for synthesis. Synthetic 
attempts of 5,7-dihydroxyflavone derivatives with the potential to inhibit GP with 
more efficacy than chrysin was explored, where a synthetic protocol provided by  
collaborators was optimised for these syntheses by exploiting the Baker-
Venkataraman re-arrangement and the flavones produced will eventually undergo 
kinetic experiments at our collaborators (University of Thessaly, Greece) to 
determine any inhibition. This data will direct for further lead optimisation efforts from 
exploiting structure activity relationship methods, with the goal of designing novel, 
effective compounds which can be used in the treatment of T2D which are safer 
than medication currently on the market.   
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Chapter 2 – Glycogen Phosphorylase 
2.1 Introduction 
Glycogen Phosphorylase (GP (EC number 2.4.1.1) is an essential enzyme in the 
regulation of blood glucose levels (Figure 2.1). GP catalyses the first step of 
glycogenolysis through phosphorylation of the terminal α-1,4-glycosidic bond to yield 
glucose-1-phosphate (Glc-1-P).[35] The equation for this phosphorylation reaction is; 
 𝑔𝑙𝑦𝑐𝑜𝑔𝑒𝑛𝑛 + 𝑃𝑖 ⇌ G1P + glycogen𝑛−1 .            Equation 1.1 
Due to the importance of GP in glycogen metabolism, this enzyme has become an 
attractive target for new therapeutic agents with the ability to directly control blood 
glucose levels in T2D by inhibition of its catalytic site activity. 
 
Figure 2.1 - Glycogen phosphorylase dimer. The known binding sites are highlighted.[36] 
2.2 Glycogenolysis and Gluconeogenesis 
Generation of glucose in the body arises from the processes of either glycogenolysis 
or gluconeogenesis (Figure 2.2), both of which are regulated by insulin. 
Glycogenolysis produces glucose by breaking down glycogen into the smaller 
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glucose subunits (which can then be used to form pyruvate through glycolysis) 
whereas gluconeogenesis is the synthesis of glucose by the use of the substrate 
pyruvate and other non-carbohydrate precursors.[37] Glycogenolysis occurs in the 
muscle, brain and liver tissues and is stimulated by hormonal responses. 
Epinephrine markedly stimulated glycogenolysis in the muscles and, to a lesser 
extent, in the liver. The liver is more responsive to glucagon, a polypeptide hormone 
secreted by the α-cells of the pancreas.[38] Gluconeogenesis occurs predominantly 
in the liver but is also known to occur in the cortex of the kidneys during periods of 
Figure 2.2 - The processes of both glycolysis and gluconeogenesis.[1] 
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fasting, starvation, low-carbohydrate diets, or intense exercise and the pathway 
requires eleven enzyme-catalysed steps.[39] The process of glycolysis has a pathway 
which requires ten enzymes and is the near reversal of gluconeogenesis, altered 
only by the use of a few differing enzymes. 
2.3 Structure of Glycogen Phosphorylase 
GP is an enzyme of relative high abundance in muscle, brain and liver that is 
composed of 842 amino acids which has a mass of 97,434 kDa. The crystal structure 
of GP is well known with over 215 solved structures published on the protein data 
bank.[40] GP is a dimer existing in two interconvertible forms controlled by allosteric 
interactions and reversible phosphorylation; GPb is the non-phosphorylated form 
and is less active. GPb is converted to GPa, the more active form, upon the enzyme 
catalysed phosphorylation of the Serine-14 (Ser-14) residue in each subunit by 
phosphorylase kinase.[41] Both forms of the enzyme can also exist in two states, the 
R state which shows high activity and high substrate binding affinity, and the T state 
which shows low activity and low substrate binding affinity (figure 2.3.) The 
equilibrium for GPa favours the R state whereas the equilibrium for GPb favours the 
T state.[42] The R and T states trigger some structural changes, the greatest 
occurring in residues 262-290, consisting of tower helices (α7 helices), α8 helices 
and the connecting 280s loop with Asp283-Asn284-Phe285. The angle between the 
two helices change from +20° in the T state to -80° in the R state. In the T state, the 
tower helices pack antiparallel with a cluster of hydrogen bonds between Asn270 
and Asn274. Tyr262 is in van der Waals contact with Pro281 of the 280s loop of the 
other subunit. This loop blocks access to the catalytic site in the T state. In the R 
state, the tower helices change the angle of tilt with respect to each other. The 
Asn/Asn contacts are broken and there are no contact between Tyr262 and the 280s 
loop of the other subunit. The 280s loop is disordered and no longer blocks access 
to the catalytic site.[43] To date, six different GP ligand binding sites have been 
identified: the catalytic, allosteric, new allosteric, inhibitor, glycogen storage and a 
very recently discovered quercetin-binding site (Figure 2.1).  
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Figure 2.3 - The structure of Glycogen phosphorylase in the inactive T state and the active R state 
respectively.[44] 
2.4 The Catalytic Site 
The catalytic site is the active site of GP, where glycogen is phosphorylated to 
glucose-1-phosphate (G-1-P) and then shortened by one sub-unit. Accessible to 
bulk solvent through a 15 Å long channel, the catalytic site is located at the junction 
of the N and C terminal domains. Each is an α/β structure consisting of a β-sheet 
core surrounded by a tier of α-helices.[36] The active site residues are located on 
flexible loops of polypeptide chain emanating from the domain boundaries. α-D-
glucose, the physiological inhibitor of GP (Ki = 1.7mM) participates in at least five 
well-defined hydrogen bonds with the surrounding residues and presents a 
complementary molecular surface to the active site at the hydrogen-bonded 
positions of the ligand. The catalytic site also contains pyridoxal 5’-phosphate (PLP) 
as an essential cofactor which is located at the center of the GP monomer subunit 
and is attached by a covalent Schiff base linkage to Lys-680 formed by a reaction of 
the aldehyde group of the PLP and the c-amino group of the lysine residue in the C-
terminal domain. 
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Figure 2.4 – The mode of action of PLP as an essential co-factor.[45] 
The role of the co-factor PLP (figure 2.4) is to donate a proton from one of its 
phosphate groups to an inorganic phosphate molecule bound to the terminal glucose 
of a glycogen chain, allowing the inorganic phosphate to in turn be deprotonated by 
the oxygen forming the α-1,4 glycosidic linkage, the glycogen chain is separated 
from the terminal glycogen in an SN1 mechanism, resulting in the formation of a 
glucose molecule with a secondary carbocation at the 1 position. The deprotonated 
inorganic phosphate acts as a nucleophile and bonds with the carbocation, resulting 
in the formation of G-1-P and a glycogen chain shortened by one glucose 
molecule.[46] The phosphorylation site, Ser-14, is contained within a region of 
polypeptide that binds across the subunit interface (residues 5–22) and is 
phosphorylated by phosphorylase kinase, and is dephosphorylated by the protein 
phosphatase, PP1.[47] When an inhibitor enters and binds to the catalytic site, there 
is a stabilization of the conformation at the 280s loop (residue 282-287) located 
between helices α-7 (residues 261-274) and α-8 (residues 289-314), which causes 
steric hindrance, blocking the substrate (glycogen) reaching the site, promoting the 
inactive T-state conformation. The most potent inhibitors of the catalytic site have 
demonstrated lowering of blood glucose levels in vivo, the majority of which are 
glucose analogues which display low micromolar Ki or IC50 values (Table 2.1.)  
16 | P a g e  
Table 2.1 - The structures of the most potent inhibitors of RMGPb catalytic site discovered to date.[36] 
Glucose based ligands have been the focus of GP catalytic site drug design with 
both α and β-substitutions on the anomeric C1 atom. The β-substitutions aim to 
exploit the catalytic subsite known as the β-cavity, an empty space at the β-1-C 
configuration lined by both polar and non-polar groups.[48] The sugar rings make  
Structure 
Ki 
[μM] 
Structure 
Ki 
[μM] 
 
0.031 
 
0.84 
 
0.16 
 
 
1.02 
 
0.35 
 
1.21 
 
0.39 
 
 
1.7 
 
 
0.41 
 
 
1.8 
 
0.63 
 
 
 
1.9 
 
0.67 
 
 
1.94 
 
0.7 
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Table 2.2 – The structures highlighting the importance of the α-substituent in inhibiting RMGPb  
 
hydrogen bonds to suitable protein groups through each of the peripheral hydroxyl 
groups including hydrogen bonds via a water bridging molecule to an aspartic acid, 
Asp283, and a hydrogen bond from 2-OH to Asn284. The importance of the α-1-OH 
is shown by the poorer inhibition constants for 1-deoxyglucose (Ki = 10.7mM)[49] and  
 α-methyl-1-deoxyglucose (Ki = 53mM).[50] A key structural feature of glucose based 
ligands is the so called linker heterocycle which connects the glucose moiety with 
an R-group,[51] this R-group is of importance with certain groups aiding to the 
greatest inhibition exploiting β-cavity features. In most cases, the most favourable 
residue to occupy the β-cavity is the 2-napthyl group owing to its large planar 
hydrophobic nature.[52] In most of these glucose analogues displaying low 
micromolar inhibition, there is an important ligand-protein interaction formed from 
the linker heterocycle consisting of a hydrogen bond between an N-H to the protein 
His377 backbone O. N-Acetyl-β-D-glucopyranosyl-amine (NAG) is a simple glucose 
analogue which forms this interaction and inhibits RMGPb (Ki = 32μM) which is 
approximately 50 times more potent than its natural physiological inhibitor, α-D-
glucose.[36] Solvation effects of the catalytic site are important, this has been 
highlighted through protein crystallographic work by E.D Chrysina et al. where 
similar glucose analogues where investigated showing nitrogen atoms of the 
heterocycle interacting with a direct hydrogen bond with Leu136 N and water-
mediated hydrogen bonds with Asp 283.[53] 
α-D-glucose 
 
Ki = 1.7mM 
1-deoxyglucose 
 
 
Ki = 10.7mM 
α-methyl-1-deoxyglucose 
 
Ki = 53mM 
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Figure 2.5 – The structure of NAG. 
The design of most GP catalytic site inhibitors are targeted at human liver GPb 
(HLGPb) however, most in vitro studies are performed using rabbit muscle GPb 
(RMGPb) due to the relative availability as well as its propensity to produce good 
quality crystals. The active sites of both HLGPb and RMGPb are identical in both 
amino acid sequence and structural architecture and the overall structure of RMGPb 
shares an 80% similarity to that of HLGPb. This similarity allows for the use of in 
vitro studies using RMGPb with a reliability that the conclusions drawn from 
experimental data gathered from these studies can also be applicable to HLGPb. 
 2.5 Allosteric Sites 
Table 2.3 - Potencies of selected dihydropyridine AMP site inhibitors that bind at the allosteric site. 
 
 
 
 
 
 
 
 
 
Entry R2 R2 R3 R4 HLGP(a) 
Ki (µM) 
Cell 
EC50 
(µM) 
1 Cl CO2H (i-Pr)-O Et 0.039 2.2 
2 H CO2H (i-Pr)-O Et 0.395 6.5 
3 Cl H (i-Pr)-O Et 15.6 NA 
4 Cl CO2H (i-Pr)-O H 0.692 11.0 
5 Cl CO2H (i-Pr)-NH Et 9.1 NA 
6 Cl CO2H (i-Pr)-O CH2Ph 0.011 1.13 
7 Cl CO2H (i-Pr)-O 
 
0.002 0.48 
8 Cl CO2H (i-Pr)-O 
 
0.004 0.27 
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The allosteric site is located roughly 30 Å from the catalytic site and is composed of 
structural elements from two subunits of the functional dimer located on opposite 
sides of the enzyme molecule. Two α-helices (residues 47-78, and 289-314, 
respectively) and four β-strands (residues 153-160, 191-193, 222-232, and 237-
247).[36] This site is partially exposed to solvent and binds the activator AMP and the 
natural inhibitor Glc-6-P but recognizes a variety of phosphorylated compounds, for 
instance ATP, nicotinamide adenine dinucleotide (NADH), inosinic acid (IMP), 
uridine diphosphate glucose (UDP)-glucose, β-glycerophosphate and inorganic 
phosphate. The equilibrium between the T and R-state can be regulated by certain 
compounds activating the allosteric site, such as Glc-6-P and adenosine 
phosphates. Indirect inhibition of substrate binding to this site can arise as a result 
of the stabilization of the T or T’ state (T’ referring to the symmetry related monomer 
subunit.). Inhibition can be a result of direct inhibition of AMP binding.[48] In resting 
muscle cells, levels of Glc-6-P are sufficient to retain the enzyme in the T state, and 
prevent wasteful glycogen degradation. Glc-6-P binds at the allosteric site and 
promotes conformational changes in the T-state GPb.[54] Binding interactions 
between Glc-6-P to the allosteric site are mostly hydrogen-bonding interactions and 
there are relatively few van der Waals interactions. In contrast, there are examples 
of interactions from compounds such as dihydropyridines (Table 2.2) that are 
dominated largely by non-polar van der Waals interactions and ionic interactions. 
The non-polar contacts appear to be the major source of binding energy that results 
in an inhibitor with nM affinity compared with the μM affinity exhibited by Glc-6-P. 
The different binding modes and contacts observed reveals a remarkable degree of 
versatility for the allosteric site, which is able to recognize specifically dissimilar 
compounds by employing the same residues.[48] 
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Figure 2.6 – Diagram showing the different ligand interactions of a dihydropyridine dicarboxylic acid. 
Black dashed lines indicate hydrogen bonds. Green solid line show hydrophobic interactions and 
green dashed lines show π-π stacking interactions.[35] 
     
A second allosteric site, the new allosteric site (commonly known as the indole 
binding site), is located 33 Å from the catalytic site and is 37 Å from the inhibitor site 
within the central cavity region of the subunit dimerization interface. Crystal 
structures of ligand binding at this site have validated the environment within the 
indole site that constitutes for the binding between the receptor-ligand. Binding 
occurs with only minor distortions of the structure, and upon binding there is a 
displacement of nine water molecules. The increasing entropy from the 
displacement of the water in combination the van der Waals, CH/π, halogen/polar, 
and the specific polar/polar interactions appear to be the major source of binding 
energy responsible for inhibitor binding.[36] Inhibitors of this site are known to 
stabilise the T-state conformation of the enzyme and hence inhibit GPb activity.[55] 
2.6 Inhibitor Site. 
The inhibitor site (commonly known as the caffeine binding site) is located 12 Å from 
the catalytic site, occupying part of the entrance. The inhibitor site has been probed 
with purines, nucleosides, nucleotides and heterocycle compounds such as uric 
acid, riboflavin,[56-59] and flavopiridol.[60, 61] In the less active T state, Phe285, 
belonging to the 280s loop is stacked close to Tyr613, belonging to the α19 helix, 
and these aromatic residues form the core of the inhibitor site. The main source of 
21 | P a g e  
the binding affinity of ligands which bind at the inhibitor site is from π-stacking 
interactions with the sidechains of Phe285 and Tyr613 forming sandwich type 
complexes; they promote the T state conformation of the enzyme through 
stabilization of the closed position of 280s loop, blocking access of the substrate to 
the catalytic site.  Conversely, on transition from the T- to the R state, the 280s loop 
becomes disordered and displaced, opening a channel that allows a crucial residue 
Arg569, to enter the catalytic site in place of Asp283 and to create the recognition 
site for the substrate phosphate; this transition enables the glycogen substrate to 
reach the catalytic site.[62] The most potent natural inhibitor site known to bind at the 
site is ellagic acid through a comprehensive kinetic and crystallographic study on 
the binding properties of gallic acid and its dimer ellagic acid to GP; [63]  The Ki values 
of ellagic acid are 7.5 and 13.4 µM for GPa and GPb respectively whereas gallic 
acid displays a weaker Ki of 3.9 and 1.7 mM, respectively. As expected, ellagic acid 
and gallic acid experience the characteristic stacking binding modes between 
Phe285 and Tyr613. Ellagic acid exploits nearly twice as many van der Waals 
interactions with GPb compared to gallic acid; it forms one direct hydrogen bond to 
the Asn 282 sidechain (ND atom) and a water-bridged interaction with Asp283, 
Ile570, Ala610, Gly612, His614 and Met615.[63] 
 
Figure 2.7 - Binding of ellagic acid at the GP inhibitor site as determined by X-ray crystallography 
(PDB code: 4YUA).[63] 
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2.7 Quercetin Binding Site  
Recent screening of 13 polyphenolic compounds obtained by extraction of Vitis 
vinifera (common grape vine) vinification by-products displayed significant inhibitory 
potency for RMGPb in vitro (IC50 values in the range of low µg/mL) revealed that the 
most active ingredient of these extracts is the flavonoid quercetin.[64] Although 
unknown at the time, quercetin was found to bind to a novel binding site. The site is 
42 Å from the allosteric site, 32 Å from the inhibitor site and 15 Å away from the 
catalytic site. The site is a shallow groove consisting of Lya544, Arg551, Lys655 and 
Tyr548 on one side with Glu120 and Glu123 on the other. The binding mode of 
quercetin to GP is well understood, with hydrogen bonds and van der Waals 
interactions forming between Arg551 and Lys544. There are also water mediated 
bridging interactions with Glu121, Lys655, Leu494, Cys495 and Glu654.  
 
 
Figure 2.7 – Binding of quercetin at the Quercetin binding site as determined by X-ray crystallography 
(PDB code: 4MRA)[64] 
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2.8 Flavonoids.  
Polyphenols are naturally occurring compounds abundant in many vegetables, 
fruits, cereals and beverages. Fruits like grapes, apples, pears, cherries and berries 
(such as strawberries and blackberries) contain up to 200-300mg polyphenols per 
100 grams of fresh weight. Polyphenols exist as secondary metabolites of plants 
and are generally involved in defence against Ultra Violet radiation or aggression by 
pathogens.[65] Flavonoids are a diverse group of polyphenols with over 10,000 
compounds that have been identified until now, with only very few being investigated 
in detail.[66] The effects flavonoids have within the body has been the center of many 
research studies in recent years and the beneficial effects are becoming abundantly 
clear. Chemically, flavonoids are based upon a fifteen-carbon skeleton consisting of 
two phenyl rings (A and B as shown in Figure 2.7) linked via a heterocyclic pyrene 
ring (C).[67] Flavonoids can be divided into a number of subclasses, flavones (e.g. 
flavone, chrysin, epigenin), flavonols (e.g. quercetin, kaemferol, myricetin), 
flavanones e.g. flavanone, hesperetin and naringenin) (Figure 2.8). 
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Table 2.4 - IC50 values (µM) for inhibition of GPa and GPb of flavonoids tested in concentrations up to 50 
µM. 
Compound 
IC50 GPa 
(µM) 
IC50 GPb (µM) 
 
Compound 
IC50 GPa 
(µM) 
IC50 GPb 
(µM) 
Flavones   
 Anthocyanidin
s 
  
DHF >50  [67] >50  [67]  Pelargonidin 43.6 [68] 6.2 [68] 
Chrysin >27.5 [68] 15.3 [68]  Cyanidin 3.0 [68] 9.0 [68] 
  19.0 [69]  Delphinidin 3.1 [68] 10.7 [68] 
  19.01 (Ki) [59]  Peonidin 25.1 [68] 17.6 [68] 
Apigenin >30 [68] No effect up to 30 [68]  Malvidin >50 [68] >50 [68]  
Luteolin 15.6 [68] 28.8 [68]  Catechins   
  29.7 [70]  Catechin No effect [68]  No effect [68] 
  31.7 [70]  Epicatechin No effect [68] No effect [68] 
Tricin >50 [68] No effect [68]    No effect [70] 
Baicalein 11.2 [68] 10.2 [68]  Epigallocatechin No effect [68] No effect [68] 
Hypolaetin  15.7 [70]    No effect [68] 
6-
hydroxyluteoli
n 
 11.6 [70] 
 
ECG 12.5 [68] 50 [68] 
Isoscullarein  46.1 [70]    27 [71] 
Flavonols    EGCG 7.7 [68] 33.9 [68] 
Quercetin 4.8 [68] 20.9 [68]     34 [71] 
  33.5 [70]  EGC  >400 [71]  
Quercetagetin  9.7 [70]  GCG  6.3 [71] 
  3.5 (Ki) [70]  CG  35 [71] 
(-)-
Epicatechin 
(EC) 
 290 [71] 
 
Other 
  
Flavanones    Ellagic acid 3.2 [68] 12.1 [68] 
Naringenin >50 [68]  No effect [68]    7.5 (Ki) [69] 13.4(Ki) [69] 
Hesperitin No effect [68]  No effect [68]   Gallic acid No effect [68] No effect [68]  
Eriodictyol No effect [68] No effect [68]   3900(Ki) [69] 1730(Ki)[69] 
Isoflavones    Caffeine  130 [51] 
Daidzein No effect [68]  No effect [68]      
Genistein >50 [68] No effect [68]     
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Figure 2.8 – Various different flavonoid structures, all follow the typical flavonoid backbone. 
Several observations have suggested that natural flavonoids have inhibitory effects 
on various types of cancer cells mediated by different molecular targets and acting 
through diverse metabolic pathways[72] and also inhibit the enzymes responsible for 
superoxide anion production, such as xanthine oxidase and protein kinase C. 
Flavonoids have also been shown to inhibit cyclooxygenase, glutathione S-
transferase, mitochondrial succin-oxides, and NADH oxidase, all involved in reactive 
oxygen species generation.[73]  
Flavonoids have also been shown to have biological activity on GP with natural 
flavonoid derivatives investigated as potential GP inhibitors[68, 71, 74]  with ongoing 
experiments of many compounds against RMGPa and RMGPb. Jakobs et al found 
in their study that almost all flavonoids tested inhibited active RMGPa and un-
phosphorylated AMP activated GPb, however inhibition of GPa was two to four times 
stronger than inhibition for RMGPb[68] with the leading flavonoid inhibitors of GP on 
the low µM range (Table 2.3). Inhibition of GP with flavonoids are sensitive to the 
different substituent groups on them, a number of flavonoids in each structural 
subclass demonstrate little or no inhibition dependent upon the different 
substituents. Of those compounds tested, no flavanone or isoflavone shows 
inhibition based on the few compounds tested. Flavone’s are known to bind at the 
inhibitor site, an investigation into the binding modes of chrysin to GPb (PDB code: 
3EBO) shows that there is the characteristic π-π stacking in between the two 
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aromatic residues (Phe285 and Tyr613), and when chrysin binds to GPb, it forms 
polar/polar interactions and exploits a number of van der Waals contacts dominated 
by the substantial contacts made to Phe285 and Tyr613 by the aromatic rings.[59] 
The most potent compound to bind at the inhibitor site discovered to date is 
flavopirodol[59, 61] and its analogues.[75] While flavopiridol has a Ki of 1.2 µM, 
analogues of flavopirodol with a flattened tetrahydro-pyridine ring and halogen 
substituted phenyl ring B have revealed potencies ranging from 0.83-2.75 µM. The 
most favourable substitution in this series is the 3-Cl analogue. Halogen substitution 
and binding effects through the σ-hole phenomenon are now widely recognized and 
exploited in drug design.[76] The crystal structure of flavopiridol in complex with 
RMGPb PDB codes: 1C8K, 3EBP) has been solved[59, 61] and the structural features 
of inhibition are similar to that of chrysin.[59] The common flavonoid core of 
flavopiridol and chrysin superimpose well stacked between Phe285 and Tyr613. 
Flavopiridol makes a few polar/polar interactions with water molecules and has a 
numerous van der Waals contacts. The chlorophenyl ring B extends towards the 
hydrophobic pocket lined by Phe771, Tyr573 and Ile380 but the chlorine atom does 
not form a strong halogen bond with GPb and is mainly involved in van der Waals 
interactions. 
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2.9 Conclusion 
Glycogen Phosphorylase presents a valid target in the treatment of T2D. Glucose 
analogues have been demonstrated to be effective in the inhibition of the GP 
catalytic site (Table 2.1) and this section also highlights the potential 
antihyperglycaemic effects of natural flavonoids acting as inhibitors of the GP 
binding site (Table 2.3). The scaffold provided from both of these structures serve in 
the potential development of more effective pharmaceuticals for T2D treatment as a 
number of these compounds are low µM inhibitors and a glucose analogue has been 
discovered which displays nanomolar inhibition of the catalytic site, 2-(β-D-
glucopyranosyl)-4(5)-(2-naphthyl)-imidazole (Ki = 31nM).[36] The structural basis of 
these compounds relative to potency as currently known has been studied in some 
detail, which provides information for further structure based drug design (SBDD) 
efforts.  
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Chapter 3 – Molecular Modelling  
3.1 Introduction 
Drug design is a complex process, from the original idea of a new drug to the launch 
of a finished product can take 12-15 years and cost in excess of $1 billion.[77] In the 
past, traditional medicines were often found through the identification of active 
compounds by chance discovery. Typically, a large library of chemical compounds 
would be tested experimentally in vitro and in vivo with the hope that some biological 
activity would be displayed in a number of compounds (high throughput 
screening).[78] This method is incredibly expensive, time consuming and is 
impractical. In recent years, increased target identification and validation enables 
increased knowledge of the relationship between the target and disease.  
Knowledge-based screening involves selecting from the chemical library a smaller 
subset of molecules that are likely to have activity at the target receptor based on 
knowledge of a target protein. This type of knowledge have given rise to early 
discovery paradigms using pharmacophores and molecular modelling to conduct 
virtual screening of compound databases.[79] A pharmacophore model is a 
geometrical description of the chemical functionalities required for a ligand to interact 
favourably with a target and pharmacophore mapping is one of the major elements 
of drug design in which there is an absence of structural data for the target receptor 
(known as ligand based drug design (LBDD).  For instance, when a set of active 
compounds are known for a given target, pharmacophore modelling is used to 
identify the common structural features as well as the relative distances between 
them that lead to this activity. Once a pharmacophore is built, a thorough search of 
available on-line databases such as ZINC[80] is performed which identifies molecules 
which share the same features of the parent compounds to be used as potential 
drug candidates. Another important modelling method is quantitative structure-
activity relationship (QSAR). QSAR models relate a set of predictor variables to the 
potency of the response variable. QSAR models first summarize a supposed 
relationship between chemical structures and biological activity in a data-set of 
chemicals and secondly, predict the activity of new chemicals. The Hansch equation 
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(Equation 3.1) relates the relationship between the biological activity of a series of 
compounds and their physicochemical properties including hydrophobic (log P), 
electronic (σ), steric (ES), and other effects; 
𝐿𝑜𝑔 
1
𝐶
 = 𝑘1(𝑙𝑜𝑔𝑃)
2 + 𝑘2𝑙𝑜𝑔𝑃 + 𝑘3𝜎 + 𝑘4𝐸𝑠 + 𝑘𝑠         (Equation 3.1) 
The Free-Wilson equation (Equation 3.2) relates the contributions that the 
substituents have to the activity of the parent structure.  
        Activity = 𝑘1𝑋1 + 𝑘2𝑋2 +….𝑘𝑛𝑋𝑛 + 𝑍                   (Equation 3.2) 
Xn is an indicator variable which is indicated by the values 1 and 0 dependent on 
whether the substituent (n) is present or not. The contribution of each substituent to 
activity is determined by the value of kn and Z is a constant representing the parent 
compound. 3D QSAR has advantages over the Hansch and Free-Wilson approach 
in that there is no reliance on experimental values, it can be applied to molecules 
with unusual substituents, and it is not necessarily restricted to molecules of the 
same class and has a higher predictive capability. Comparative Molecular field 
Analysis (CoMFA) generates a 3D grid where molecules are described by values of 
molecular fields calculated on a point within the grid. These molecular fields are 
usually steric and electrostatic and this grid is able to derive a correlation between 
the biological activity of a set of molecules and their 3D shape, electrostatic and 
hydrogen bonding characteristics. 
Figure 3.1 – Overview of drug discovery based on Structure based drug design (SBDD).  
Structure based drug design (SBDD) is employed when the structure of the target is 
known. Recent advances in protein X-ray crystallography, nuclear magnetic 
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resonance (NMR) and electron microscopy have allowed for the precise mapping of 
atoms that make up the different residues of a protein structure, with over 40500 
distinct protein sequences available.[40]  Crystal structures of ligand-protein 
complexes are considerably valuable in drug design effects as they allow for visual 
representations of the environment which the ligand occupies within a binding site, 
and thus prediction of modifications could be added to provide increased potency or 
selectivity. In SBDD the most common type of drug design is molecular docking, 
where ligand binding to the receptor is predicted by exploiting the many known 
biological macromolecular targets solved and deposited in the RCSB Protein 
Database[40] These solved targets can be used to screen potentially active 
compounds and this aids in the ability to find hit compounds. With the advancement 
of computers and algorithms, docking accuracy has increased exponentially in 
recent years due to the increasing sophistication of docking software. Docking may 
also help in lead optimization efforts, suggesting modifications that have the 
potential to improve activity.  
In the current work, the structure of GP is well known and by extension, the core 
interactions and binding modes of glucose based analogues and the surrounding 
residues are also well understood. Accurate modelling of these interactions must 
ensure that constraints are placed on groups whose relative positions and 
interactions are known. The current chapter will describe the many key 
computational screening programmes used in virtual docking as well as the role 
molecular mechanics (MM) has in molecular modelling, which forms the basis of 
molecular-mechanics-Generalized Born Surface Area (MM-GBSA), the post-
docking method used in this study. 
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3.2 Molecular Mechanics. 
3.2.1. Introduction 
Molecular Mechanics (MM) forcefields are the method of choice for protein 
simulations, which are essential in the study of conformational flexibility.[81] 
Computational structure-based drug design involves studies based on the three-
dimensional structure of the biomolecular target, usually a protein. Whilst quantum 
mechanical (QM) methods are useful for studying properties of isolated ligands and 
for limited studies on simple models of protein binding sites, it can be more desirable 
to perform simulations on the entire protein. Molecular docking studies on entire 
proteins therefore are performed often exploiting molecular mechanic force fields, 
which approximate QM energy surfaces with a classic mechanical model, thus 
decreasing computational cost of simulations on large systems by orders of 
magnitude. Furthermore, MM potential energy functions allow for relatively accurate 
representations of dispersion interactions.[82] Molecular mechanics works on the 
principle of an additive potential energy function which represent the vast majority 
of force fields currently used. (Equation 3.3, Equation 3.4)                                            
              𝐸𝑡𝑜𝑡𝑎𝑙  =  𝐸𝑏𝑜𝑛𝑑𝑒𝑑  + 𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑                                (Equation 3.3) 
𝐸𝑏𝑜𝑛𝑑𝑒𝑑 =   ∑ 𝐾𝑏(𝑏 − 𝑏0)
2
𝑏𝑜𝑛𝑑𝑠 + ∑ 𝐾𝜃(𝜃 − 𝜃0)
2 + ∑ ∑ 𝐾∅,𝑛(1 + 𝑐𝑜𝑠(𝑛∅ − 𝛿𝑛))
6
𝑛=1𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑎𝑛𝑔𝑙𝑒𝑠     
         𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 = ∑
𝑞𝑖𝑞𝑗
4𝜋𝐷𝑟𝑖𝑗
+𝑒𝑠𝑡𝑎𝑡. ∑ 𝜀𝑖𝑗𝑉𝑑𝑊 [(
𝑅𝑚𝑖𝑛,𝑖𝑗
𝑟𝑖𝑗
)
12
− 2 (
𝑅𝑚𝑖𝑛,𝑖𝑗
𝑟𝑖𝑗
6
)]          (Equation 3.4) 
The total energy of the system is found by addition of the bonded and non-bonded 
terms. The bonded interactions arise from bond stretching terms, angle bending 
terms and dihedral or torsion terms whereas the non-bonded terms arise from 
electrostatic forces as well as van der Waals interactions.  The bond and angle terms 
dominate the local covalent structure around each atom and in this approximation, 
only 2 parameters are needed for each bond and angle: the reference or equilibrium 
value (b0 and 𝜃0) and the force constants (Kb and Kθ).[82] Finally, the torsional energy 
is represented by a sum of cosine functions with multiplicities n = 1,2,3… and 
amplitudes KΦ,n. The phases δn are usually constrained at 0° or 180° so that the 
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energy surface of achiral molecules is symmetric and so that enantiomers have the 
same energetic properties. Electrostatic terms in force fields are handled by 
Coulomb interactions between fixed point charges qi and qj centred on the atoms. 
Electrostatic interactions are additive because the charges do not affect each other 
and all the individual atom-atom electrostatic interactions may simply be summed to 
yield the total electrostatic energy of the system. For the van der Waals interaction 
component, a classic Lennard-Jones 6-12 potential, defined by the radius Rmin,ij and 
the well depth εij, is typically used.  
3.2.2 Forcefield 
Many forcefields have been developed by various groups and are often designed 
for different purposes and will therefore differ slightly in the types of simulations they 
may run independent on the parameterization used. The most commonly used 
forcefields include: Assisted Model Building and Energy Refinement (AMBER)[83] 
which is often used for proteins and DNA. Chemistry at HARvard Molecular 
Mechanics (CHARMM)[84] which is widely used for both small molecules and 
macromolecules. Merck Molecular Force Field (MMFF)[85] which is used for a broad 
range of molecules, but predominately organic. The forcefield of concern being used 
in this project is the Optimized Potential for Liquid Screening 3 (OPLS3) used in 
Schrodinger’s maestro software.[86] All of these forcefields share basic 
characteristics; they rely on a fixed charged electrostatic model, they employ a 
standard Lennard-Jones 6-12 van der Waals potential to model electronic repulsion 
and dispersive nonbonded interactions, and they utilize harmonic stretching and 
bending terms, and dihedral angle based torsional potentials, to model the valence 
component of the energy.[87] 
To adequately cover medicinal chemical space, the OPLS3 forcefield employs over 
an order of magnitude more reference data and associated parameter types relative 
to other commonly used small molecule force fields (e.g., MMFF and OPLS_2005). 
As a consequence, OPLS3 achieves a high level of accuracy across performance 
benchmarks that assess small molecule conformational propensities and solvation. 
In the OPLS3 forcefield, stretching and bend terms are fit to quantum chemical data. 
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These terms are insensitive to the other terms in the forcefield and so are determined 
as the first step in the protocol. The van der Waals (vdw) terms are obtained from 
liquid state simulations, along with the core charge set used in the liquid simulations. 
Bond charge corrections (BCC’s) for the CM1A-BCC charge model are defined and 
tested (using, for example, calculations of solvation free energies in water). Finally, 
in the last step the torsional parameters are fit to ab initio quantum chemical data. A 
number of key assumptions are made with OPLS3 with regard to whether significant 
predictive power compared to experiment will be created. The assumptions are as 
follows: (1) Classical treatment of nuclear motion does not systematically distort 
results compared to experiment. (2) The use of a fixed charge force field provides 
an adequate description of electrostatic interactions in the condensed phase 
problem of interest. The use of a gas phase model on water for instance is that there 
is a drastic underestimation of the cohesiveness of liquid water.[88] Protein and water 
contribute the vast majority of atoms in a simulation and it is important that physically 
reasonable structures and energies emerge given the tuning at average polarization. 
(3) Torsional terms fit to gas phase potential surface can be transferred to 
condensed phase with minimal errors. (4) The contribution of fundamentally non-
classical quantum mechanical non-bonded interactions, such as oxygen-sulphur 
interactions, π-π interactions, and non-linear vdW coupling, is negligible.[87]   
3.3 Molecular Docking 
3.3.1 Introduction  
In silico Ligand-Protein docking is perhaps the most widely used procedure in 
computer aided structure based drug design.   Molecular docking programs are able 
to predict the most likely binding modes and geometries of a given ligand against a 
target, referred to as poses, as well as the predicted binding affinities between small 
molecules and the receptor target. A scoring function is used which predicts the 
binding energies between a ligand and the receptor for each of the poses generated, 
which are then ranked based on the energies; the top ranked pose, in theory should 
be the most favourable conformation of the ligand in the binding site. 
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Figure 3.2 – A workflow showing the general process followed in docking. 
3.3.2 Search Algorithms 
Flexible and rigid docking constitute the two types of docking. Flexible docking is the 
most common form of docking used and the software generates different 
conformations of each ligand ‘on-the-fly’ by using a search algorithm.[89] Flexible 
docking is much more effective when conformational changes become a bigger 
factor; an example being that hydrogen bonds and other features might be missed 
to the lack of flexibility. The vast amount of ligands have a degree of flexibility and 
may be incorrectly dismissed if they are docked as rigid bodies in the wrong 
conformation.[90] In one flexible docking approach, the ligand is divided into rigid 
fragments and connecting flexible chains. All rigid fragments are docked to all 
possible places in the cavity independently of each other, yielding either a small or 
large amount of acceptable combinations of poses. The flexible chains are then fitted 
to the specific rigid fragment poses that comprise a matching pose-set. The 
reconstructed solutions then define a rough binding pose and conformation of the 
ligand. These poses are refined by a local energy minimization in the active site of 
the receptor, driven by the scoring function 
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In rigid docking (Figure 3.3), the protein and ligand are treated as rigid, thus 
restricting the search space. The ligands are built before-hand, and an image of the 
target binding site is built up from multiple overlapping spheres of varying sizes, 
which are mapped via the molecular surfaces of the target protein conformation and 
structure. With this map, the ligand is then superimposed with the center of the 
spheres. If the conformation of the ligand fits well with the spheres, it is placed into 
the receptor, minimised, and the position is then scored.  
  
Figure 3.3 - Overview of rigid docking ligand ensemble method. A: rigid atoms are fixed in position 
and the conformational space of the rest of the molecule is systematically sampled at 60° or 120° 
increments. B: The rigid fragment is orientated in the target site. C: All n flexible fragments of the 
molecule are scored in the orientation of the rigid fragment.[110] 
3.3.3 Scoring functions 
Scoring functions allow us to discriminate whether ligands are predicted to be active 
or inactive, by calculating the binding energy of a particular pose. If a ligand has a 
high binding affinity, the ligand is deemed active and is therefore predicted to exhibit 
biological activity.  Docking scoring functions are often forcefield based. 
The sum all of all the various contributions to the binding free energy (ΔGbind) are 
predicted upon docking as part of the scoring function. The binding free energy is 
found through the sum of the additive equation, for example the Prime MM-GB/SA 
function; 
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∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐺𝑠𝑜𝑙𝑣𝑒𝑛𝑡 + ∆𝐺𝑐𝑜𝑛𝑓 + ∆𝐺𝑖𝑛𝑡 + ∆𝐺𝑟𝑜𝑡 + ∆𝐺𝑡/𝑟 + ∆𝐺𝑣𝑖𝑏        (Equation 3.5) 
ΔGsolvent describes the energy contribution by solvation effects and is calculated from 
the interactions between the solvent and the ligand, protein and intermolecular 
complex.  ΔGconf arises from the conformational changes arising from changes within 
the protein and/or ligand. Most docking methods assume a rigid receptor and so 
there is usually no conformational changes from the protein. However, the ligand 
changes conformation in solution to a dominant conformation in the bound state. 
ΔGint  is the free energy from specific protein-ligand interactions. ΔGrot is the loss of 
free energy associated with holding internal rotations of the protein and ligand in 
place. ΔGt/r is the loss in translational and rotational free energy due to the two 
bodies (the ligand and the receptor forming a single body (the intermolecular 
complex)). This is usually assumed to be the same for all ligands and is largely 
ignored when looking at relative binding strengths of numerous ligands to a certain 
protein. ΔGvib is the free energy due to changes in vibrational modes. This 
contribution is hard to calculate and so is generally ignored. 
3.3.4 Glide Docking 
In this work, Glide, as part of Schrodinger’s molecular modelling package,[91] was 
used to simulate protein-ligand docking. Glide uses a funnel like system of 
hierarchical filters to search for possible conformations of the ligands in the active-
site of the target receptor. The shape and properties of the receptor are mapped to 
a grid, which is prepared in the pre-processing steps, by different sets of fields that 
provide sequentially more accurate scoring of the ligand pose. In the next step, a 
set of initial ligand conformations are produced. The initial ligand conformations are 
subjected to initial screening to find promising ligand poses, skipping poses that 
sterically clash with the receptor. These poses are then taken forward and minimised 
using the OPLS3 forcefield. Finally, the minimised poses are re-scored with 
Schrödinger’s GlideScore scoring function, which ranks the successful poses. 
Glidescore is derived from the ChemScore function, as follows: 
GS = (vdW) + (Coul) + (Lipo) + (H-bonds) + (Metal) + (Rewards) + (RotB) + (Site)   
(Equation 3.6) 
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The (vdW) van der Waals energy term takes into account non-bonding interactions. 
Where (Coul) is the Coulombic term accounting for electron-electron repulsion. The 
lipophilic (Lipo) term is derived from previous experimental data. The metal (Metal) 
term represents any metal-ligand interactions may be present. (Rewards) takes into 
account favourable bindings whilst penalising polar groups in regions of 
hydrophobicity. The rotable bond (RotB) term scores lower for non-moving rotable 
ligand binding bonds. Finally, (Site) gives a higher score for non-hydrogen bonding 
areas of hydrophobicity. 
Root mean square deviation (RMSD) calculations are standardly used to assess the 
accuracy of docking calculations, in particular, the poses generated from the 
calculation. The RMSD is the measure of the average distance between atoms of a 
superimposed ligand. The poses created by docking software are compared to the 
native protein-ligand complex obtained from the PDB. [40] The lower the RMSD value 
of a particular ligand, the more similar to the native ligand in the complex it is. The 
RMSD is calculated using the following equation: 
𝑅𝑀𝑆𝐷 = √
1
𝑁
∑ 𝛿𝑖
2
𝑁
𝑖=1
 
where δi is the distance between atom i in the predicted and reference structure. 
3.3.5 Quantum-Mechanics Polarized Ligand Docking  
Quantum-Mechanics Polarized Ligand Docking (QM-PLD or simply QPLD) [86] aims 
to improve the partial charges on the ligand atoms during docking by replacing them 
with charges derived from quantum mechanical calculations on the ligand in the field 
of the receptor instead of a molecular mechanic forcefield. Polarization of the 
charges on the ligand by the receptor is accounted for and redocking of the ligands 
with the new charges can result in improved docking accuracy. In the QM-PLD 
protocol, ligands are docked with Glide, then charges on the ligand induced by the 
protein are calculated using QSite, and the ligand poses are then redocked. 
 
(Equation 3.7) 
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3.3.6 GOLD.  
Genetic Optimization for Ligand Docking.[92] (GOLD) is distributed by Cambridge 
Crystallographic Data Centre. GOLD employs a genetic algorithm (GA) to explore 
the full range of conformational flexibility of the ligand and also the rational flexibility 
of selected receptor hydrogens as well as the water molecules. The mechanism for 
ligand placement is based on fitting points, similar to Glide. Fitting points are added 
to hydrogen-bonding groups on protein and ligand and the program maps acceptor 
points in the ligand on donor points in the protein and vice versa. GOLD maps ligand 
CH groups onto hydrophobic fitting points generated on the protein binding site 
cavity. GOLD also optimizes flexible ligand dihedrals, ligand ring geometries, 
dihedrals of protein hydroxyl and amino groups and mappings of the latter. GOLD 
offers a choice of fitness functions: GoldScore, ChemScore, ASP, CHEMPLP and 
User Defined Score. CHEMPLP[93] has been found to give the highest average 
success rates for both pose prediction and virtual screening experiments against 
diverse validation test sets and is therefore the default scoring function in GOLD. 
The piecewise linear potential (ƒPLP) is used to model the steric complementarity 
between protein and ligand, whereas CHEMPLP additionally considers the distance- 
and angle- dependent hydrogen bonding and metal bonding terms (ƒchem-hb, ƒchem-cho, 
ƒchem-met). The internal score of the ligand consists of the heavy-atom clash potential 
(ƒlig-clash) as well as the torsion potential used within ChemScore (ƒlig-tors). Both fitness 
functions are capable of covalent docking (ƒchem-cov), considering side-chains (ƒchem-
prot) and explicit water molecules aswell as handling constraints (ƒcons).  
ƒitnessPLP = -(wPLP • ƒPLP + wlig-clash • ƒlig-clash + wlig-tors • ƒlig-tors + ƒchem-cov + wprot • ƒchem-prot + 
wcons • ƒcons) 
ƒitnessCHEMPLP = ƒitnessPLP – (ƒchem-hb + ƒchem-cho + ƒchem-met)          (Equation 3.8)  
3.3.7 Prime MM-GBSA 
The Prime molecular mechanics-Generalized Born surface area (MM-GBSA)[94] post 
docking method is used to calculate the binding-free energy (ΔGbind) of each ligand 
pose generated from Glide and GOLD. Prime adopts a surface-generalized Born 
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model using a Gaussian surface instead of a van der Waals surface for better 
representation of the solvent-accessible surface area.[95] Prime allows the use of 
protein flexibility, permitting the residues around the ligand to adopt more specific 
geometries for individual ligands being screened and should therefore give more 
accurate results. Poses are minimized using the local optimization feature of Prime 
and the energies of complex were calculated. The binding free energy (ΔGbind) is 
then estimated using the equation: 
                                      Gbind = ER:L – (ER + EL)                    (Equation 3.9) 
Where ER:L is energy of the complex, ER + EL is sum of the energies of the ligand and 
unliganded receptor, the outcome of the OPLS3 force field.[96]  
3.4 Conclusion 
Computational chemistry has given rise to an extremely powerful tool that can aid in 
the design of potentially new therapeutic drugs. Molecular docking presents itself as 
a valuable tool that is used in modern day drug discovery throughout the medical 
field. In this work, its effectiveness will arise from its ability to narrow down a library 
of β-D-glucopyranosyl derivatives which may possibly display activity on the GP 
catalytic site, which has already been demonstrated with a number of successful 
computationally driven studies.[48, 51] Recent advances in computer technology have 
allowed for more computationally demanding methods to be used for predicting 
more accurately the binding energies and a reduction in prediction of false positives.  
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Chapter 4 – In silico screening of β-D-glucopyranosyl analogues as 
inhibitors of Glycogen Phosphorylase. 
4.1 Introduction 
Type-2 Diabetes (T2D) is a heterogeneous disease which is characterised by 
hyperglycaemia. T2D is characterised by three factors; (1) some resistance of insulin 
action on glucose uptake in tissues such as adipocytes, liver tissue and skeletal 
muscle tissues. (2) A relatively low production of insulin from the β-cells of the 
pancreas and (3) an impaired insulin action to inhibit the hepatic glucose production, 
70% of which comes from the breakdown of glycogen by GP via the glycogenolysis 
pathway.[9] The inhibition of GP is therefore a promising treatment of T2D. The 
catalytic site, where glycogen is broken down to G-1-P (and subsequently to 
glucose) is the main focus in this study, and β-D-glucopyranosyl derivatives, with 
some known examples showing nanomolar inhibition.[97] The catalytic site is 
accessible to bulk solvent through a 15 Å long channel (Figure 2.1), and is located 
at the junction of the N and C terminal domains. Each is an α/β structure consisting 
of a β-sheet core surrounded by a tier of α-helices.[36] Inhibition of the catalytic site 
promotes the T-state conformation of the enzyme via stabilisation of the 280s loop, 
blocking access to the site, hindering biological activity. In this chapter, the virtual 
screening of β-D-glucopyranosyl derivatives with different 5-membered heterocyclic 
linkers is presented. Initial screening was performed using both Glide-SP and –XP 
and GOLD. This was followed by MM-GBSA post-docking calculations which were 
then used to predict binding free energy (ΔGbind). A training set of ligands was first 
employed so as to optimize the predictive capability of the derived model. This 
training set consisted of 27 previously studied β-D-glucopyranosyl derivatives with 
5-membered heterocyclic linkers as GP inhibitors (Table 4.1). The best MM-GBSA 
model was then used to predict inhibition constant (Ki) values of a series of unknown 
inhibitors of this type. 
 
 
41 | P a g e  
4.2 Aim. 
Using the most accurate derived computational screening method for a training set 
of ligands, to predict the binding affinity of a set of new β-D-glucopyranosyl 
derivatives with different 5-membered heterocyclic linkers as GP inhibitors. 
4.2.1 Specific Objectives. 
 To explore the effect of different protein conformations from the PDB 
database on docking results for a training set of ligands. 
 To explore the effect of explicit cavity H2O molecules on the docking and post-
docking MM-GBSA results. 
 Compare the performance of Glide and GOLD with different scoring functions 
for ranking the ligand potencies at the GPb catalytic site. 
 To identify an effective computational model to screen for new catalytic site 
inhibitors. 
 Analyse modification to standard Prime MM-GBSA so as to improve 
predictive capabilities.  
4.3 Computational details. 
4.3.1 Ligand Preparation 
A set of 80 glucose analogues (Table 4.1) were built using Schrodinger’s Maestro 
programme.[91] This consisted of 27 training set ligands with known Ki values and a 
set of 53 ligands whose Ki’s were to be predicted. The ligands where then minimized 
generating energetically correct molecular structures using the LigPrep application 
with default settings except for the determination of stereoisomers, which was set to 
determine chiralities from 3D structures. The compounds were prepared for docking 
in terms of correct protonation, ionization states which were generated at a target 
pH of 7.0 ± 2.0, tautomerisation (where 32 tautomers were created) and 
stereochemistry to produce broad chemical and structural diversity so as to achieve 
more accurate docking simulations.  
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Table 4.1 – Set of training set ligands used in computational studies and their known inhibitory 
constants. Ligands to be predicted are highlighted in red.a 
1,2,3-Triazole_4R 
 
 
R group Ki (μM) 
1-Napthyl 136[53] 
2-Napthyl 16[53] 
CH2OH 14[53] 
Phenyl 151[53] 
 
2N-Pyrrole_3R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
CH2OH 382 
H N/A 
 
2N-Pyrrole_5R 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl 
No inh. At 
625 
Phenyl 
No inh. at 
625 
 
         2S5N-Thiazole_4R 
           
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl 158 
Phenyl 310 
 
GlucoPyrrole_3R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
2,3,4,5-Tetrazole_3R 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
Me N/A 
 
2,3,4-Triazole_4R 
 
 
 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
2,3,5-Triazole_4R 
 
R group Ki (μM) 
1-Napthyl 4.98[97] 
2-Napthyl 0.41[97] 
Phenyl 7[97] 
Me 499[97] 
Ph-Me 1.7[97] 
CH2OH 105[97] 
 
2,3-Diazole_4R 
 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl 400 
 
2,4,5-Triazole-3-One_4R 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl 80 
Phenyl 191 
H No inh. at 625 
 
2,4N-5-Oxadiazole_3R 
 
 
 
R group Ki (μM) 
1-Napthyl 19[98] 
2-Napthyl 12[98] 
Phenyl 64[98] 
 
2,5-Diazole_4R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl 0.031 
Phenyl 0.28 
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2,5N-3-Oxadiazole_4R 
 
R group Ki (μM) 
1-Napthyl No inh. at 625 
2-Napthyl 38 
Me N/A 
Phenyl No inh. at 625 
 
2S4N-Thiazole_3R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
2,4-Diazole_3R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
2N3O-Isoxazole_4R 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
CH2OH 218 
Phenyl No inh. at 625 
 
2O3N-Oxazole_4R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
2O-4,5N-Oxadiazole_3R 
 
R group Ki (μM) 
1-Napthyl 
10% inh. at 
625 
2-Napthyl 
10% inh. at 
625 
Me 145[99] 
Phenyl 
10% inh. at 
625 
 
3S5N-Thiazole_4R 
 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
Ar-2,3,4,5-
Tetrazole_Glc-4R 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
Me N/A 
 
Ar-2S4N_Thiazole_Glc-
3R 
 
 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
GlucoPyrrole_4R 
 
R group Ki (μM) 
1-Napthyl N/A 
2-Napthyl N/A 
Phenyl N/A 
 
Me-2,3,4_Triazole_Glc-
4R 
 
 
R group Ki (μM) 
Me N/A 
 
a Ki = N/A = not available and to be included in test set for prediction. 
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4.3.2 Protein Preparation 
A set of 12 known protein structures containing a glucose analogue with a 5-
membered heterocyclic linker bound at the catalytic site was downloaded from the 
protein database[40] (PDB Code: 5JTU, 5JTT, 3G2H, 3G2I, 3G2K, 3G2L, 1XL0, 
1XL1, 5LRC, 5LRF, 5LRE and 5LRD). Notable differences in structure where 
recognized for residues Asn282, Asp283, Asn284 and Phe285 from the 280s loop 
in solved 3G2H (bound ligand 1,2,3-Triazole_4R=phenyl)[53] and 3G2L (bound 
ligand 1,2,3-triazole_4R=1-napthyl)[100] where these residues had different 
orientations (residues facing outwards relative to the catalytic site) in contrast to the 
remaining 10 proteins (residue facing inwards relative to the catalytic site) whose 
residues superimpose relatively well (Figure 4.1). As these residues are within the 
catalytic site, protein-ligand binding may be influenced by interactions between the 
ligand and these residues. Accordingly, two protein structures for calculations were 
generated (PTO)  
Figure 4.1 – The different orientation of residues Asn282, Asp283, Asn284 and Phe285 using the 
5JTU protein with bound ligand 2,5-Diazole_4R=2-Napthyl (ClusterResidueIn shown in brown) and 
the 3G2H protein with bound ligand 1,2,3-Triazole_4R=Phenyl (ClusterResidueOut shown in blue). 
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whose orientations belong to the two different orientation/geometries observed to 
explore the effects these residue conformations may have on predicted binding 
energies and a third general protein was generated (PDB code: 5JTU) to represent 
the common solvation seen for all 12 proteins (vide infra). Protein 5JTU was also 
chosen to represent the most common orientation seen (residues in), due to the fact 
this crystal structures native ligand shows the best known inhibition to date, and the 
R group of 2-napthyl occupying the β-cavity allows for multiple R groups to be 
explored and protein PDB code: 3G2H was chosen to represent the less common 
orientation found (residues out). Protein structures were downloaded from the PDB 
database (www.rcsb.org) and the crystallographic waters subsequently removed. 
Water molecules generated from the ClusterWaters algorithm were then 
superimposed onto the protein, explained in the Solvation Modelling subsection 
(4.3.3). All protein structures were preprocessed using the default settings in the 
Import and Process tab of the Protein Preparation Wizard.[86] This tool assigns bond 
orders on untemplated residues using the chemical component dictionary (CCD) 
and automatically adds missing hydrogen atoms to the protein residues and other 
structures. The protein structures were analysed using the Review and Modify tab, 
the DMSO molecules were deleted and issues with alternative residue positions 
were corrected to optimize interactions. The Refine tab was kept at default settings, 
where orientations of water molecules (if present) were sampled into orientations 
which maximize interactions. Protonation states of protein residues were found 
using the PROPKA[101] program predicting pKa values at pH 7. Minimization was 
performed with and without the conserved waters detailed in the solvation 
subsection to decipher the effects of the docking results in terms of binding 
geometries and predicted related potencies using the OPLS3 forcefield. 
4.3.3 Solvation Modelling. 
Solvation effects are usually overlooked when performing VS docking simulations 
as the presence of explicit water molecules in such systems is one of the most 
controversial factors in terms of their overall effect on VS efficacy, and the currently 
accepted view is that such effects are system-dependent to a considerable 
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degree.[102] Some authors have reported significant improvement in docking 
performance when water molecules were included,[103, 104] whereas other authors 
found that the inclusion of water molecules had little effect in the quality of their 
docking calculations.[105, 106] The GP catalytic site in solved structures contains a 
number of crystallographic water molecules, some being well ordered and 
conserved. A number of determined crystal structures of GP in complex with various 
ligands reveals the importance of solvent for inhibition binding,[107] some water 
molecules providing key beneficial interactions often bridging the ligand to certain 
residues through hydrogen bonding networks. As the residues of the two different 
protein conformations being explored have two different orientations, the catalytic 
site water molecules for the proteins will also likely be different due to steric and 
electrostatic effects. ‘Cluster waters’ is a statistical analysis algorithm in the form of 
a python script which allows for the identification of conserved water molecules in a 
set of protein structures.[86] The set of proteins are superimposed, and clustering 
identifies those waters that overlap through a region of space at distances we set at 
0.5 Å. Those that met the statistical requirement were retained and those which did 
not were discarded. The protein used was 5JTU representing the set of all 12 
proteins irrespective of 280’s loops conformation but with all 12 proteins used to 
identify common/conserved water molecules. Applying this method, 107 water 
molecules were retained, 5 of these occupying the catalytic site. The Protein 
prepared with these explicit water molecules as described in 4.3.2 was labelled 
GeneralClusterProtein. For the less common occurring residue orientation 
(residue out) clustering of the waters from proteins PDB codes: 3G2H and 3G2L 
was performed. In total 510 water molecules were found within the two structures, 
and 172 of these were mutually conserved, 5 of these occupying the catalytic site. 
This Protein prepared from 3G2H was labelled ClusterResidueOut. The set of 
common water molecules related to the most common orientation (residue in) were 
generated from a cluster of the other remaining 10 aforementioned proteins, 
including 5JTU. In total 3034 water molecules were found within the 10 protein 
structures, and 134 of these were common to all proteins, 7 of these occupying the 
catalytic site. The protein was labelled ClusterResidueIn.  The results of the cluster 
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waters solvation model of each protein is summarised in Table 4.2. The file 
generated from the cluster waters script contain only the oxygen atoms of the water 
molecules which were superimposed onto the corresponding protein and then the 
Protein Preparation process as outlines in 4.3.2 performed. 
Table 4.2 - Table showing the solvation of the various receptors using Cluster Waters.  
Water Model PDB model 
structure 
used 
Number of 
Proteins 
used for 
clustering 
Total 
Number of 
Waters 
Cavity 
H2O’s 
GeneralClusterProtein 5JTU 12 107 5 
ClusterResidueIn 5JTU 10 134 7 
ClusterResidueOut 3G2H 2 172 5 
 
4.3.4 Docking with the Imidazole receptor (PDB code: 5JTU) with 
GeneralClusterProtein Water Model. 
Docking of all ligands were performed first using the imidazole protein (PDB code: 
5JTU) solvated with 107 water molecules. The shape and properties of the catalytic 
site were mapped onto grids with dimensions of 27 Å x 27 Å x 27 Å centered on the 
native glucose analogue inhibitor so as to ensure full exploration of the catalytic site 
and the surrounding residues. Default settings were applied, including van der 
Waals radius scaling (1.0). As glucose in the GP catalytic site has 5 well defined 
hydrogen bonds with the surrounding residues, core constraints were placed on the 
glucose ring. Trial simulations revealed that constraining the glucose ring too tightly 
causes incorrect pose generation, as a certain degree of flexibility is needed. Core 
constraints (maximum RMSD of 0.75 Å for core atom positions) were applied to the 
glucose ring atoms and positional constraints (maximum RMSD of 0.75 Å for atom 
positions) were placed on the hydrogen atoms of the hydroxyl groups of the glucose 
ring also to encourage the correct orientation of the hydrogen atoms. Docking 
calculations were performed using both Glide standard precision (SP) and extra-
precision (XP) with and without water molecules, both of which included post-
docking minimization with strain correction. 10 poses per ligand were saved for each 
docking calculation in order to generate a large number of diverse poses.  
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4.3.5 Docking using the Proteins Considering Different Residue Orientations. 
Docking was also performed again using the imidazole protein structure (PDB code: 
5JTU) this time solvated instead with 134 water molecules – ClusterResidueIn 
(Table 4.2). Alternatively, docking with the least common orientation of the protein 
residues (ClusterResidueOut; Table4.2) was performed using the PDB code: 
3G2H protein structure which was solvated with 172 water molecules. The shape 
and properties of both the catalytic sites were mapped onto grids as per 4.3.4 and 
the same atomic constraints were also used. Docking calculations were performed 
using both Glide SP and XP with and without water molecules, and post-docking 
minimizations were performed. 
4.3.6 Quantum-Mechanics Polarized Ligand Docking (QPLD) 
The same grid previously created for GeneralClusterProtein without waters was 
used in QPLD calculations. This protein/solvation model was chosen on the basis of 
its superior performance for the standard Glide and post-docking MM-GBSA 
calculations (vide infra). During the Initial Glide docking, the precision was set to SP 
and ligand van der Waals scaling was kept at default, as well as the protocol for 
discarding duplicate poses. The charges for ligands were calculated in the field of 
the receptor using quantum mechanics (QM) and the Jaguar accurate charge model, 
and the ligands were then redocked with the updated QM charges using the same 
default parameters set for the previous Glide docking. Poses, as before, were 
ranked using GlideScore. 
4.3.7 GOLD Docking Details 
GOLD (Genetic Optimisation for Ligand Docking)[92] uses .mol2, .pdb or the .sdf file 
format. The GOLD wizard allows a protein taken from our previous protein 
preparation calculations with the Protein Preparation Wizard (4.3.2) without 
modifications. The protein is selected and the co-crystallised native ligand is 
removed, but used to define the binding site. The binding site is generated and a 
residue interaction at a distance set to 10 Å from the native ligand was chosen. The 
detect cavity option was selected, restricting atom selection to solvent-accessible 
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surface, and also forces all H-bond donors/acceptors to be treated as solvent 
accessible. GOLD has many options regarding water molecules, including the toggle 
state and/or spin state. Three solvation models were explored using the 
GeneralClusterProtein receptor as this outperformed other the receptor models on 
the basis of Glide docking poses. The first solvation model contained 25 water 
molecules; GOLD docking only allows for a maximum of 25 water molecules to be 
used for docking and as these water molecules were in and around the catalytic site 
at a distance of 8 Å, they were retained and were kept stationary. Two other solvation 
models were created consisting of two water molecules (HOH 467 and HOH 469 in 
PDB code: 5JTU) that make favourable binding interactions with the ligand 
heterocycle moiety within the within the catalytic site. Two solvation modes were 
considered for the latter which allowed these two water molecules to both toggle and 
spin whereas another solvation model held the two waters stationary. Lastly, docking 
was performed without any water molecules present for comparison. The scoring 
function used was CHEMPLP (piecewise linear potential)[93] throughout. The search 
efficiency was kept at the default (100%). Constraints were placed on the glucose 
ring scaffold as well as the individual hydrogen atoms of the hydroxyl groups of 
glucose with a constraint weight of 5 for both. Docking was set to generate 10 poses 
per ligand to achieve a large number of diverse poses.   
4.3.8 Docking performance Assessment  
Geometry. 
For all 12 solved protein-ligand complexes, comparative RMSD calculations were 
performed for both Glide-SP and –XP with and without water molecules comparing 
the predicted pose for a ligand with its native conformation. The aim was to see 
which protein residue orientation (in or out) and solvation model performs the most 
accurate docking calculation with respect to geometry and whether SP or XP gave 
similar poses for the same receptor. An RMSD of less than 1.5 Angstroms was 
considered accurate.[108]   
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Scoring.  
The highest ranked poses for each training set ligand with Glide and GOLD were 
selected and the corresponding Glidescores (GSs) for Glide and ChemPLP fitness 
for GOLD were plotted against the ln Ki values for each known ligand to give a 
correlation plot. In the case of ligands with tautomers only the best scoring tautomer 
was plotted so that each ligand only one receives one rank. 
4.3.9 Prime MM-GBSA docking 
The Prime MM-GBSA method[109] was used to calculate the binding-free energy 
(∆𝐺𝑏𝑖𝑛𝑑) of each ligand, using the following equation: 
                                        ∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐸𝑀𝑀 + ∆𝐺𝑠𝑜𝑙𝑣                             (Equation 4.1) 
where ∆𝐸𝑀𝑀 is the difference in the minimized energies between the receptor-
inhibitor complex and the sum of the energies of the free protein and unbound 
inhibitor. ∆𝐺𝑠𝑜𝑙𝑣 is the difference in the GBSA solvation energies comparing solvation 
energy of the receptor-ligand complex and the sum of the solvation energies for the 
unliganded protein and inhibitor. These simulations were performed on the receptor-
ligand pose viewer structures obtained from the molecular docking calculations and 
should in theory give more accurate results than the preliminary docking calculations 
if the receptor is relaxed using  Prime, as the residues around the ligand were in 
more optimal positions to the specific ligands; additionally a more accurate model 
for solvation is used. Pose viewer files were taken from the docking simulations 
performed on all receptors from Glide –SP and -XP and GOLD – ChemPLP, and 
used in MM-GBSA calculations as implemented in the Prime[94] module from the 
Schrodinger Suite using default settings. For this, the ligand poses were minimized 
using the local optimization feature in Prime, with the OPLS3 force field[87] and the 
variable-dielectric generalized Born solvation model, to more accurately account for 
solvation effects. During the simulation process, the ligand strain energy was also 
considered so that MM-GBSA calculations were ran with both the receptor rigid and 
also with residues within 5 Å of the ligand poses are allowed to be flexible for 
comparison. 
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4.4 Results and Discussions 
4.4.1 Glide Docking  
RMSD Calculations. 
Exploiting the 12 known/solved crystallographic structures previously mentioned, we 
explored the potential of our receptor models and effect of conserved waters on pose 
prediction, as well as the effect of protein conformation. The root mean square 
deviation (RMSD) was compared for ligand heavy atoms from the top ranked poses 
for both SP and XP that have solved crystal structures. An RMSD cut off less than 
1.5 Å was considered similar. The results of these RMSD calculations as shown in 
Tables 4.3-4.5 
Table 4.3 – Ligand RMSDs (Å) achieved from Glide-SP & -XP docking compared with their 
crystallographic equivalents for the GeneralClusterProtein (PDB Code 5JTU) receptor considered 
with and without conserved water molecules retained. Ligands above the cut-off RMSD for accuracy 
(>1.5 Å) are highlighted in orange. 
PDB Code GeneralClusterProtein 
  With Waters Without Waters 
  SP XP SP XP 
5JTU 0.068 0.099 0.107 0.130 
5JTT 0.09 0.084 1.031 0.101 
3G2H 0.24 0.229 1.028 1.523a 
3G2I 0.243 1.146 (3)a 0.189 1.147 (3)a 
3G2K 0.183 1.666 0.184 1.671a 
3G2L 1.902b 1.548 (2)ab 1.680b 1.509ab 
1LX0 0.188 0.217 0.203 1.098 (3)ab 
5LRC 0.108 0.093 1.032 0.104 
5LRD 1.015 1.015 1.014 1.014 
5LRE 0.149 0.16 0.166 0.146 
5LRF 0.112 0.124 0.128 0.109 
Average 0.391 0.580 0.615 0.777 
Standard 
Deviation 
0.567 0.631 0.552 0.660 
a The Heterocycle has flipped and has a different orientation to the ligand native to the receptor. 
b The R-Group has flipped and has a different orientation to the ligand native to the receptor. 
ab The Heterocycle & R-group has flipped and has a different orientation to the ligand native to the receptor. 
(n) Given in parenthesis, the rank of the pose generated that correlates to the correct pose. 
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Table 4.4 – Ligand RMSDs (Å) achieved from Glide-SP & -XP docking compared with their 
crystallographic equivalents for the ClusterResidueIn (PDB Code 5JTU) receptor considered with 
and without conserved water molecules retained. Ligands above the cut-off RMSD for accuracy (>1.5 
Å) are highlighted in orange. 
PDB Code ClusterResidueIn 
  With Waters Without Waters 
  SP XP SP XP 
5JTU 0.138 0.13 0.131 0.129 
5JTT 0.097 0.12 0.120 1.031 
3G2H 1.031 1.031 1.298 (3)a 1.299 
3G2I 1.145 (2)a 1.143 (2)a 1.166 (2)ab 1.133 (2)ab 
3G2K 1.662 (2)a 1.669a 0.164 1.668a 
3G2L 1.837b 1.533 (2)a 1.541 (2)ab 1.474a 
1LX0 0.217 0.16 0.166 1.087 (2)ab 
5LRC 0.152 0.146 0.130 0.119 
5LRD 1.02 1.022 1.017 1.021 
5LRE 0.163 0.189 0.182 0.192 
5LRF 0.139 0.164 0.182 0.192 
Average 0.691 0.664 0.554 0.850 
Standard Deviation 0.667 0.619 0.569 0.581 
a The Heterocycle has flipped and has a different orientation to the ligand native to the receptor. 
b The R-Group has flipped and has a different orientation to the ligand native to the receptor. 
ab The Heterocycle & R-group has flipped and has a different orientation to the ligand native to the receptor. 
(n) Given in parenthesis, the rank of the pose generated that correlates to the correct pose. 
 
Overall, both Glide –SP and –XP with/without waters give very accurate results with 
respect to pose generation, but a few consistent outliers exist. All receptors used 
consistently generate inaccurate poses for the native ligand of 3G2L (1,2,3-
Triazole_4R-1-Napthy; Table 4.1) usually due to the imprecise positioning of the 1-
napthyl R group, which are usually 90° perpendicular to the native structures, so this 
ligand could arguably be classed as an outlier. In general, -SP gives better results 
with respect to pose accuracy than –XP, both with and without waters. 
GeneralClusterProteins (Table 4.3) gives the most experimental consistent results 
in most cases whereas ClusterResidueIn, on average, gives the highest RMSD 
values, and therefore, generates the least accurate poses. Docking without waters  
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Table 4.5 – Ligand RMSDs (Å) achieved from Glide-SP & -XP docking compared with their 
crystallographic equivalents for the ClusterResidueOut (PDB Code 3G2H) receptor considered with 
and without conserved water molecules retained. Ligands above the cut-off RMSD for accuracy (>1.5 
Å) are highlighted in orange. 
PDB Code ClusterResidueOut 
  With Waters Without Waters 
  SP XP SP XP 
5JTU 0.120 0.126 0.142 0.143 
5JTT 1.032 1.033 0.108 0.157 
3G2H 1.041 0.145 1.046 0.178 
3G2I 0.334 1.317 (3)a 0.300 1.051(2)a 
3G2K 0.206 1.602 a 0.244 0.332 
3G2L 1.879b 1.511 a 1.956(3)b 1.941b 
1LX0 0.114 0.126 0.186 0.186 
5LRC 0.117 0.145 0.130 0.109 
5LRD 0.106 0.136 0.141 1.018 
5LRE 1.507b 0.145 0.167 0.156 
5LRF 1.498b 0.128 0.129 0.121 
Average 0.723 0.583 0.414 0.490 
Standard Deviation 0.682 0.636 0.578 0.595 
a The Heterocycle has flipped and has a different orientation to the ligand native to the receptor. 
b The R-Group has flipped and has a different orientation to the ligand native to the receptor. 
ab The Heterocycle & R-group has flipped and has a different orientation to the ligand native to the receptor. 
(n) Given in parenthesis. The rank of the pose generated that correlates to the correct pose. 
 
gives the best results for ClusterResidueOut, with only the outlying 3G2L protein-
ligand above the cut-off with Glide- SP yielding an average RMSD of 0.414 Å and –
XP yielding an average RMSD of 0.490 Å but not for the two other receptor 
conformation. Using Glide-XP, 1,2,3-Triazole glucose analogue poses had a 
tendency to  be imprecise as the heterocycle “flipped” so that position of the nitrogen 
atoms are roughly 180° relative to the known ligand-protein complex. Usually, if the 
highest ranked pose generated has the incorrect orientation, a pose is generated 
which is similar to that of the known ligand in the protein complex and has a glide-
score close to that of the highest ranking ligand pose. Glide-SP generated poses 
with the most accuracy, although Glide–SP (average RMSD = 0.691 Å) using the 
ClusterResidueIn (Table 4.4) receptor generated inaccurate poses similar to that 
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of Glide-XP (average RMSD = 0.664 Å) in the same receptor when docking with 
waters. When docking to this receptor with no waters, only two protein-ligands are 
above the cut-off point, however, overall give relatively poor RMSD values. Docking 
to ClusterResidueOut with waters is the only example of a receptor whose highest 
scoring pose for the 5LRE and 5LRF native ligands are incorrect. It was the 
orientation of the R group which was unlike that of the known ligand in the protein 
complex. This may be due to the environment in which the R-group occupies within 
this receptor having a different structure making up the β-cavity, therefore forming 
different interactions contributing to the common orientation seen. 
4.4.2 Docking – Relative Ranking of Ligands and Scoring Results 
Glide Results for GeneralClusterProtein. 
The aim of docking was to derive an accurate model so as to screen a range of 
glucose analogues with heterocyclic linkers in order to predict their relative binding 
affinities to the catalytic site of GPb. 80 ligands (2 with known inhibitory (Ki) 
constants) were generated which after including tautomers gave 111 structures, 
which were then docked using Glide -SP and –XP with and without water molecules. 
Solvation of the GeneralClusterProtein was carried out with ClusterWaters 
considering all 12 proteins. 107 water molecules were retained, 5 of these occupying 
the catalytic site. The results of these calculations docking with and without waters 
are shown in Table 4.6.  When docking with these water molecules retained, 440 
diverse poses were generated using SP whereas only 147 poses were generated 
using XP; when docking with the absence of water molecules, fewer poses were 
generated with SP (409) and slightly more for XP (165). The ligands were ranked by 
best GlideScore (GS) and the highest ranked pose for each ligand was selected and 
then plotted against the ln Ki values. As aromatic R group substituents (Table 4.1) 
have been found to be the most effective for β-cavity binding we performed separate 
correlations studies (R2, the square of the Pearson correlation coefficient) for these 
groups (phenyl, 1 and 2-naphthalene) and also considering all ligands. The best 
correlation was from Glide-SP for hydrophobic aromatic R groups where values of 
R2 = 0.48 without waters were obtained but which still cannot be called a reasonable 
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correlation (Figure 4.2). The best correlation received for all ligands was achieved 
when docking with Glide-XP with waters, obtaining a correlation of R2 = 0.38. 
Ligands that ranked well usually had an available N-H on the heterocycle to 
hydrogen bond with the His377 backbone O. Large, hydrophobic R groups 
extending into the β-cavity of the catalytic site usually show the most favourable 
binding over small, polar groups.[36] Comparing the results of the QPLD calculations 
without waters, we can see that the reparametrized charges did not lead to an 
improved correlation. 
Table 4.6. – Table showing the results of the Glide-SP & -XP and quantum mechanics polarized 
ligand docking (QPLD) for GeneralClusterProtein in terms of number of poses obtained and 
correlation between predicted (Glidescore) and experimental (ln Ki) binding affinities  
SP/XP 
Number of Poses with 
(without) H2O's a 
Correlation (R2) 
With H2O's Without H2O's 
All 
Ligands 
Aromatic R 
groups 
All 
Ligands 
Aromatic R 
groups 
SP 440 (409) 0.25 0.24 0.29 0.48 
XP 147 (165) 0.38 0.45 0.31 0.26 
QPLD 409 - - 0.24 0.30 
a  Without H2Os are given in parentheses 
    
 
Figure 4.2 – Correlation of the Aromatic R groups ln Ki against glide gscore using SP without H2O’s 
present 
 
y = 0.2164x - 6.0485
R² = 0.48
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Glide Results for ClusterResidueIn 
The results of these calculations are shown in Table 4.7. Docking to this receptor 
model with Glide –SP and –XP generated 324 and 134 poses with waters, 
respectively. Docking without waters generated 378 poses for –SP and 141 poses 
for –XP. Docking without waters generated an increased amount of poses compared 
to with waters (as expected) but notably less poses were generated than the 
GeneralClusterProtein with waters. This is likely due to the increased amount of 
H2O molecules (2 more) occupying the catalytic site sterically hindering orientations 
required for pose generation. The correlation achieved for this receptor was in 
general, slightly higher than for the previous receptor. A best correlation was 
obtained for hydrophobic aromatic R groups where values of R2 = 0.38 with waters 
and R2 = 0.53 without waters were achieved but which still cannot be called a 
reasonable correlation. Glide-XP gave a correlation of R2 = 0.42 which was obtained 
for all ligands without waters, The increased amount of water molecules in the 
catalytic site will contribute to an increased amount of binding interactions with 
surrounding residues, the larger R groups having less space to adopt different 
conformations in the β-cavity, but in theory more correct poses. Finally correlations 
with this receptor model are generally slightly better without the H2Os present. 
Table 4.7 – Table showing the correlation achieved from Glide-SP & -XP for the ClusterResidueIn. 
SP/XP 
Number of Poses with 
(without) H2O's a 
Correlation (R2) 
With H2O's Without H2O's 
All 
Ligands 
Aromatic 
R groups 
All 
Ligands 
Aromatic 
R groups 
SP 324 (378) 0.30 0.38 0.36 0.53 
XP 134 (141) 0.35 0.36 0.42 0.45 
a  Without H2Os are given in parentheses 
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Glide Results for ClusterResidueOut. 
Docking to the receptor model ClusterResidueOut with Glide –SP and –XP 
generated 445 and 142 poses respectively with water and 440 and 178 poses 
respectively without water. The results of these calculations are shown in Table 4.8. 
Docking to this receptor generated a similar amount of poses to the 
GeneraClusterProtein, and contained the same amount of water molecules (5) 
occupying the catalytic site, showing that steric hindrance caused by the water 
molecules may indeed have an effect on pose generation. The best correlation of 
R2 = 0.46 was obtained with Glide-SP for aromatic R groups and Glide-XP (R2 = 
0.36) for ligands with aromatic R groups without waters, values which can be 
considered modest. This protein conformation performs notably poorer when 
docking with waters in comparison to the other receptors. It is possible that this 
protein orientation is unfavourable for binding of most ligands, consistent with only 
2 of the 12 PDBs studied adopting this orientation. In the most common orientation 
of the Asn282, Asp283, Asn284 and Phe285 residues (ClusterResidueIn), ligands 
whose heterocycle is able to act as a H-bond acceptor also benefits from hydrogen 
bonding the with Asn284 residue NH; in ClusterResidueout, Asn284 is facing a 
different direction in the orientation away from the binding site and cannot therefore 
achieve this favourable binding interaction, leading to a lower average Glide-Score 
across all of the ligands. 
Table 4.8 – Table showing the correlation achieved from Glide-SP & -XP for the ClusterResidueOut. 
SP/XP 
Number of Poses with 
(without) H2O's a 
Correlation (R2) 
With H2O's Without H2O's 
All 
Ligands 
Aromatic R 
groups 
All 
Ligands 
Aromatic R 
groups 
SP 445 (440)                                                    0.22 0.21 0.23 0.44 
XP 142 (178)                                                  0.19 0.25 0.31 0.45 
a  Without H2Os are given in parentheses 
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GOLD Results for GeneralClusterProtein 
Table 4.9 – Table showing the correlations achieved from GOLD for GeneralClusterProtein 
Water Model Number of poses 
Correlation (R2) 
All ligands Aromatic R groups 
Without H2O 334 0.37 0.42 
25 Static H2O 343 0.34 0.35 
2 Static H2O 337 0.36 0.41 
2 Spin/Toggle H2O 363 0.35 0.40 
 
Docking with GOLD using the GeneralClusterProtein receptor model generated 
343 and 334 poses with static water molecules and without water molecules, 
respectively, as well as 337 and 363 poses with two static waters and when two 
waters were allowed to toggle and spin, respectively. The results of these calculation 
are shown in Table 4.9 Both GOLD and Glide were set to generate 10 poses per 
ligand and docking to this protein with GOLD generated on average less poses than 
that of Glide. Similar correlations were achieved for all docking models tested: 
without H2Os and these explicit H2O models. These ranged from 0.34-0.37 for all 
ligands and 0.35-0.42 for the aromatic R groups. In comparison with the Glide 
docking (Table 4.6), the correlations without waters was slightly better for all ligands 
(r2 = 0.37 vs r2 = 0.29). Overall, for the GOLD water models, slightly improved 
correlations were observed compared to Glide –SP and –XP, however, these 
improvements cannot be considered significant, so that none of the docking models 
tested yielded predictive capability. 
Summary of docking results 
Overall, docking performance with Glide-SP was better than that of –XP and 
generated vastly more poses, which were on average more accurate based on the 
RMSDs. Each receptor displayed an improved correlation when docking was 
performed with no water molecules and the best correlations were achieved with 
aromatic R groups and in particular the best correlations were achieved with the 
ClusterResidueIn receptor. Docking to this receptor with Glide-SP and no waters 
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achieved a correlation of R2 = 0.53 for the aromatic R groups. However, the 
correlations achieved overall from Glide are relatively modest and docking with 
GOLD considering different water models did not lead to improved results. More 
accurate Prime MM-GBSA post-docking calculation should in theory yield better 
results.   
4.4.3 Prime MM-GBSA Results  
GeneralClusterProtein Post-docking 
Prime post-docking calculations were performed on the docking poses (up to 10 for 
each structure) and ΔGbind values calculated according to Equation 4.1. These 
calculations were performed with and without explicit waters, and also with and 
without strain correction. Strain correction corresponds to relaxation of the protein 
and/or ligand in the free unbound state as compared with its conformation in the 
bound state. The results of the Prime MM-GBSA post-docking calculations for 
GeneralClusterProtein poses revealed that the poses gathered from both Glide –
SP and –XP achieve better correlations compared to docking alone when the 
predicted ΔGbind values were plotted against ln Ki values (Table 4.10). The 
correlations achieved without explicit waters from Glide-SP outperforms all other 
solvation models with this receptor which suggests a better estimation of the relative 
ΔGbind values. The Prime-MM-GBSA calculations give better correlations from the –
SP poses as opposed to –XP; this is consistent with the poses generated from Glide-
SP having the most accurate pose orientations based on the RMSD calculations. 
Additionally Glide –SP poses performed better without including ligand strain for the 
rigid receptor but performed better with the protein/ligand strain at a receptor 
flexibility of 5 Å. Glide –XP poses performed better including strain correction for 
both a rigid receptor and that of 5 Å flexibility but overall performed better with a rigid 
receptor, suggesting that Prime calculations for both Glide –SP and –XP are more 
accurate when keeping the protein rigid. Overall, the best correlation achieved for 
this receptor was using Glide –SP poses without waters using a rigid receptor and 
without including ligand strain. 
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Table 4.10. - Table showing the correlation achieved from Prime MM-GBSA for the 
GeneralClusterProtein. 
a Previous Glide docking correlations are given in square parentheses  
Figure 4.3 – Prime (No strain) correlation of Aromatic R groups without waters using input poses 
from glide-SP.  
Glide-
SP/ 
XP 
Protein 
Flexibility 
Prime Correlation (R2) with Strain (No Strain) 
With H2O's Without H2O's 
All ligands a 
Aromatic R 
groups a  
All ligands a 
Aromatic R 
groups a 
SP 
0 Å 
flexibility 
0.62 (0.73) 
[0.25] 
0.69 (0.80) 
[0.24] 
0.71 (0.75) 
[0.29] 
0.73 (0.86) 
[0.48] 
5 Å 
flexibility 
0.50 (0.51) 0.58 (0.65) 0.70 (0.59) 0.81 (0.72) 
XP 
0 Å 
flexibility 
0.54 (0.52) 
[0.38] 
0.55 (0.51) 
[0.45] 
0.59 (0.58) 
[0.31] 
0.58 (0.51) 
[0.26] 
5Å 
flexibility 
0.44 (0.47) 0.43 (0.47) 0.53 (0.49) 0.56 (0.50) 
y = 2.603x - 44.885
R² = 0.86
-100
-90
-80
-70
-60
-50
-18 -16 -14 -12 -10 -8 -6
ln Ki
∆G Bind
61 | P a g e  
With this, R2 correlations for all ligands and for the aromatic R groups of 0.75 and 
0.86 (Figure 4.3), respectively, were obtained. However, similar favourable 
correlations were also achieved with waters for all ligands (R2 = 0.73) and the 
aromatic R groups (R2 = 0.80) also using a rigid receptor without ligand strain of 
particular significance. These correlations are considerable improvements on those 
gathered from docking with Glide –SP with waters for all ligands (R2 = 0.25) and for 
the aromatic R groups (R2 = 0.24), and without waters for all ligands (R2 = 0.29) and 
aromatic R groups (R2 = 0.48).  
For comparative purposes, the poses gathered from GOLD were then also used as 
input for Prime MM-GBSA calculations. Again, the Prime MM-GBSA results 
consistently gave significantly better correlations than those gathered from the Gold-
ChemPLP docking alone. As with the Glide poses, Prime calculation using the 
GOLD docking poses with a rigid receptor outperformed Prime with 5 Å protein 
flexibility for all of the solvation models used. The best correlation achieved was from 
using the poses from the docking with two toggle and spin water molecules model 
for all ligands (R2 = 0.66) and also for the aromatic R groups (R2 = 0.67) including 
the ligand strain term. Poses from the same model also gave the best correlation 
without including the ligand strain term for all ligands (R2 = 0.58) and for the aromatic 
R groups (R2 = 0.62).  Similar correlation were also obtained for the 2 static H2Os. 
In contrast to Glide, these particular solvation models with H2O’s produced better 
correlations than without explicit H2Os. Significantly, this was one of the few explicit 
water models that outperformed MM-GBSA without H2Os included. The best 
correlations without H2Os with no strain where values of R2 = 0.59 (all ligands) and 
R2 = 0.62 (Aromatic R groups) were obtained. The correlations achieved can be 
considered reasonable, but are poor in comparison to the poses generated from 
Glide –SP for the same receptor. 
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Table 4.11 – Table showing the correlation achieved from GOLD using ChemPLP and Prime for 
GeneralClusterProtein 
Protein 
Flexibility 
Prime Correlation (R2) with Strain (No Strain) 
Without 
 H2O's  
With static  
H2O's 
With two Static 
H2O’s 
With two 
Spin/Toggle 
H2O’s 
All 
ligands a 
  
Ar R 
groups a 
 
All 
ligands a 
 
Ar R 
groups a 
 
All 
ligands a 
 
Ar R 
groups a 
 
All 
ligands a 
 
Ar R 
groups a 
 
0 Å 
flexibility 
 
0.59 
(0.56)  
 
[0.37] 
0.62 
(0.55)  
 
[0.42] 
0.56 
(0.56)  
 
[0.34] 
0.59 
(0.56)  
 
[0.35] 
0.62 
(0.58)  
 
[0.36] 
0.64 
(0.59)  
 
[0.41] 
0.66 
(0.58)  
 
[0.35] 
0.67 
(0.62)  
 
[0.40] 
5 Å 
flexibility 
 
0.45 
(0.53) 
0.49 
(0.57) 
0.47 
(0.49) 
0.48 
(0.51 
0.56 
(0.56) 
0.59 
(0.59) 
- - 
 a Previous GOLD docking correlations are given in square parentheses 
Quantum Mechanics Polarized Ligand Docking Post-docking results 
With respect to MM-GBSA results with the QPLD docking poses from Glide, the new 
quantum mechanics partial charges calculated for the ligands in the field of the 
receptor achieved good correlations, but does not lead to improvements over the 
standard Glide results using molecular mechanic forcefield based parametrisation. 
The correlations are shown in Table 4.12. The best correlation achieved was using 
a rigid receptor for all ligands (R2 = 0.69) and for the aromatic R groups, a value of 
R2 = 0.81 was obtained. In comparison, post-docking using the same receptor with 
MM forcefield parameters achieved correlation for all ligands (R2 = 0.75) and for the 
aromatic R groups (R2 = 0.86). 
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Table 4.12. - Table showing the correlation achieved from QM-PLD for the GeneralClusterProtein. 
  Protein Flexibility 
Prime Correlation (R2) with Strain (No Strain) 
Without H2O's 
All ligands  Aromatic R groups  
Glide N/A 0.24 0.30 
Prime 
0 Å flexibility 0.67 (0.69) 0.75 (0.81) 
5 Å flexibility 0.61 (0.48) 0.68 (0.61) 
 
ClusterResidueIn Post-docking 
For this protein conformation, Prime MM-GBSA post-docking calculations revealed 
that the poses gathered from both Glide –SP and XP achieve similar correlations 
with and without water when the predicted ΔGbind values were plotted against ln Ki 
values (Table 4.13). Similar to the previous receptor, the correlations achieved from 
Glide–SP without waters slightly outperform all other solvation models used in this 
receptor which again suggests a better estimation of the relative ΔGbind values. Also, 
Prime calculations using Glide –SP gave better correlations than that of –XP. In 
agreement; the RMSD calculations (4.4.1) show again that Glide –SP was more 
accurate than -XP on average in terms of pose generation, although they were not 
as accurate as the last receptor. The correlations achieved with Prime from Glide –
SP were again best using a rigid receptor with no ligand strain. This again suggests 
that Prime MM-GBSA calculations are more accurate when keeping the protein rigid. 
The best correlation achieved for this receptor was gathered from using Glide –SP 
without waters using a rigid receptor for all ligands (R2 = 0.75) and for the aromatic 
R groups (R2 = 0.81) without including the ligand strain term. Similar favourable 
correlations were also achieved with waters for all ligands (R2 = 0.75) and the 
aromatic R groups (R2 = 0.81) also using a rigid receptor without ligand strain. These 
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correlations are again significant improvements on those gathered from docking with 
Glide –SP with waters for all ligands (R2 = 0.30) and for the aromatic R groups (R2 
= 0.38) and without waters for all ligands (R2 = 0.36) and for the aromatic R groups 
(R2 = 0.53). This receptors residue orientation is the same as the previous receptor 
and differs only in solvation; with the catalytic site containing 2 more water molecules 
and the overall protein containing 27 more water molecules altogether. As discussed 
previously, the presence of these waters in the catalytic site likely impacted 
negatively on the RMSD of the poses generated and therefore, correlations 
achieved for this receptor are slightly less than that of the previous receptor.  
Table 4.13. - Table showing the correlation achieved from Prime MM-GBSA for the 
ClusterResidueIn. 
Glide-SP/ 
XP 
Protein 
Flexibility 
Prime Correlation (R2) with Strain (No strain) 
With H2O's Without H2O's 
All 
ligands a 
Aromatic 
R groups 
a  
All 
ligands a 
Aromatic 
R groups 
a 
SP 
0 Å flexibility 
0.60 (0.75) 
[0.30] 
0.72 
(0.81) 
[0.38] 
0.69 
(0.75) 
[0.36] 
0.69 (0.81) 
[0.53] 
5 Å flexibility 0.54 (0.56) 
0.49 
(0.55) 
0.42 
(0.54) 
0.52 (0.64) 
XP 
0 Å flexibility 
0.54 (0.49) 
[0.35] 
0.57 
(0.54) 
[0.36] 
0.58 
(0.52) 
[0.42] 
0.57 (0.49) 
[0.45] 
 5Å flexibility 0.45 (0.48) 
0.44 
(0.47) 
0.55 
(0.56) 
0.56 (0.59) 
a Previous Glide docking correlations are given in square parentheses. 
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ClusterResidueOut Post-docking 
For this receptor model, unlike the previous receptors, Prime MM-GBSA post 
docking calculations show that poses gathered from both –SP and –XP achieve 
better correlations post-docking with explicit water molecules present in the protein 
when the predicted ΔGbind values were plotted against ln Ki values (Table 4.14). 
Prime calculations using Glide –SP poses gave better correlations than those of –
XP both with and without water. The poses that were generated from Glide –SP with 
waters generated the least accurate geometry across all receptors based on the 
RMSD calculations (4.4.1), however, the most accurate poses without waters. The 
inaccurate poses generated are often due to the wrong orientations of the R-group 
substituents and not the heterocyclic linkers themselves. Similar to the previous 
receptors, the correlations achieved with Prime from the Glide–SP poses are greater 
than those of Glide-XP, but displayed better correlations than the previous receptors 
for –XP in general. Interestingly, this receptor revealed greater correlations with 5 Å 
flexibility and with the strain term included as opposed to holding the receptor rigid. 
With flexibility, the receptor has the ability to adopt a geometry similar to those in the 
more common receptors which are more favourable for binding. The best correlation 
achieved for this receptor was gathered from using Glide –SP with waters and a 
receptor flexibility of 5 Å for all ligands (R2 = 0.71) and for the aromatic R groups (R2 
= 0.75). Favourable correlations were also achieved using Glide –XP with water 
using a receptor flexibility of 5 Å without the ligand strain for all ligands (R2 = 0.63) 
and for the aromatic R groups (R2 = 0.66). A good correlation was also achieved 
using Glide-SP without waters with the strain term included for the aromatic R groups 
(R2 = 0.72). These correlations are significant improvements on those gathered from 
docking with Glide –SP with waters for all ligands (R2 = 0.22) and for the aromatic R 
groups (R2 = 0.21) and without waters for all ligands (R2 = 0.23) and aromatic R 
groups (R2 = 0.44). Surprisingly, however, the correlations achieved from Prime 
(0.22-0.29) are worse than those gathered from using Glide –XP without waters for 
all ligands (R2 = 0.31) and the aromatic R groups (R2 = 0.45). However, with H2Os 
present, the post-docking Prime MM-GBSA results revealed considerable 
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improvements (R2 = 0.51-0.68) compared to the docking alone (R2 = 0.19 – all 
ligands; R2 = 0.09 – Aromatic R groups) 
Table 4.14. - Table showing the correlation achieved from Prime MM-GBSA for the 
ClusterResidueOut. 
Glide-SP/ 
XP 
Protein 
Flexibility 
Prime Correlation (R2) with Strain (No strain) 
With H2O's Without H2O's 
All 
ligands a 
Aromatic 
R groups 
a  
All 
ligands a 
Aromatic 
R groups 
a 
SP 
0 Å flexibility 
0.62 (0.66) 
[0.22] 
0.60 
(0.67) 
[0.21] 
0.38 (0.35) 
[0.23] 
0.48 
(0.43) 
[0.44] 
5 Å flexibility 0.71 (0.46) 
0.75 
(0.53) 
0.55 (0.46) 
0.72 
(0.50) 
XP 
0 Å flexibility 
0.53 (0.53) 
[0.19] 
0.51 
(0.51) 
[0.09] 
0.29 (0.27) 
[0.31] 
0.25 
(0.22) 
[0.45] 
 5Å flexibility 0.58 (0.63) 
0.68 
(0.66) 
0.28 (0.28) 
0.29 
(0.25) 
a Previous Glide docking correlations are given in square parentheses 
Summary 
For Prime MM-GBSA post-docking calculations, -SP poses generally scored better 
than their –XP counterparts; also without waters generally gave slightly better 
correlations. However, for MM-GBSA using GOLD poses retaining just two waters, 
both static and in spin/toggle mode, better correlations were obtained compared to 
without explicit H2O. Nevertheless, these correlations were still less than those 
obtained for post-docking with the Glide poses. No strain predominantly produced 
better results compared to experimental in terms of correlations; likewise retaining a 
rigid receptor for these calculations. Reparameterization of ligand partial charges 
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using quantum mechanics also led to good correlations but were not superior to 
those obtained using standard (Glide) MM forcefield charges. Overall, the best MM-
GBSA model obtained was for GeneralClusterProtein using Glide-SP poses, 
without waters, with a rigid receptor and with no strain correction. This model 
produced a correlation of R2 = 0.86 (aromatic R groups) and r2 = 0.75 (all ligands). 
On this basis, we took this model forward as the optimal model obtained. However, 
in the next section, we looked at this model in more detail considering refinements 
that may improve its predictive capability when applied to the unknown ligands from 
Table 4.1. 
4.4.4 Refinement of MM-GBSA Model. 
Inclusion of Entropy Effects 
An estimate for the loss of ligand entropy (∆SMM) on binding was calculated using 
MM with the OPLS3 forcefield and the Rigid Rotor Harmonic Oscillator (RRHO) 
approximation. Using this method, the change in vibrational, rotational and 
translational entropy (ΔSMM) of the ligands on binding was considered. RRHO 
calculations was performed using MacroModel 11.0.[86] The ∆Gbind values from 
GeneralClusterProtein using Glide-SP poses, without waters and a rigid receptor 
were corrected with the entropy term; 
                         ΔGbind = ΔEMM + ΔGsolv – TΔSMM                     (Equation 4.2) 
This model produced a correlation of R2 = 0.70 (Aromatic R groups) and R2 = 0.69 
(all ligands) including the strain term (Table 4.10). The model also gave a correlation 
of R2 = 0.83 (Aromatic R groups) and R2 = 0.75 (all ligands) without the strain term. 
Hence, inclusion of the extra entropy term gave similar correlations as to those 
obtained with standard Prime (Equation 4.1). 
Inclusion of Tautomeric Correction. 
Our set of 27 training set ligands (Table 4.1) consists of 4 ligands shown in Table 
4.15 (2,3-Diazole_4R, 2,4-Diazole_4R, 2,5-Diazole_4R, 2,3,5-Triazole_4R) with the 
potential to form tautomers and/or different ionization states. Until now, we have 
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considered the best ∆Gbind as the predicted experiment value of each ligand 
irrespective of ionization/tautomeric state. However, to consider more accurately the 
potential of these ligands to bind in these different states, quantum mechanics (QM) 
calculations were performed by a collaborator[110] to establish which of the 
tautomeric states of the ligands are the most favourable in the unbound state. The 
results of the calculation are also shown in Table 4.15. 
Table 4.15. – Relative energies (gas and solution phase (in parentheses)) of the tautomeric forms of 
ligands considered in this work calculated using quantum mechanics. Relevant Ionization states are 
also shown. 
 
Ligand 
 
Neutral state 
Ionized form 
Tautomer 1 Tautomer 2 Tautomer 3 
2,3-
Diazole_4R 
-phenyl 
 
+3.0 (+2.3) 
 
0.0 (0.0) 
- 
 
 
- 
2,4-
Diazole_4R 
 
 
+4.8 (+4.6) 
 
 
0.0 (0.0) 
- 
 
 
N/A 
2,5-
Diazole_4R 
 
0.0 (0.0) 
 
+0.61 (+2.09) 
- 
 
N/A 
2,3,5-
Triazole_4R 
 
0.0 (0.0) 
 
+3.18 (+1.61) 
 
+6.12 (+6.19 
- 
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The most favouring binding state of the 2,4-diazole_4R and 2,5-diazole_4R ligands 
were consistently protonated (+1) state. The calculated pKa values of these ligands 
(R = phenyl), by our collaborator, were 5.9 and 5.5, respectively, meaning that these 
ligands will be partially protonated in solution, favourable for binding. For 2,3,5-
triazole_4R, the most stable tautomer in the free state (tautomer 1) was almost the 
most favourable in terms of ∆Gbind. Hence, there was no tautomeric correction. 
However, for 2,3-diazole_4R-phenyl, the most stable tautomer in the free state was 
tautomer 2, but ∆Gbind was stronger for its tautomer 1. Taking the ∆Gbind value instead 
for tautomer 2, led to a significant improvement in correlation (Table 4.16, models 3 
and 4) leading to R2 values as large as 0.95-0.97 for the aromatic R group. 
Table 4.16. – Correlations of the best MM-GBSA models with and without the entropy term as well 
as the tautomeric correction.a 
Model 
Number 
  Correlation (R2) 
MM-GBSA model 
All Ligands 
Aromatic R 
groups 
Strain (No Strain) Strain (No Strain) 
1 Best Prime model, Eq. (4.1) 0.71 (0.75) 0.73 (0.86) 
2 
MM-GBSA model, Eq. (4.2) - 
including entropy 
0.69 (0.75) 0.70 (0.83) 
3 
Eq. (4.1) with tautomeric 
correction 0.82 (0.83) 0.84 (0.97) 
4 Eq. (4.2) with tautomeric 
correction 0.82 (0.83) 0.86 (0.95) 
a Calculations were performed using Strike 5.01[86] 
Based on the results in Table 4.16, we considered the models for prediction of 
heterocyclic linkers with different aromatic R groups without the strain term included, 
the most useful based on their excellent R2 values. We then looked at these models 
in more detail using Strike 5.01[86] so as to obtain a full set of statistics and make 
predictions on the unknown compounds in Table 4.1. 
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Table 4.17. – Results of the Strike statistics performed for models 1-4. 
Model Equation R2 
LOO 
Cv Q2 
RMSE F[df1,df2] p-value 
1 
(lnKi)pred =  0.33701(±0.036963)  ∆𝐺𝑏𝑖𝑛𝑑
𝑝𝑟𝑒𝑑
 
                                       +13.890(±2.7190) 0.86 0.84 1.013 
83.1 
[1,13] 
5.2e-7 
2 
(lnKi)pred =  0.32118(±0.040879)  ∆𝐺𝑏𝑖𝑛𝑑
𝑝𝑟𝑒𝑑
 
                                       +6.5651(±2.2290) 0.83 0.79 1.149 
61.7 
[1,13] 
2.7e-6 
3 
(lnKi)pred =  0.33911(±0.17491)  ∆𝐺𝑏𝑖𝑛𝑑
𝑝𝑟𝑒𝑑
 
                                       +13.795(±1.2746) 
0.97 0.96 0.50 
375.9 
[1,13] 
5.6e-11 
4 
(lnKi)pred =  0.32590(±0.020994)  ∆𝐺𝑏𝑖𝑛𝑑
𝑝𝑟𝑒𝑑
 
                                       +6.5347(±1.1279) 
0.95 0.93 0.62 
241.0 
[1,13] 
9.0e-10 
 
The results of the multiple linear regressions using the four models for the training 
set of 15 ligands with aromatic R groups and the equations relating to them are 
shown in Table 4.17. A comprehensive statistical evaluation of the relationship 
between predicted and experimental activities (ln Ki) was obtained which included 
the correlation coefficient R2, leave-one-out cross validation (LOO-cv) Q2, F and p-
values and also the root mean square error (RMSE). All models gave consistently 
excellent R2 values and LOO-cv Q2 values (Q2 values only slightly less that their R2 
counterparts), and all of the models have corresponding p-values <<0.05 showing 
statistical significance. These models are shown in Figures 4.4 - 4.7. All of the 
aforementioned models were then used to predict the Ki values of the set of 
unknown compounds in Table 4.1. in order to consider a number of factors that are 
relevant to inhibition; including entropy and tautomeric correction. All models have 
favourable attributes and give similar excellent statistical values. Accordingly, using 
these models 1-4, predicted Ki values were produced and given as a range 
(incorporating RMSE values) which should provide considerable insight into the 
inhibitory potential of the unknown compounds.  
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Table 4.18. – Ligands used in models 1-4 along with the codes present on Figure 4.4-4.7.a 
a N/A = not available and included in test set for prediction  
 
 
Figure 4.4 – Correlation between predicted and experimental ln Ki from Prime (NS) using Model 1. 
(Table 4.17) 
 
 
  
1b
1c
1a
2c
2a
3c
3a
4a
5c
5a
6c
6a
7c
7a
8c
y = 0.8597x - 1.503
R² = 0.86
-18.5
-16.5
-14.5
-12.5
-10.5
-8.5
-6.5
-4.5
-18 -16 -14 -12 -10 -8 -6
ln Ki 
(Experimental)
ln Ki
(Predicted)
Ligand 
Code 
Phenyl 1-Napthyl 2-Napthyl 
1,2,3-Triazole_4R 1a 1b 1c 
1-Glc-2S5NThiazole_4R 2a N/A 2c 
2,3,5-Triazole_4R 3a N/A 3c 
2,3-Diazole_3R 4a N/A N/A 
2,4,5-Triazole3-one_4R 5a N/A 5c 
2,4N-5Oxodiazole_3R 6a N/A 6c 
2,5-Diazole_4R 7a N/A 7c 
2,SN3O-Oxodiazole N/A N/A 8c 
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Figure 4.5 – Correlation between predicted and experimental ln Ki from Prime (NS) using Model 2. 
(Table 4.17) 
 
Figure 4.6 – Correlation between predicted and experimental ln Ki from Prime (NS) using Model 3. 
(Table 4.17) 
1b1c
1a
2c
2a
3c
3a
4a
5c 5a
6c
6a
7c
7a
8c
y = 0.826x - 1.8732
R² = 0.83
-18.5
-16.5
-14.5
-12.5
-10.5
-8.5
-6.5
-4.5
-18 -16 -14 -12 -10 -8 -6
ln Ki 
(Experimental)
ln Ki
(Predicted)
1b
1c
1a
2c
2a
3c
3a
4a
5c
5a
6c
6a
7c
7a
8c
y = 0.9666x - 0.36
R² = 0.97
-18.5
-16.5
-14.5
-12.5
-10.5
-8.5
-6.5
-4.5
-18 -16 -14 -12 -10 -8 -6
ln Ki 
(Experimental)
ln Ki 
(Predicted)
73 | P a g e  
Figure 4.7 – Correlation between predicted and experimental ln Ki from Prime (NS) using Model 4 
(Table 4.17) 
4.4.5 Prediction of Inhibitory Potential for Unknown Compounds. 
The results of the predictions using models 1-4 (Table 4.17) are shown in Table 4.18. 
Table 4.19. - The predicted Ki values of unknown set of ligands in Table 4.1. 
Heterocycle R group 
Predicted Activities as ln Ki (Ki in µM)  
[Ki range]a 
Overall 
Ki 
Range 
(µM) Model 1 Model 2 Model 3 Model 4 
 
2N-Pyrrole_3R 
1-Napthyl 
-7.33 
(658) 
[239-
1813] 
-7.57 
(518) 
[164-
1636] 
-7.55 
(525) 
[318–
865] 
-7.80 
(409) 
[219-762] 
164-
1813 
2-Napthyl 
-7.31 
(672) 
[244-
1850] 
-7.5 (553) 
[175-
1745] 
 
-7.53 
(535) 
[345 – 
882] 
-7.74 
(436) 
[234-814] 
175-
1850 
 
2N-Pyrrole_5R 
Phenyl NI.b NI.b NI.b NI.b NI.b 
1-Napthyl 
-4.41 
(12155) 
[4413-
33480] 
-4.33 
(13207) 
[4185-
41677] 
-4.62 
(9862) 
[5982 – 
16260] 
-4.52 
(10911) 
[5850 -
20349] 
4185-
41677 
2-Napthyl NI.b NI.b NI.b NI.b NI.b 
1b1c
1a
2c
2a
3c
3a
4a
5c 5a
6c
6a
7c
7a
8c
y = 0.9488x - 0.5516
R² = 0.95
-18.5
-16.5
-14.5
-12.5
-10.5
-8.5
-6.5
-4.5
-18 -16 -14 -12 -10 -8 -6
ln Ki 
(Experimental)
ln Ki
(Predicted)
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2S5N-
Thiazole_4R 
1-Napthyl 
-8.78 
(154) 
[56-424] 
-8.37 
(233) 
[74-735] 
-9.02 
(121) 
[74-200] 
-8.62 
(181) 
[97-338] 
56-735 
 
GlucoPyrrole_3R 
Phenyl 
-5.51 
(4042) 
[1468 - 
11133] 
-6.24 
(1960) 
[621-
6184] 
-5.73 
(3257) 
[1975–
5370] 
-6.45 
(1576) 
(845-
2938] 
621-
11133 
1-Napthyl 
-7.75 
(431) 
[156-
1186] 
-7.78 
(418) 
[133-
1320] 
-7.98 
(342) 
[208–
564] 
-8.02 
(328) 
[176-613] 
133-
1320 
2-Napthyl 
-7.21 
(741) 
[269-
2040] 
-7.26 
(705) 
[223-
2223] 
-7.43 
(591) 
[358–
974] 
-7.49 
(558) 
[299-
1040] 
223-
2223 
 
2,3,4,5-
Tetrazole_3R 
Phenyl 
-8.45 
(214) 
[78-589] 
-8.73 
(162) 
[51-511] 
-8.68 
(169) 
[103-279] 
-8.98 
(126) 
[67-234] 
51-589 
1-Napthyl 
-10.93 
(18) 
[7-49] 
-10.84 
(20) 
[6-62] 
-11.18 
(14) 
[9–23] 
-11.12 
(15) 
[8-28] 
6-62 
2-Napthyl 
-10.74 
(22) 
[8-60] 
-10.46 
(29) 
[9-90] 
-10.99 
(16.87) 
[10–28] 
-10.74 
(22) 
[12-40] 
8-90 
 
2,3,4-Triazole_4R 
Phenyl 
-8.89 
(138) 
[50-381] 
-9.41 (82) 
[26-258] 
-9.12 
(109) 
[66–180] 
-9.68 (63) 
[34-117] 
26-381 
1-Napthyl 
-9.87 
(52) 
[19-142] 
-9.95 (48) 
[15-150] 
-10.11 
(45) 
[25–70] 
-10.23 
(36) 
[19-68] 
15-150 
2-Napthyl 
-10.59 
(25) 
[9-69] 
-10.70 
(23) 
[7-71] 
-10.84 
(20) 
[20-32) 
-10.98 
(17) 
[9-32] 
7-71 
 
2,3-Diazole_4R 
1-Napthyl 
-10.91 
(18) 
[7-50] 
-10.93 
(18) 
[6-56] 
-11.16 
(14) 
[9-23] 
-11.22 
(13) 
[7-25] 
6-56 
2-Napthyl 
-11.95 
(6.5) 
[2-18] 
-11.91 (7) 
[2-21] 
-12.20 (5) 
[3-8] 
-12.22 (5) 
[3-9] 
2-21 
 
2,4,5-Triazole3-
one_4R 
1-Napthyl 
-7.53 
(536) 
[194-
1477] 
-7.28 
(688) 
[218-
2173] 
-7.76 
(426) 
[259–
703] 
-7.52 
(545) 
[292-
1016] 
194-
2173 
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2,5-Diazole_4R 
1-Napthyl 
-17.74 
(0.02) 
0.007-
0.1] 
-17.30 
(0.03) 
[0.01-0.1] 
-18.03 
(0.015) 
[0.009-
0.024] 
-17.68 
(0.02) 
[0.01-
0.04] 
0.007-
0.1 
 
2,5N-3-
Oxadiazole 
1-Napthyl 
-10.46 
(29) 
[10-79] 
-10.39 
(31) 
[10-97] 
-10.71 
(22) 
[14-37] 
-10.67 
(23) 
[12-43] 
10-97 
 
2S4N-
Thiazole_3R 
Phenyl -10.71 
(22) 
[8-62] 
-11.15 
(14) 
[5-46] 
-10.96 
(17) 
[11-29] 
-11.44 
(11) 
[6-20] 
5-62 
1-Napthyl -11.32 
(12) 
[4-33] 
-11.17 
(14) 
[4-45] 
-11.57 (9) 
[6-16] 
-11.46 
(11) 
[6-20] 
4-45 
2-Napthyl -11.81 
(7) 
[3-21] 
-11.78 (8) 
[2-24] 
-12.06 (6) 
[4-10] 
-12.07 (6) 
[3-11] 
2-24 
 
2,4-Diazole_3R 
Phenyl -12.71 
(3) 
[1-8] 
-13.22 (2) 
[1-6] 
-12.97 (2) 
[1-4] 
-13.55 (1) 
[0.7-2] 
0.7-8 
1-Napthyl -16.06 
(0.1) 
[0.04-
0.3] 
-15.95 
(0.1) 
[0.04-0.4] 
-16.33 
(0.08) 
[0.05-0.1] 
-16.31 
(0.08) 
[0.04-
0.15] 
0.04-
0.15 
2-Napthyl 
-15.34 
(0.2) 
[0.1-0.6] 
-15.31 
(0.2) 
[0.07-0.7] 
-15.62 
(0.17) 
[0.1-0.3] 
-15.67 
(0.16) 
[0.08-
0.29] 
0.07-
0.7 
 
2N30-
Isoxazole_4R 
Phenyl -9.43 
(81) 
[29-222] 
-9.71 (60) 
[19-191] 
-9.67 (63) 
[39-105] 
-9.98 (46) 
[25-86] 
19-222 
1-Napthyl -10.18 
(38) 
[14-105] 
-10.28 
(35) 
[11-111] 
-10.42 
(30) 
[18-49] 
-10.54 
(27) 
[14-50] 
11-111 
2-Napthyl -10.80 
(21) 
[7-56] 
-10.62 
(25) 
[8-77] 
-11.04 
(16) 
[10-26] 
-10.90 
(18) 
[10-34] 
7-77 
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2O3N_Oxazole_4
R 
Phenyl -10.03 
(44) 
[16-122] 
-10.49 
(28) 
[9-88] 
-10.27 
(35) 
[21-57] 
-10.77 
(21) 
[11-39] 
9-122 
1-Napthyl -10.11 
(41) 
[15-112] 
-10.11 
(41) 
[13-129] 
-10.35 
(32) 
[19-53] 
-10.38 
(31) 
[17-58] 
13-129 
2-Napthyl -10.97 
(17) 
[6-47] 
-9.82 (54) 
[17-171] 
-11.22 
(13) 
[8-22] 
-11.30 
(12) 
[7-23] 
6-171 
 
2O-4,5N-
Oxadiazole_3R 
Phenyl -7.90 
(372) 
[135-
1023] 
-8.23 
(268) 
[95-845] 
-8.13 
(295) 
[179-487] 
-8.47 
(209) 
[112-390] 
95-
1023 
1-Napthyl -9.88 
(51) 
[19-141] 
-9.85 (53) 
[17-167] 
-10.13 
(40) 
[24-66] 
-10.12 
(40) 
[22-75] 
17-167 
 
3S5N-
Thiazole_4R 
Phenyl -7.59 
(508) 
[184-
1399] 
-7.99 
(340) 
[108-
1074] 
-7.81 
(404) 
[245 -
666] 
-8.23 
(267) 
[143-497] 
108-
1399 
1-Napthyl -9.89 
(51) 
[18-140] 
-9.62 (66) 
[21-209] 
-10.14 
(40) 
[24-65] 
-9.89 (51) 
[27-94] 
18-209 
2-Napthyl -8.62 
(180) 
[65 – 
496] 
-8.81 
(149) 
[47-470] 
-8.86 
(142) 
[86-235] 
-9.07 
(115) 
[62-215] 
47-496 
 
Ar-2,3,4,5-
Tetrazole_Glc-4R 
Phenyl -9.07 
(115) 
[42-318] 
-9.47 (77) 
[24-244] 
-9.31 (91) 
[55-150] 
-9.73 (59) 
[32-110] 
24-318 
1-Napthyl -10.73 
(22) 
[8-61] 
-10.87 
(19) 
[6-60] 
-10.98 
(17) 
[10-28] 
-11.15 
(14) 
[8-27] 
6-61 
2-Napthyl -10.52 
(27) 
[10-74] 
-10.48 
(28) 
[9-88] 
-10.77 
(21) 
[13 – 35] 
-10.77 
(21) 
[11-39] 
9-88 
 
GlucoPyrrole_4R 
Phenyl -9.70 
(61) 
[22-169] 
-10.23 
(36) 
[11-114] 
-9.94 (48) 
[29-79] 
-10.51 
(27) 
[15-51] 
11-169 
1-Napthyl -10.58 
(26) 
[9-70] 
-10.60 
(25) 
[8-79] 
-10.82 
(20) 
[12-40] 
-10.88 
(19) 
[10-35] 
8-79 
2-Napthyl -10.98 
(17) 
[6-47] 
-11.07 
(16) 
[5-49] 
-11.23 
(13) 
[8-22] 
-11.35 
(12) 
[6-22] 
5-49 
a Models as per Table 4.17 with the range for Ki values including RMSE given in square parentheses.  
bNI = No inhibition. Poses not generated for these structures. 
 
77 | P a g e  
The four models used gave quite similar ln Ki predictions and a range incorporating 
the RMSE values was generated for each ligand. The ligand that was predicted to 
be the most potent biological inhibitor of GP was 2,5-diazole with a 1-napthyl 
substituent (Figure 4.8), which had a predicted Ki range of 0.007-0.1 µM. The 
position of the NH of this ligand heterocycle has the ability to form a favourable H-
bond interaction with the His377 backbone and the heterocycle can also form 
interactions with Asp283 backbone O. The 2,4-diazole heterocycle was also 
predicted to be efficient with predicted Ki’s for phenyl of 0.7-8 µM, 1-napthyl 0.04-
0.15 µM and 2-napthyl of 0.07-0.7 µM (Figure 4.8). This ligand also has the ability 
to form favourable H-bond interactions with His377 (3.58 Å), but primarily with 
Asp283 (2.88 Å for Model 3). 2,3-Diazole with the 2-napthyl substituent (2-21 µM) 
has been predicted to be a good inhibitor and can again form favourable H-bond 
interactions with His377. Although thiazoles usually show relatively poor inhibition 
of GPb (Table 4.1), 2S4N-thiazole with the phenyl (5-62 µM), 1-napthyl (4-45 µM) 
and 2-napthyl substituent (2-24 µM) is predicted to be relatively potent µM inhibitors, 
further analysis shows the potential of the heterocycle to form a favourable H-bond 
with Asn284 NH, which could contribute to the low micromolar inhibition. 
Glucopyrrole with the 1-napthyl (8-79 µM) and 2-napthyl substituent (5-49 µM) also 
shows predicted low micromolar inhibition of GP, this ligand also having the ability 
to form a H-bond with His377. Other ligands that have been predicted to show low 
micromolar inhibition of GP include; 2,3,4,5-tetrazole with the 1-napthyl (6-62 µM) 
and 2-napthyl substituents (8-90 µM), 2,3,4-triazole with the 2-napthyl substituent 
(7-71 µM), 2,5N-3O-oxodiazole with the 1-napthyl substituent (10-97 µM), 2N3O-
isoxazole with the 2-napthyl substituent (7-77 µM), 203N-oxazole with the phenyl (9-
122 µM) and 2-napthyl substituent (6-171 µM). 
 
 
78 | P a g e  
 
Figure 4.8. - Predicted binding pose of 2,5-Diazole using model 3. 
 
Figure 4.9. - Predicted binding pose of 2,4-Diazole using model 3. 
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4.5 Conclusion.  
Computational drug design has many important and useful applications and gives 
information regarding the inhibition of GP for the treatment of T2D. By controlling 
many of the different parameters that effect ligand-protein binding, including 
exploration of solvation effects, atomic constraints of the glucose core and it’s 
adjoined hydrogen atoms as well as the exploration of the two varying catalytic site 
structures based on residues Asn282, Asp283, Asn284 and Phe285, we were able 
to see how these different factors contribute to the binding of potential inhibitors at 
the GPb catalytic site. Firstly, solvation of the enzyme using the cluster waters 
algorithm using a cut-off distance of 0.5 Angstroms revealed that over 100 explicit 
water molecules were found in common across relevant solved GP-inhibitor 
complexes and 5-7 common waters in the catalytic site. In general, the correlations 
achieved for both Glide-SP, -XP and post-docking Prime MM-GBSA are better with 
a receptor containing no water molecules. Overall, the atomic constraints applied to 
the glucose analogues on the glucose ring itself and the hydrogen atoms on the 
hydroxyl groups of glucose produced experimentally consistent poses like that of 
known ligands in the protein complex with only a few exceptions.  The different 
residue orientations displayed interesting features when binding. Docking 
calculations to the ClusterResidueOut receptor performed worse in general than 
the other receptors, indicating that there may be a crucial interactions for favourable 
binding with the Asn284 residue, which points away from the catalytic site in this 
orientation. However, this same protein conformation outperforms the others when 
the receptor has 5 Å flexibility; here, the receptor has the ability to adopt a geometry 
similar to those in the more common receptors. The GeneralClusterProtein and 
the ClusterResidueIn featured the same residue orientation and correlations 
achieved for Prime MM-GBSA post-docking are impressive and similar, with the 
GeneralClusterProtein achieving a slightly higher correlation demonstrating that 
the more common orientation found across the 10 proteins (Code: 5JTU, 5JTT, 
3G2I, 3G2K, 1XL0, 1XL1, 5LRC, 5LRF, 5LRE and 5LRD) contribute to a better 
correlation. A comprehensive statistical evaluation of the relationship between 
predicted and experimental activities (ln Ki) was performed for all four models 
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generated from the GeneralClusterProtein. The predictive capabilities of these 
models are significant and give excellent statistical values which provide 
considerable insight into the inhibitory potential of the unknown compounds. This is 
the first time that an MM-GBSA model(s) has been demonstrated to show such 
predictive capability for the GPb catalytic site. Applying the statistical models 
indicate that some unknown ligands have low micromolar/nanomolar inhibition such 
as 2,5-diazole with the 1-napthyl substituent (0.007-0.1 µM) as well as 2,4-diazole 
the phenyl (0.7-8 µM), 1-napthyl (0.04-0.15 µM) and 2-napthyl substituents (0.07-
0.7 µM). These compounds are therefore worthy of future synthesis and in vitro 
kinetics experiments. 
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Chapter 5 - Synthetic Methods 
5.1 Introduction 
 
Figure 5.1 – Binding of the flavone chrysin at the GP inhibitor site (PDB code: 3EBO). A sandwich 
type complex has formed with chrysin in between residues Phe285 and Tyr613 which exploit π-π 
stacking interactions and a number of water bridging (blue) interactions.[59] 
The flavone nucleus is an important scaffold, since both natural and synthetic 
derivatives draw a large variety of biological and pharmacological activities; 
including antitumor, anti-inflammatory, antiviral and antioxidant properties.[111] 
Interest in flavonoids as a potential treatment for T2D is growing, with some 
flavonoids. such as chrysin, inhibiting GP by binding to the caffeine binding site, 
found at the surface of GP roughly 12 Å from the catalytic site.[68] Interactions are 
made through the flavone skeleton as the A & C rings are able to form π-π stacking 
with the two aromatic residues within the inhibitor site: Phe285 and Tyr613 (Figure 
5.1). Binding at this site leads to stabilisation of the T-state conformation (section 
2.6), blocking access to the catalytic site. Previous computational screening 
performed by Chetter. B. et al [110] has predicted that a subgroup of flavonoids known 
as flavones can bind to the inhibitor site with some efficacy. The previous 
computational screening performed ranked a series of 5,7-dihydroxy flavones based 
on their expected performance, with the only difference being the substituents of the 
82 | P a g e  
B ring (Figure 5.2). In this project, attempts will be made to synthesise a number of 
these flavones which are predicted to bind at the inhibitor site. Future kinetic studies 
will determine whether these compounds are biologically active.  
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Figure 5.2 - Basic backbone structure of flavone, showing the hydroxyl groups at the 5 and 7 
position. 
Many synthetic methods exist to synthesize these phenolic structures whilst keeping 
the hydroxyl group at the 5 and 7 position intact (Figure 5.2). Most procedures start 
with the A and B ring, joined by a carbon chain, then cyclized into the C ring. This 
section explores the different methods of synthesizing flavones.  
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5.2 Baker-Venkataraman Rearrangement. 
    Enolate
(Formation)
43
21
Baker-Venkataraman
rearrangement
 
Scheme 5.1 – The mechanism involved in the Baker-Venkataraman rearrangement. 
One of the most commonly used methods to obtain flavones involves the cyclization 
of 1, 3-diphenylpropane-1,3-diones or 2’-hydroxychalcones which are prepared from 
2’hydroxyacetophenone (5) and benzoylating agents (6) or benzaldehydes. 
Exploited numerous times in the preparation of flavones, the Baker-Venkataraman 
Rearrangement (BVR) has been shown to be effective in the preparation of 
flavones.[112, 113] 2’-Hydroxyacetophenones are converted into benzoyl esters, (7) 
and the BVR is used under basic conditions to form 1, 3-diphenylpropane-1, 3-
diones (8) which, following cyclization with sodium acetate or sulphuric acid in acetic 
acid, yield the flavones (9).  Further steps can be added in the synthesis for more 
diverse compounds; for instance, demethylation (10), (Scheme 5.1) oxidation or 
reduction.  The next method of synthesis looks at forming the same β-diketone 
intermediate structure without exploiting the Baker-Venkataraman rearrangement.  
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Scheme 5.2 – A general method of synthesizing 5,7-dihydroxyflavone exploiting the Baker-
Venkataraman rearrangement. 
5.2.1 β-diketone cyclization 
Tricin, a 5,7-dihydroxyflavone derivative was prepared by M. Ninomiya, et al[114] with 
a reasonable yield of 68%. The synthesis involved the condensation reaction of 4-
O-tert-butyldimethylsilyl-3,5-dimethoxy-benzoate (11) and 1.5 equivalents 2’,4’-O-
bis(tert-butyldimethylsilyl)-6’-hydroxyacetophenone (12) using 8 equivalents of 
lithium bis(trimethylsilyl)amide (LiHMDS) in THF at -78°C raised to room 
temperature over 3 days to form the β-diketone (13) as a mixture of tautomers. 
These were subjected to acid cyclodehydration and deprotection with 0.5% H2SO4 
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in acetic acid at 100°C overnight to yield tricin (14). The next method of synthesis 
will explore the use of a microwave assisted synthesis, known for an efficient, 
‘greener’ synthesis. 
 
Scheme 5.3 – Synthesis of tricin (14) through using a β-diketone intermediate. 
5.3 Microwave Synthesis  
Synthesis following a β-diketone pathway is the most commonly used method of 
synthesis for flavone derivatives, but an extremely efficient synthesis has been found 
using microwave radiation of similar β-diketones; which has numerous advantages 
over thermal methods. Microwaves provide high efficiency of heating, low operating 
costs, purity in final product, reduction in unwanted side reactions and often a 
reduced use of solvents.[115] 
Kabalka. G.W, et al reported achieving impressive yields of over 90% for numerous 
flavone derivatives using a microwave-assisted synthesis.[116] This method of 
microwave synthesis involves irradiation of a 1,3-diketone to yield the desired 
LiHMDS
THF
-78C - RT
H2SO4
CH3COOH
11 12 13
14
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flavone. To the reaction 0.1 mmol CuCl2 and 1.0 mmol of the 1,3-diketone in 3ml of 
ethanol was subjected to microwave irradiation at 80°C at 100W for 5 minutes. The 
product was separated and purified using flash column chromatography. A solvent 
free microwave method (Scheme 5.3) was investigated by Seijas. J.A, et al achieved 
by irridation of phloroglucinol (16) and β-ketoesters (15),[117] such as ethyl 
benzoylacetate as opposed to the benzoyl chloride and o-hydroxyacetophenone. 
Due to the solvent free synthesis, a substantially more powerful microwave was 
used, heating to 240°C at 800W with irridation times ranging from 3-12 minutes.  
15 16 10
μW
 
Scheme 5.4 – Flavone synthesis using highly the efficient Microwave synthesis. 
Solvent free microwave syntheses are highly efficient as well as safer, as there are 
no harmful solvents, acids or bases associated with this synthesis method. High 
yields can be achieved, with Seijas. J.A, et al achieving yields of 96% when 
synthesising chrysin (10).[117]  Microwave synthesis is often a fast process, with some 
reactions taking several minutes as opposed to some thermal methods taking 
several hours, making for a more energy efficient process. The next synthetic 
pathway looks at the rearrangement of 2’-methoxyflavones under drastic conditions 
to give diverse structures. 
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5.4 Demethylation rearrangement 
Rearrangement reactions are used extensively in organic chemistry as formation of 
the desired structural isomer may be difficult to achieve using other synthetic 
methods. 
17
18
2019
Scheme 5.5 – Rearrangement of 2’-methoxyflavones upon demethylation. 
Gallagher. K, et al found that certain 2’-methoxyflavones are rearranged during 
demethylation (Scheme 5.5) by hydroiodic acid under sufficiently drastic conditions 
to give the related 2’-hydroxyflavones in which the 2-phenyl group (B-ring) and the 
fused aromatic ring (A-ring) of the original flavone are interchanged.[118] Their 
suggestion is that an intermediate disalicyloylmethane (19) occurs in the 
rearrangement. Both 5,8,2’-trimethoxyflavone (17) and the 2’,3’,6’-isomer (18) give 
5,6,2’-trihydroxyflavone (20) on treatment with hydroiodic acid. 
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232221
Scheme 5.6 – The general scheme showing the 2-phenyl group and the fused aromatic ring 
interchanging upon demethylation [119] 
Table 5.1 – Table showing the different products forming from demethylation of (21) 
Reactant (21) Product (22) 
Name R R’ R’’ Name R R’ R’’ 
2’:5’-
Dimethoxyflavone 
H OMe H 6’:2’-
Dihydroxyflavone 
H OH H 
2’:4’-
Dimethoxyflavone 
OMe H H 2’:4’-
Dihydroxyflavone 
OH H H 
2’:6’-
Dimethoxyflavone 
H H OMe 2’:6’-
Dihydroxyflavone 
H H OH 
2’:4’:6’-
Trimethoxyflavone 
OMe H OMe 2’:4’:6’-
Trihydroxyflavone 
OH H OH 
 
2-Methoxyflavones corresponding to (21) were prepared for demethylation 
experiments from the Baker-Venkataraman method from the appropriate o-
aroylacetophenones with satisfactory yields which were demethylated with 
hydroiodic acid under suitable conditions to form the different compounds seen in 
Table 5.1. 
All previous methods explored in this chapter have exploited the use of a β-diketone 
intermediate, the next method of synthesis involves the cyclisation of the less 
commonly used single ketone intermediate to yield flavones. 
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5.5 Single Ketone synthesis 
Reaction pathways involving single ketone groups as an intermediate have been 
observed in the synthesis of flavones. The single ketones are derivatives of 
2’hydroxychalcone (24) (Figure 5.3) or 1-(2-hydroxyphenyl)-3-phenyl-2-propenone 
(25) (Figure 5.4) and these structures are able to undergo cyclocondensation, which 
forms the C ring of the flavone. 
24   25                                                 
Figure 5.3 - 2’-hydroxychalcone   Figure 5.4 - 1-(2-hydroxyphenyl)-3-phenyl-2-propenone 
Both of these compounds are usually prepared under basic conditions. The 
synthesis of 2’hydroxychalcone (24) was achieved by Sashidhara. K.V, et al;[120] 
through the reaction of salicylaldehyde (26) and acetophenone (27) with 10% aq. 
potassium hydroxide and ethanol at reflux via the Claisen-Schmidt condensation, a 
variation of the aldol condensation.  
26 27 24
KOH/Ethanol
reflux
 
Scheme 5.7 – Synthesis of 2’-hydroxychalcone 
1-(2-hdroxyphenyl)-3-phenyl-2-propenone (25) was prepared by Zambare. A.S, et 
al using sodium hydroxide in ethanol at 15-20°C in an aldol condensation as seen 
in Scheme 5.8 .[121] 
 
90 | P a g e  
2528 29
NaOH/Ethanol
15-20°C
 
Scheme 5.8 – Synthesis of 1-(2-hydroxyphenyl)-3-phenyl-2-propenone 
The cyclocondensation of 2’-hydroxychalcone (24) was investigated by Sashidhara. 
K.V, et al with the use of different catalysts and solvents. Many catalysts were 
explored, as well as the time under reflux (Table 5.2).[120] 
Table 5.2 – Table showing the use of different catalysts including reaction time and the effect this 
has on the yield in synthesising 4-methoxyflavone from (26).[120] 
26 27
Catalyst, reflux
time
 
Entry Catalyst Time (h) Yield (%) 
1 Aluminium chloride 2.5 28 
2 Zinc chloride 3.0 10 
3 Boron trifluoride diethyl etherate 3.0 0 
4 Tin (II) chloride dehydrate 2.0 54 
5 Mercury (II) chloride 3.0 5 
6 Iron (III) chloride 3.0 5 
7 Tin (IV) chloride  3.0 0 
8 Iodine 1.5 74 
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It was reported that iodine as a catalyst gave the best results in terms of yield and 
reaction time for this reaction, reporting that the use of a 10 mol % of iodine was 
most favourable. Surprisingly, the solvent used had a large impact on the reaction 
and the absence solvent achieved the most impressive yield of 74% with the use of 
the iodine catalyst (Table 5.2). However, this is still not the highest yield reported 
thus far. 
Sashidhara. K.V, et al has suggested a mechanism using iodine as a catalyst. 
Intramolecular cyclisation results in a hemiacetal species (29), which gets converted 
to more reactive flavylium ion (30). Water molecules then attack on the more reactive 
3-position of (30) to form adduct (31), that on oxidation in the presence of iodine 
yields flavone (27).[120] 
 
Scheme 5.9 – The synthesis of 4’-methoxyflavone using an Iodine catalyst without the use 
of a solvent.  
 
 
-H2O
H2O
26
27
29 30
31
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Table 5.3 – Table showing the use of different solvents and the effect this has on yield in synthesising 
4-methoxyflavone from (26)[120] 
Entry Solvent Yield (%) 
1 1,4-Dioxane 56 
2 Acetonitrile 0 
3 Ethanol 33 
4 Methanol 12 
5 Tetrahydrofuran 15 
6 Dimethyl sulfoxide 20 
7 Neat 74 
 
H. Kumar, et al [122] found that using iron (III) chloride hexahydrate (FeCl3.6H2O) in 
methanol at reflux was a viable procedure for the cyclocondensation of 1-(2-
hydroxyphenyl)-3-phenyl-2-propenone (25) to form a flavone (32) (Scheme 5.10), 
ethanol was also found to be an effective solvent, but this synthesis seems to be 
unsuccessful in non-alcohol solvents (dimethylformamide (DMF), 
dimethylsulphoxide (DMSO), tetrahydrofuran (THF), toluene and ethyl acetate). 
FeCl3.6H2O in methanol acquired a 55% yield, with a reaction time of 10 hours and 
in comparison, this method is therefore less efficient than others previously 
discussed.   
25 32
FeCl3.6H2O
methanol
 
Scheme 5.10 – cyclocondensation of 1-(2-hydroxyphenyl)-3-phenyl-2-propenone to give (32) as a 
product. 
Formation of the C ring using ethanol has been observed repeatedly; Zambare. A, 
et al[121] have used 10 mol% oxalic acid in ethanol to give the cyclised flavone (32) 
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with reported yields of 95% over 6 hours. Methanol with 10 mol% oxalic acid was 
also used to give the cyclised flavone to give slightly less yields of 92% after 6.5 
hours, therefore validating the aforementioned solvent choice in this reaction.[122] 
Using oxalic acid as a catalyst allowed for a wider range of solvents to be used, 
unlike the iron (III) chloride hexahydrate route; acetonitrile over 12 hours gave an 
85% yield and THF over 10 hours gave an 88% yield. The oxalic acid method is 
therefore more efficient than that of the iron (III) chloride procedure. Both of these 
methods are both less favourable than that of the greener microwave assisted 
methods mentioned earlier.  
KOH EtOH, H2O
HBr
AcOH
33
36
34
35
V2O5, H2O2, NH4Br
CH2Cl2   0-5°C
 
Scheme 5.11 – The synthesis of 8’-bromochrysin from 2’-hydroxy-4’,6’-dimethoxychalcone. 
Khan. A, et al observed the synthesis of the cyclised product with the use of 
ammonium bromide and vanadium pentoxide with hydrogen peroxide. This method 
achieved a modest yield of 62%; this method is therefore more inefficient in 
comparison to other aforementioned methods, and also introduces a bromine at the 
8-position of the A-ring (34), which required further synthetic manipulation to 
remove, such as exploiting a Pt(III) surface for hydro-debromination.[123] 
Demethylation of the methoxy groups to yield the corresponding hydroxyl groups 
must also be performed via the use of HBr with AcOH at reflux for 24 hours, as 
reported by Yenjai. C, et al [124] whom achieved a 95% yield using such an approach. 
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Scheme 5.12 – Method of synthesizing flavones with the use of protecting groups.                                                             
Mavel. S, et al synthesised a series of 5,7-dihydroxyflavone derivatives via an enone 
intermediate (Scheme 5.12).[125] The trihydroxyacetophenone (36) we protected in a 
step-wise manner using methoxymethyl (MOM) chloride and K2CO3, the third 
addition of the MOM group required the addition of a stronger base, NaOH, and the 
phase transfer catalyst tetrabutyl ammonium chloride. MOM-ether protected 
hydroxyacetophenone (28) was then transformed into the chalcone derivative (39) 
through a base-catalysed condensation with benzaldehyde (29). Hydrolysis of 
MOM-protected groups were performed with dilute HCl in methanol followed by 
cyclization (40) with solid sodium acetate under reflux. Oxidation of the crude 
intermediate with iodine in pyridine led to the target flavones (10). 
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5.6 Metal Catalysed Synthesis.  
6-endo-trig cyclisation
41
44
42 43
47
4645
LnPd(0)
base
R''R'''NH
6-endo-dig cyclisation
Scheme 5.13 – The synthesis of flavones with the use of a palladium catalyst. 
The use of a palladium-based catalyst has been explored to synthesise flavone-type 
compounds. For example, Miao. H, et al achieved high yields under basic conditions 
under a carbon monoxide atmosphere.[126] This catalytic approach starts with 
iodophenol (41), which undergoes an oxidative addition to form the organometallic 
intermediate complex (42) (Scheme 5.13). Carbon monoxide is then inserted to give 
the carbon monoxide insertion product (43); the desired R group is then introduced, 
with base, attached to an alkyne carbon-carbon triple bond (44). For the synthesis 
of flavones, the R group must be aromatic. This compound can then undergo a 6-
endo-dig cyclisation which is a direct path to form the desired flavone (47). 
Alternatively, the former compound can undergo a Michael addition, to apply the 
diethylamine (NR’’R’’’) group, forming alkene (45); this compound can then undergo 
a 6-endo-trig cyclisation (46) which then rearranges to form the desired flavone. The 
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drawback of this method lies with the possibility of compound (44) to rearrange to 
form a palladium compound. This issue was resolved by Torii and Kalinin using an 
excess of diethylamine to form (45). The conditions required for this reaction require 
heating the reaction to 120°C under a pressure of 20kg/cm2, which is impractical 
with regards to previously the previously aforementioned methods.  
5.7 Conclusion 
T2D is a widespread illness affecting millions of people worldwide. Flavones present 
themselves as potentially promising treatment of T2D through inhibition of the GP 
caffeine binding site. Synthetic methods presented in this chapter all represent 
viable options available for the synthesis of flavones, and can be used for the 
synthesis of chrysin and other 5,7-dihydroxy flavone  analogues. However, synthesis 
using the Baker-Venkataraman rearrangement is well understood and can be used 
to yield diverse flavone structures that have undergone previous computational 
screening by a collaborator and are predicted to be potentially active against the 
caffeine binding site. Kinetic experiments can be performed on the synthesised 
compounds to determine their activity against GP. These kinetic results can then 
influence future drug design as structure activity relationships can be used to closely 
refine and then predict future ligands for synthesis which aim for greater biological 
activity. 
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Chapter 6 – Synthetic Results 
6.1 - Introduction  
Type 2 diabetes (T2D) is a chronic illness that is becoming more prevalent, with a 
significant increase of those diagnosed with diabetes from 1980 to 2016, rising from 
108 million to approximately 420 million people worldwide; this is predicted to rise to 
above 640 million by the year 2040 at the current rate.[3] Multiple adverse health 
effects arise from T2D and sufferers are at a higher risk of developing other health 
complications as a direct result, which could otherwise be avoidable; such as angina, 
cardiac failure, strokes retinopathy, renal replacement therapy and amputations.[127] 
Diabetes mellitus is characterized by high levels of glucose in the bloodstream 
(hyperglycemia), peripheral insulin resistance and low insulin production in the 
pancreas.[128] Glycogen Phosphorylase (GP) has been identified as a key enzyme 
in T2D, as it catalyses the first step in the intracellular degradation of glycogen to 
give α-D-glucose-1-phosphate (G-1-P), via the glycogenolysis pathway, shown in 
Figure 6.1. Inhibition of this enzyme will therefore reduce glucose production, 
making it a promising target for T2D treatment. Studies in both diabetic and non-
diabetic rats have shown that flavonoids have anti-hyperglycemic properties as they 
inhibit glycogen metabolism and are known to bind at multiple sites on GP (c.f. 
Chapter 2.6-2.8).[129, 130]  
 
Glycogen
Glycogen
Phosphorylase
+cAMP
Debranching Enzyme
Glucose
1-Phosphate Phosphoglucomutase
Mg2+
Glucose
6-Phosphate
Pi
Glucose
6-phosphatase
Glucose
Inhibition here prevents
downstream glucose production
Figure 6.1 – The glycogenolysis pathway.[131] 
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Figure 6.2 – The basic structure of a flavone. Hydroxyl substituents are shown at the 5 and 7 
position. 
Many synthetic pathways have been reported for the synthesis of flavonoids; The 
focus on this work are a group of flavonoids known as flavones and the possible 
biological effect of different substituents on the B ring may have on GP at the caffeine 
binding site. There are many synthetic routes and methods available which can yield 
the flavone structure with the desired substituents on the B. For GP inhibition, 
hydroxyl groups on the 5 and 7 position of the A ring are required to increase 
bioavailability (Figure 6.2), and as such, synthetic routes must be followed which 
allow for the protection of the hydroxyl groups in order to stop undesired products 
from forming. Chetter. B, reported an efficient synthetic method (Scheme 6.1),[110] 
capable of producing diverse 5’,7-dihydroxy flavones in relatively high yields with the 
use of 2’-hydroxy-4’,6’-dimethoxyacetophenone as a starting material, which allows 
for reactions of the lone hydroxyl group, whilst leaving the methoxy groups intact, 
which can later be removed, yielding the di-hydroxyl compound. 2’-Hydroxy-4’,6’-
dimethoxyacetophenone is reacted with a benzoyl chloride, with varying 
substituents in an esterification mechanism, followed by the Baker-Venkataraman 
rearrangement; the resultant product is then cyclised and then the methoxy groups 
removed to form hydroxyl groups at the 5 and 7 position. 
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Scheme 6.1 – The method used to synthesise a number of 5’,7’-dihydroxy flavones. 
The method outlined above was used to synthesise a number of flavone analogues 
(see R-groups) as these compounds were predicted through previous computational 
screening to show inhibitory potential against GP (Section 5.1), however, there were 
limits found with this method when synthesising certain derivatives, and as a result, 
other synthetic methods were explored further on which are explained later in this 
chapter.    
 
 
R = 4’-Br 
       3’-F 
       3’-Cl, 4’-F 
       3’-Br, 4’-F 
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6.2 Attempted Synthesis of 2-(4-bromophenyl)-5’,7’-dihydroxy-
chromen-4-one 
5 48 49
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Scheme 6.2– The method used to synthesise 2-(4-bromophenyl)-5’,7’-dihydroxy-chromen-4-one 
This reaction followed the synthetic pathway mentioned in Scheme 6.1 The ester 
was formed using 2-hydroxy,-4’6’-dimethoxyacetophenone (5) which was added to 
1.1 equivalents of 4-bromobenzoyl chloride (48) in a mixture of dichloromethane 
(DCM), 4-dimethylaminopyridine (4-DMAP) and trimethylamine (TEA), this was 
stirred under a nitrogen atmosphere at room temperature until the reaction was 
determined complete by TLC. The product was acidified with hydrochloric acid (HCl). 
The organic layer was washed with distilled water and brine then dried (MgSO4) and 
isolated in vacuo leaving a pale yellow solid. The Baker-Venkataraman 
rearrangement was then performed with equivalent amounts of sodium hydride 
(NaH) in tetrahydrofuran (THF), which was refluxed until deemed complete by TLC. 
This was extracted with ethyl acetate (EtOAc) and washed with HCl, water and brine 
then isolated in vacuo to yield a yellow solid. This was then cyclised using (sulphuric 
acid) H2SO4 in acetic acid (CH3COOH), heated at reflux for 15 hours until 
completion, as determined by TLC. This was poured over an ice/water slurry, and 
vacuum filtration was used to collect a pale yellow solid. The demethylation was 
performed with hydrobromic acid (HBr) which was heated at reflux for 40 hours until 
completion, as determined by TLC. This was poured over an ice/water slurry, and 
vacuum filtration was used to collect the desired compound as a yellow solid 
obtaining a 25% yield (49), which was washed with water. 
101 | P a g e  
6.3 Attempted Synthesis of 2-(3-fluorophenyl)-5’,7’-dihydroxy-
chromen-4-one. 
5 51 52
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Scheme 6.3 – The method used to synthesise 2-(3-fluorophenyl)-5’,7’-dihydroxy-chromen-4-one. 
The same pathway that was highlighted in Scheme 6.1 was also used to synthesise 
the meta-para flavone analogue, using the same reagents with the exception of the 
benzoyl chloride; where 1.1 equivalents of 3-fluorobenzoyl chloride (51) was used 
in the esterification step instead. The Baker-Venkataraman step was performed with 
an equivalent amount of NaH in anhydrous THF heated at reflux until completion, as 
determined by TLC. This was then acidified with HCl and extracted with EtOAc, 
washed with water and brine and then dried (MgSO4). This was then isolated in 
vacuo to yield a brown crystalline solid. The cyclisation step performed with H2SO4 
and CH3COOH yielded a crude product which was recrystallized from hot ethanol to 
yield the desired compound. The demethylation step using HBr and CH3COOH also 
required less time to reach completion, and after 20 hours, the reaction was 
determined complete by TLC. The reaction was neutralised with NaOH an extracted 
with EtOAc, washed with water and brine, and isolated in vacuo to yield a brown 
crystalline solid as pure compound with an overall yield of 22%. (52). 
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6.4 Attempted Synthesis of 2-(3-chloro-4-fluoro-phenyl)-5’,7’-
dihydroxy-chromen-4-one 
53 54 55
DMF
DCM
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Scheme 6.4 – The method used to synthesise 2-(3-chloro-4-fluoro-phenyl)-5’,7’-dihydroxy-chromen-
4-one 
The method used to synthesise the 3’-chloro,4’-fluoro analogue (56) was the same 
as mentioned previously in (Scheme 6.1) with the exception of the first step, where 
the acid (53) had to be transformed into the corresponding acyl chloride (55) using 
1.1 equivalents of oxalyl chloride (54) and 2 drops of dimethylformamide (DMF) in 
DCM until completion, as determined by TLC. The product was isolated in vacuo to 
yield a viscous yellow oil (55). The esterification step was performed with 1.1 
equivalents of the benzoyl chloride, and after 24 hours, there was still presence of 
(5) and so flash column chromatography was to isolate the ester as a pale brown 
crystalline solid. The Baker-Venkataraman step was again performed with 
equivalent amounts of NaH in anhydrous THF and heated at reflux until completion, 
as determined by TLC. The solution was acidified using HCl, and vacuum filtration 
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was used to collect an orange crystalline solid. The cyclisation step was performed 
using an excess of H2SO4 in CH3COOH heated at reflux until completion, and poured 
over an ice/water slurry, then vacuum filtration was used to collect a pale brown 
crystalline solid which was purified using flash column chromatography 
Demethylation was achieved using an excess of HBr in CH3COOH heated at reflux 
for 30 hours until completion, as determined by TLC. This was poured over an 
ice/water slurry and then vacuum filtration was used to collect a brown crystalline 
solid as pure product with an overall yield of 6%. (56). 
6.5 Attempted Synthesis of 2-(3-bromo-4-fluoro-phenyl)-5’,7’-
dihydroxy-chromen-4-one 
57 54 58
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Scheme 6.5 – The method used to synthesise 2-(3-bromo-4-fluoro-phenyl)-5’,7’-dihydroxy-chromen-
4-one. 
The method used to synthesise the 3’-bromo,4’-fluoro analogue (59) was the same 
as mentioned previously in Scheme 6.1, however, the acid (57) again had to be 
transformed into the corresponding acyl chloride (58) with the use of 1.1 equivalents 
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of oxalyl chloride (54), along with 2 drops of DMF in DCM, which were allowed to 
react until completion, as determined by TLC. The esterification was achieved with 
the use of 1.1 equivalents of the benzoyl chloride, as well as 4-DMAP, TEA and 
DCM which were allowed to react until completion and then purified using flash 
column chromatography, yielding pale yellow crystals. The Baker-Venkataraman 
rearrangement was achieved with equivalent amounts of NaH in anhydrous THF, 
heated at reflux for 20 hours until completion, as determined by TLC. The solution 
was acidified with HCl and then collected using vacuum filtration to yield a yellow 
solid. The cyclisation step was performed with excess H2SO4 in CH3COOH, which 
was heated at reflux until completion, as determined by TLC. This was poured over 
an ice/water slurry and vacuum filtration was used to collect a pale brown crystalline 
solid. Demethylation was performed using an HBr in CH3COOH heated at reflux for 
40 hours until completion. This was poured over an ice/water slurry and then vacuum 
filtration was used to collect an orange crystalline solid with an overall yield of 8.5% 
(59).  
6.6 The method limitations 
Despite the successful synthesis of a number of flavone analogues using the 
described method (Scheme 6.1), there was a significant limitation encountered that 
had not been observed before, but which has subsequently been identified in a 2011 
publication after a careful literature search on the proposed structure.[132] When an 
o-chloro (or possibly any ortho-halogen) benzoyl chloride substituent was used to 
form the B-ring under the conditions of the general procedure, spectroscopic data 
such as 1H-NMR spectroscopy of the products formed from these reactions revealed 
peaks which are characteristic of extra aromatic hydrogens, as well as C-NMR 
showing peaks characteristic of extra aromatic carbons and an extra carbonyl peak. 
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Figure 6.3 – The structure of 3’-hydroxyflavone 
Chee. C.F, et al[132] observed the formation of 3-benzoyl flavones (Figure 6.3) during 
a one-pot synthesis which can occur during either the esterification or the Baker-
Venkataraman rearrangement in the presence of excess remaining benzoyl 
chloride. A mechanism was proposed be Chee. C.F, et al (Scheme 6.6); when 2’-
hydroxyacetophenone (60) was treated with benzoyl chloride and base, addition of 
the first equivalent of benzoyl chloride produces 2’-benzoylacetophenone (61). In 
the presence of a base, the enolate of the acetyl group is formed and attacks the 
carbonyl of the ester to give the hemiacetal (62), which presumably undergoes ring-
opening to give the β-diketone (64), the Baker-Venkataraman rearrangement 
product. In excess of benzoyl chloride, the phenolic group of the β-diketone 
undergoes esterification with another equivalent of benzoyl chloride to form 
benzoyloxydiketone (65). Rearrangement of the benzoyldiketone gives a triketone 
intermediate (66), which finally dehydrates upon cyclisation to produce the 3-benzoyl 
flavone (68) via a hemiacetal (67).[132]  
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Scheme 6.6 – The proposed mechanism of the formation of 3’-benzoylflavone 
Once the 3-benzoylflavone has formed along with the desired flavone, they are 
difficult to separate using recrystallisation or column chromatography as the 
polarities of the compounds are near identical. The formation of 3-benzoyl flavones 
were only observed when using o-chloro-benzoyl chlorides, showing that these 
substituents may have a higher affinity than other benzoyl chlorides in forming 3-
benzoyl flavones, which could be due to the electronic or steric effects of the 2-chloro 
substituent. Although the reaction pathways followed in this project are different to 
those performed by Chee, C.F et al, remaining benzoyl chloride that hasn’t been 
removed from the reaction may still undergo an esterification of the remaining 
alcohol group at the Baker-Venkataraman stage, and then rearrangement of the 
benzoyldiketone would ultimately lead to the formation of the 3-benzoyl flavone. 
Most synthetic attempts involving an ortho-chloro substituent don’t lead to the 
formation of the pure 3-benzoyl flavone but instead form a mixture of the desired 
flavone and the unwanted structure. Formation of pure 3-benzoyl flavone are 
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produced in relatively low yields, as it is with excess benzoyl chloride that these 
products can form. 
6.7 Attempted synthesis of 2-(5-bromo-2-chloro-phenyl)-5’,7’-
dihydroxy-chromen-4-one 
i. 4-DMAP, TEA, DCM
ii. NaH / THF
iii. H
2
SO
4
 / CH
3
COOH
iv. HBr / CH
3
COOH
69 5 70
71
Scheme 6.7 – The method used to synthesise 2-(5-bromo-2-chloro-phenyl)-5’,7’-dihydroxy-
chromen-4-one 
The synthesis of the 2’-chloro,5’-bromo flavone compound was adapted since, once 
again, the starting 2’-chloro-5’-bromo benzoyl chloride is only commercially available 
as a carboxylic acid and therefore must be activated as its acid chloride (69).  2’-
Chloro-5’-bromo benzoic acid was dissolved in DCM and stoichiometric amounts of 
oxalyl chloride was added followed by 2 drops of DMF. The reaction was performed 
at room temperature under a nitrogen atmosphere. Upon completion, the product 
was isolated in vacuo to yield a viscous yellow oil (69). 0.9 equivalents 2’-hydroxy-
4’,6’-methoxyacetophenone (5) was added in a mixture of DCM, 4-DMAP and TEA. 
The reaction was left until completion, as determined by TLC however a spot 
remained with similar rf values to 2’-chloro-5’-bromobenzoyl chloride which was 
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thought to be removable by the work-up. The organic layer was separated and 
washed, then concentrated under vacuum to leave a golden oil. LC-MS confirmed 
the presence of unreacted 2’-hydroxy-4’,6’-methoxyacetophenone (5) and so 
aqueous NaOH was added to wash impurities from the product and no further 
purification was performed. Equivalents amounts of NaH was added along with 
anhydrous THF as a solvent. The reaction was heated to 120°C and allowed to stir 
overnight. After 20 hours, the solution was acidified and vacuum filtration was used 
to obtain a pale yellow crystalline solid. An NMR of the crude product were 
performed, and peaks characteristic of β-diketone enol tautomerisation was 
observed. Cyclization was performed with an excess of H2SO4 was added along with 
CH3COOH. This was refluxed at reflux for 6 hours and poured over an ice/water to 
yield pale brown coloured crystals formed, which were collected through vacuum 
filtration. Demethylation was performed with excess HBr in CH3COOH, and this was 
allowed to react for 20 hours until completion, as determined by TLC. This was 
poured over an ice/water slurry to yield brown crystals. The first NMR performed 
was indicative of two compounds formed, and this was primarily thought to be the 
presence of partially demethylated product. A TLC was performed using a different 
solvent system (2:8 acetone:petroleum ether) and the presence of two compounds 
were confirmed. The demethylation step was repeated for a further 20 hours and a 
TLC using the same solvent system showed the presence of one compound. This 
was poured over an ice/water slurry to obtain a small amount of pale brown crystals 
with an overall yield of 11.5% (71).  
 
Figure 6.4 – The 3’-benzoylflavone structure formed from this reaction (71).   
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The H-NMR performed on this compound has an integration of 8H when the desired 
compound should integrate to 6H in the aromatic area. Identification of the desired 
flavone can be confirmed by a diagnostic H-NMR peak that typically appears at 
around 7ppm which indicates a hydrogen atom in the 3-position (Figure 6.4) 
adjacent to the ketone group; and this peak is no longer present when the 3’-benzoyl 
flavone forms. The C-NMR shows 22 carbon atoms, and the presence of two 
carbonyl groups, whereas the 5’,7’-dihydroxyflavone only contains 15 carbons. 
There are no methyl peaks present on both the carbon and the proton NMR and the 
presence of hydroxyl groups integrate to 1H showing that the product had fully 
demethylated. An LC-MS was performed which showed a mw of 582, indicative of 
the compound as well as the isotope pattern of  2Cl and 2Br atoms in a singular 
molecule owing to the different isotope ratios of 35Cl:37Cl and 79Br:81Br 
 
Figure 6.5 – 1H-NMR of 3-(5-bromo-2-chloro-benzoyl)-2-(5-bromo-2-chloro-phenyl)-5,7-dihydroxy-
chromen-4-one 
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6.8 Attempted synthesis of 2-(2-chlorophenyl)-5’,7’-dihydroxy-
chromen-4-one 
Three separate attempts were made to synthesize 2-chloroflavone, with two 
synthetic attempts forming the unwanted 3-benzoyl flavone in differing amounts 
when reacted under different conditions; including the base used in the esterification 
and the Baker-Venkataraman rearrangement, temperature and reaction time.   
                    
 O-Cl(a)      O-Cl(b) 
Figure 6.6 – The mixture of products formed in the attempted synthesis of 2-(2-chlorophenyl)-5,7-
dihydroxy-chromen-4-one 
Table 6.1 – Table showing the different conditions used in an attempt to synthesise 2-(2-
chlorophenyl)-5,7-dihydroxy-chromen-4-one 
 
6.8.1 First Attempt at Synthesis of 2-(2-chlorophenyl)-5’,7’-
dihydroxy-chromen-4-one 
Attempt one of the synthesis followed the general procedure (Scheme 6.1) with 2’-
hydroxy-4’,6’-methoxyacetophenone and 2’chlorobenzoyl chloride. This attempt 
involved the use of 4-DMAP and TEA as a base, at room temperature, for the 
Attempt 
Esterification 
Baker-Venkataraman 
rearrangement Ratio 
O-Cl(a) : O-
Cl(b) 
 
Base 
 
Temperature 
(°C) 
 
Base 
 
Temperature 
(°C) 
1 4-DMAP/TEA RT NaH/THF 120 1.5:8.5 
2 K2CO3 
H2O/Toluene 
60 C5H5N/KOH 120 
- 
3 K2CO3 
H2O/Toluene 
60 NaH/THF 110 4:1 
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esterification with 1.5 equivalents of the benzoyl chloride. These were allowed to 
react over 20 hours, forming an orange solution. TLC showed the formation of a new 
compound, but a second compound also persisted which was thought to be 
unreacted benzoyl chloride. The organic layer was washed and separated, then 
added to an equivalent amount of NaH and THF which was heated at reflux for 20 
hours; the mixture was acidified, then washed and separated forming a crystalline 
brown solid. The crystalline compound was then boiled in glacial acetic acid and 
sulphuric acid and refluxed for 19 hours, then poured onto an ice/water slurry to form 
a pale brown solid. TLC showed the presence of three compounds and so 
recrystallization from ethanol was performed leaving only a small amount of product. 
The product was then refluxed in hydrobromic acid and glacial acetic acid for 35 
hours, then poured onto an ice/water slurry to achieve a small yield of brown crystals. 
Analysis of this product showed that only the pure 3-benzoylflavone remained. 
 
Figure 6.7 – 1H-NMR of 3-(2-chlorobenzoyl)-2-(2-chlorophenyl)-5,7-dihydroxy-chromen-4-one 
1H NMR (300 MHz, DMSO-d6) δ 12.15 (s, 1H), 11.21 (s, 1H), 7.68 (dd, J = 1.6 Hz, 1H), 7.56 
– 7.30 (m, 7H), 6.47 (d, J = 2.1 Hz, 1H), 6.31 (d, J = 2.1 Hz, 1H). 
112 | P a g e  
6.8.2 Second Attempt at Synthesis of 2-(2-chlorophenyl)-5’,7’-
dihydroxy-chromen-4-one 
The second attempt followed the same general procedure (Scheme 6.1), with slight 
modifications on the reagents used using the same amount of 2’-hydroxy-4’,6’-
methoxyacetophenone with only 1.1 equivalents of  2’chlorobenzoyl chloride using 
potassium carbonate in H2O/toluene as a base for the esterification which was 
heated at 60°C and allowed to react until completion, as determined by TLC. The 
organic layer was separated, washed and isolated in vacuo. This was then added to 
an equivalent amount of pyridine and potassium hydroxide which was heated at 
reflux for 20 hours. TLC showed the presence of two compounds of which seemed 
to be 2’-chlorobenzoic acid and the 2’-hydroxy-4’,6’-methoxyacetophenone, which 
was likely due to hydrolysis of the ester. The solution was acidified, then washed 
and separated forming a crystalline brown solid. The presence of starting material 
was then confirmed using LC-MS and NMR.  
6.8.3 Third Attempt at Synthesis of 2-(2-chlorophenyl)-5’,7’-
dihydroxy-chromen-4-one 
As the esterification of the second attempt was a success, the same conditions were 
kept in the third synthetic attempt keeping the same moles of 2’-hydroxy-4’,6’-
methoxyacetophenone  with 1.1 equivalents of 2’chlorobenzoyl chloride; 
modifications were made to the BVR step whereby the aforementioned conditions 
and base used in attempt one were replicated. 2’-Hydroxy-4’,6’-
methoxyacetophenone and 2’-chlorobenzoyl chloride were added to potassium 
carbonate in H2O/toluene which was heated at 60°C and allowed to react until 
completion, as determined by TLC. The organic layer was separated, washed and 
isolated in vacuo forming a yellow oil; which solidified into pale yellow crystals when 
left in a desiccator. Equivalent amounts of NaH and THF were then added and 
heated at reflux for 20 hours to form an amber solution. TLC showed the formation 
of the new product as well as a faint spot indicative of a small amount of another 
compound which persisted. The organic layer was acidified, then washed and 
separated forming a crystalline brown solid. Crude NMR analysis confirmed 
production of the β-diketone. The compound was then heated at reflux in glacial 
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acetic acid and sulphuric acid for 4 hours, then poured onto an ice/water slurry to 
form a pale brown solid. TLC showed the formation of two compounds with r.f values 
on silica gel TLC plates near identical. 
 
 
Figure 6.8 – LC-MS showing the 1:1 ratio of OCl(a):OCl(b) 
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6.9 Attempted Synthesis of 5,7-dihydroxy-2-(2-
hydroxyphenyl)chromen-4-one 
x
DCM
4-DMAP, TEA
NaH
THF
110°C
5 72 73
74
755
Scheme 6.8 – The hydrolysis of (2-acetyl-3,5-dimethoxy-phenyl) 2-methoxybenzoate reforming 
starting materials. 
An attempt to synthesize 5,7-dihydroxy-2-(2-hydroxyphenyl)chromen-4-one was 
performed using the Baker-Venkataraman rearrangement route highlighted in 
Scheme 6.1. 2’-Hydroxy-4’,6’-dimethoxyacetophenone (5) was added to 1.1 
equivalents 2-methoxybenzoyl chloride (72) in a mixture of dichloromethane, 
triethylamine and 4-dimethylaminopyridine and stirred forming a slight yellow 
solution. The reaction was left until completion, as determined by TLC. The organic 
layer was separated and washed, then an equivalent amount of sodium hydride was 
added along with tetrahydrofuran and stirred at reflux in an attempt to form (74).  
Confusingly, TLC showed the formation of two products and further analysis showed 
to be hydrolysis products of the ester (5 & 75). Due to the lack of success with this 
synthetic attempt, a new synthetic route was approached and the use of anhydrous 
THF was used to minimize ester hydrolysis.  
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6.9.1 Second Attempted synthesis of (2-acetyl-3,5-dimethoxy-
phenyl) 2-methoxybenzoate 
i. 4-DMAP, TEA, DCM
DMF
ii. NaH / THF
iii. H
2
SO
4
 / CH
3
COOH
76 54 77
HI
Phenol
2877 78
79  
Scheme 6.9 – The method used to synthesise (2-acetyl-3,5-dimethoxy-phenyl) 2-methoxybenzoate 
The second attempt of synthesising 5,7-dihydroxy-2-(2-hydroxyphenyl)chromen-4-
one was performed using a method observed by Gallagher. K.M, et al,[119] who found 
that certain 2’-methoxyflavones rearrange during demethylation by hydroiodic acid 
under sufficiently drastic conditions, to give the related 2’-hydroxyflavones in which 
the B and the A ring of the original flavone are interchanged. The starting materials 
were adapted in order to form a compound which demethylated in order to form (79). 
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The reaction pathway followed for this reaction is similar to the one described in 
Scheme 6.1 with the exception of the demethylation step, whereby the reagents 
used are modified. 2’,4’,6’-Trimethoxybenzoic acid (76) was transformed into the 
corresponding benzoyl chloride (77) by the introduction of 1.1 equivalents of oxalyl 
chloride (54) in DCM followed by one drop of DMF and reacted until completion to 
form the corresponding benzoyl chloride. TLC showed the presence of two 
compounds, likely from unreacted acid (76) and the newly formed 2’,4’,6’-
trimethoxybenzoyl chloride (77). The esterification was performed with 1.1 
equivalents of 2’-hydroxyactetophenone (28) in a mixture of 4-DMAP, TEA and DCM 
and allowed to react for 20 hours, forming a yellow solution. TLC showed the 
presence of multiple compounds and so the organic layer was washed with aqueous 
NaOH to remove any of the unreacted acidic materials, followed by water and brine 
and no further purification was performed. The organic layer was then separated 
and isolated in vacuo leaving a viscous yellow oil (78). The ester was added to an 
equivalent amount of NaH in THF and heated at reflux for 20 hours forming an amber 
solution; this was acidified with HCl, forming a yellow crystalline powder which was 
collected using vacuum filtration. Flash column chromatography was performed on 
silica gel to isolate the product. This was then added to glacial acetic acid 
(CH3COOH) and sulphuric acid (H2SO4) and refluxed for 7 hours before being 
poured over an ice/water slurry, yielding a small amount of white crystalline material 
which was collected using vacuum filtration. This was then refluxed in a mixture of 
hydroiodic acid and phenol. This modification in the demethylation step forms the 
intermediate disalicyloylmethane (Figure 5.6), which undergoes a ring closure, with 
the A and B-rings interchanged. After 2 hours this was then poured onto an ice/water 
slurry, forming a small amount of white crystals (79), which were collected using 
vacuum filtration. 
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6.10 Conclusion 
The Baker-Venkatarman rearrangement has shown to be effective in the synthesis 
of multiple 5,7-dihydroxyflavones. The BVR route successfully lead to the synthesis 
of five flavone analogues, four of these containing halogen groups and one of these 
containing a hydroxyl group. Method limitations were discovered, however, when 
attempts were made to functionalise the B ring with a 2’-chloro substituent. This 
limitation lead to the formation of 3’-benzoylflavones with the desired flavone usually 
synthesised alongside. Two near pure 3’-benzoyl flavones have been synthesised 
in this study and confirmed using spectroscopic data. The synthesised compounds 
will be taken forward and undergo kinetic studies by our collaborators in Thessaly, 
Greece, to compare the previous computational results to the experimental results. 
The data gathered from these kinetic experiments can be used to refine a search for 
a more ideal ligand and more potent compounds could be found.  
6.11 Experimental 
Reactions were followed by analytical thin layer chromatography (TLC) using plastic-
backed TLC plates coated in silica G/UV254, run in a variety of solvent systems and 
visualized with a UV light at 254 nm, p-anisaldehyde stain and/or potassium 
permanganate stain. Commercially available solvents and reagents were purchased 
from Fisher, Sigma Aldrich, TCl and Fluorochem and were used without further 
purification unless specified in the syntheses. Flash column chromatography was 
carried out on Davisil silica 60 Å (40 -63µm) under bellows pressure. 1H and 13C 
NMR were carried out on a Brucker Fourier 300 (300 MHz). GCs were ran with DSQ 
II, Trace GC ultra, Triplus, trace1800 GC & ITQ700. LC-MS were ran with the 
Finnigan LCW Advantage Max, Finnigan PDA Plus detector. Infrared spectra were 
recorded on a solid sample using a Thermo Nicolet IR-200 FT-IR. 
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6.11.1 - 2-(4-Bromophenyl)-5’,7’-dihydroxy-chromen-4-one 
 
The general procedure was followed using 2’-Hydroxy-4’,6’-methoxyacetophenone 
(5) (1.5g, 7.6mmol) which was added to 4’-bromobenzoyl chloride (48) (1.85g, 
8.41mmol) dissolved in DCM (55mL), 4-DMAP (0.065g) and TEA (1.75mL) was 
added and the reaction was allowed to stir for 24 hours under a nitrogen atmosphere. 
The product was acidified with HCl (30mL) and the organic layer was washed with 
distilled water (2 x 25mL), brine (30mL) and then dried (MgSO4) The solution was 
evaporated in vacuo leaving a pale yellow solid behind (3g, 7.9 mmol). NaH (1.0 eq, 
0.31g) was added along with dry THF (75mL) and the reaction was heated to 66 °C 
for 20 hours. The solution was washed with HCl (30mL) and EtOAc (70mL) was 
added to extract. The organic layer was washed with distilled water (2 x 25mL), brine 
(30mL) and then dried (MgSO4). The solution was evaporated in vacuo leaving a 
pale brown crystalline solid behind (2.6g, 6.9mmol). Conc. H2SO4 (5mL) was added 
along with CH3COOH (50mL) and this was allowed to stir at 118 °C for 15 hours. 
After allowing to cool, the warm solution was poured onto an ice/water slurry 
(300mL) forming a pale yellow crystalline solid (1.2g, 3.3mmol) which was collected 
using vacuum filtration. HBr (35mL) and CH3COOH (20mL) was added and heated 
at 122 °C for 40 hours. The warm solution was poured onto an ice/water slurry 
(300mL) yielding the title compound as a pure yellow crystalline product (49) (0.62 
g, 1.9mmol).  
2-(4-Bromophenyl)-5’,7’-dihydroxy-chromen-4-one (0.62g, 25%) Chromatography 
solvent 1:5 ethyl acetate:petroleum ether. Mp 278-280°C. 1H NMR (300 MHz, DMSO-
d6) δ 12.78 (s, 1H, OH), 10.97 (s, 1H, OH), 8.03 (d, J = 8.5 Hz, 2H, Ar), 7.78 (d, J = 8.5 
Hz, 2H, Ar), 7.04 (s, 1H, Ar), 6.53 (d, J = 2.0 Hz, 1H, Ar), 6.22 (d, J = 2.0 Hz, 1H, Ar). 
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13C NMR (100.6 MHz, DMSO): δC (181.75, C=O), (164.44, Ar-OH), (162.01, Ar-C), 
(161.37, Ar-OH), (157.32, Ar-C), (132.09, Ar-C), (129.89, Ar-C), (128.32, Ar-C), (125.74, 
Ar-Br), (105.47, Ar-C), (103.92, Ar-C), (99.02, Ar-C), (94.11, Ar-C). m/z = 333 [M+] IR 
(neat, cm-1) ν = 3342 (O-H), 1651 (C=O), 1508 (Ar C=C), 1267 (O-H), 1185 (C-O-C). 
632 (C-Br), 
6.11.2 - 2-(3-fluorophenyl)-5’,7’-dihydroxy-chromen-4-one. 
 
The general procedure was followed using 2’-hydroxy-4’,6’-Methoxyacetophenone 
(5) (1.0g, 5mmol) added to 3’-fluorobenzoyl chloride (51) (0.7ml, 5.8mmol) dissolved 
in DCM (50ml), 4-DMAP (0.069g) and TEA (1.1mL) was added and the reaction was 
allowed to stir for 24 hours under a nitrogen atmosphere until presumed to be 
complete by TLC. The product was washed with HCl (25mL). The organic layer was 
washed with distilled water (2 x 25mL), brine (30mL) and then dried (MgSO4). The 
solution was evaporated in vacuo leaving a white crystalline solid behind (1.57g, 
4.9mmol). NaH (1.0 eq, 0.21g) was added along with dry THF (50mL) and the 
reaction was heated to 66 °C for 20 hours. The solution was acidified with HCl 
(45mL) and EtOAc (70mL) was added. The organic layer was washed with distilled 
water (2 x 25mL), brine (30mL) and then dried (MgSO4). The solution was 
evaporated in vacuo leaving a pale brown crystalline solid behind (1.2g, 3.7mmol). 
Conc. H2SO4 (5mL) was added along with CH3COOH (50mL) and this was allowed 
to stir at 118 °C for 20 hours. The warm solution was poured onto an ice/water slurry 
(350mL) forming a crude yellow crystalline solid (1.0g, 3mmol) which was collected 
using vacuum filtration. This was recrystallized from ethanol yielding a white 
crystalline solid (0.6g, 2mmol). HBr (25mL) and CH3COOH (25mL) was added and 
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heated at 122 °C for 20 hours. The solution was neutralised with NaOH (2 x 25mL) 
and EtOAc (60mL) was added. The organic layer was washed with distilled water 
(2x30mL), brine (50mL) and then dried (MgSO4). The solution was evaporated in 
vacuo leaving a pale brown crystalline solid behind as pure product (52) (0.31g, 
1.1mM). 
2-(3-fluorophenyl)-5’,7’-dihydroxy-chromen-4-one (0.31g, 22%) Mp 269-271°C. 
1H NMR (300 MHz, DMSO-d6) δ 12.76 (s, 1H, OH), 10.98 (s, 1H, OH), 8.02 – 7.91 (m, 
2H, Ar-H), 7.63 (dt, J = 8.5, 6.0 Hz, 1H, Ar-H), 7.47 (td, J = 8.0 Hz, 2.5 Hz , 1H, Ar-H), 
7.08 (s, 1H, Ar-H), 6.56 (d, J = 2.0 Hz, 1H, Ar-H), 6.23 (d, J = 2.0 Hz, 1H, Ar-H). 13C 
NMR (100.6 MHz, DMSO): δC (181.78, C=O), (164.49, Ar-OH), (161.54, Ar-C), (161.33, 
Ar-OH), (157.32, Ar-F), (132.24, Ar-C), (122.50, Ar-C), (118.62, Ar-C), (118.01, Ar-C), 
(113.37, Ar-C), (113.13, Ar-C), (105.91, Ar-C), (103.96, Ar-C), (99.03, Ar-C), (94.18, Ar-
C). m/z = 273 [M+]. IR (neat, cm-1) ν = 3144 (O-H), 1652 (C=O), 1507 (Ar C=C), 1250 
(C-F), 1286 (O-H), 1180 (C-O-C). 
6.11.3 - 2-(3-chloro-4-fluoro-phenyl)-5,7-dihydroxy-chromen-4-one. 
 
3-Chloro-4-fluorobenzoic acid (53) (1.2g 5.5mmol) was added to oxalyl chloride (54) 
(0.51mL, 6.1mmol) in 60mL DCM followed by 2 drops of DMF. This was allowed to 
react for 1 hour and was isolated in vacuo to yield a viscous yellow oil (55).The 
general procedure (Scheme 6.1) could then be followed using 2’-hydroxy-4’,6’-
methoxyacetophenone (5) (1g, 5mM) which was added to 3’-chloro-4’-fluorobenzoyl 
chloride (55) (1.3g, 5.5mM) dissolved in DCM (55ml), 4-DMAP (0.065g) was added 
and the reaction flask was purged under nitrogen for 10 minutes. TEA (1.1mL) was 
added and the reaction was allowed to react for 20 hours and the progress of the 
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reaction was monitored by TLC, the presence of starting material was still present 
and therefore flash column chromatography was used to obtain product as pale 
yellow crystals (1.03g, 3mmol). NaH (1.0 eq, 0.12g) was added along with 
anhydrous THF (65mL) and the reaction was heated to 66 °C for 20 hours. The 
solution was acidified with HCl (200mL) and the precipitate formed was collected 
using vacuum filtration leaving an orange solid (0.7g, 2mmol). H2SO4 (5mL) was 
added along with CH3COOH (50mL) and this was allowed to stir at 118 °C for 20 
hours. The warm solution was poured onto an ice/water slurry (400mL) forming a 
brown solid (0.35g, 1mM) which was collected using vacuum filtration. HBr (25mL) 
and CH3COOH (25mL) was added and heated at 122 °C for 20 hours. The warm 
solution was poured onto an ice/water slurry (450mL) yielding the title compound as 
a pure brown crystalline product (56) (0.09g, 0.3mmol). 
2-(3-chloro-4-fluoro-phenyl)-5,7-dihydroxy-chromen-4-one (0.09g, 6%) Mp 268-
270°C. 1H NMR (300 MHz, DMSO-d6) δ 12.74 (s, 1H), 10.99 (s, 1H), 8.35 (dd, J = 7.1, 
2.4, 0.9 Hz, 1H), 8.18 – 8.05 (m, 1H), 7.62 (t, J = 9.0, 1.0 Hz, 1H), 7.07 (s, 1H), 6.56 (d, 
J = 2.1, 1.0 Hz, 1H), 6.21 (d, J = 2.1, 1.0 Hz, 1H). 13C NMR (100.6 MHz, DMSO): δC 
(181.65, C=O), (164.46, Ar-OH), (161.30, Ar-C), (160.62, Ar-OH), (157.82, Ar-F), 
(157.25, Ar-C), (128.73, Ar-C), (127.50, Ar-C), (127.42, Ar-C), (120.76, Ar-Cl), (117.69, 
Ar-C), (105.73, Ar-C), (103.80, Ar-C), (99.02, Ar-C), (94.21, Ar-C). m/z = 305 [M-]. IR 
(neat, cm-1) ν = 3221 (O-H), 1654 (C=O), 1501 (Ar C=C), 1248 (O-H), 1116 (C-O-C), 
840 (C-F), 632 (C-Cl). 
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6.11.4 - Synthesis of 2-(3-bromo-4-fluoro-phenyl)-5,7-dihydroxy-chromen-4-
one. 
 
3-Bromo-4-fluorobenzoic acid (57) (1.2g, 5.5mmol) was added to oxalyl chloride (54) 
(0.55mL, 6.5mmol) in 60mL DCM followed by 2 drops of DMF. This was allowed to 
react for 1 hour and was isolated in vacuo to yield a viscous yellow oil (1.4g, 6mmol) 
(58). The general procedure was then followed using 2-hydroxy-4’,6’-
methoxyacetophenone (5) (1.25g, 5.9mmol) and 3’-chloro-4’-fluorobenzoyl chloride 
(58) (1.4g, 6mmol) and this dissolved in DCM (55ml), 4-DMAP (0.065g) was added 
and the reaction flask was purged under nitrogen for 10 minutes. TEA (1.1mL) was 
added and the reaction was allowed to react for 20 hours and the progress of the 
reaction was monitored by TLC, the presence of starting material (5) was still present 
and therefore flash column chromatography was used to obtain product as pale 
yellow crystals (1.15g 3mmol). NaH (1.0 eq, 0.12g) was added along with dry THF 
(65mL) and the reaction was heated to 66 °C for 20 hours. The solution was acidified 
with HCl (200mL) and the precipitate formed was collected using vacuum filtration, 
leaving a pale brown crystalline solid behind (0.95g, 2.4mmol). H2SO4 (5mL) was 
added along with CH3COOH (50mL) and this was allowed to stir at 118 °C for 20 
hours. The warm solution was poured onto an ice/water slurry (400mL) forming a 
brown solid (0.6g, 2.4x10-4mmol) which was collected using vacuum filtration. HBr 
(25mL) and CH3COOH (25mL) was added and heated at 122 °C for 20 hours. The 
warm solution was poured onto an ice/water slurry (450mL) yielding the title 
compound as a pure brown crystalline product (0.16, 0.5mmol). 
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2-(3-bromo-4-fluoro-phenyl)-5,7-dihydroxy-chromen-4-one (0.16g (8.5%) Mp 
269-271°C. 1H NMR (300 MHz, DMSO-d6) δ 12.71 (s, 1H, O-H), 10.94 (s, 1H, O-H), 
8.37 (dd, J = 7.0, 2.0 Hz, 1H, Ar-H), 8.09 (ddd, J = 8.7, 4.5, 2.0 Hz, 1H, Ar-H), 7.53 (t, J 
= 8.7 Hz, 1H, Ar-H), 7.01 (s, 1H, Ar-H), 6.51 (d, J = 2.0 Hz, 1H, Ar-H), 6.18 (d, J = 2.0 
Hz, 1H, Ar-H). 13C NMR (100.6 MHz, DMSO): δC (181.13, C=O), (164.92, Ar-OH), 
(161.80, Ar-C), (161.05, Ar-OH), (159.41, Ar-F), (157.73, Ar-C), (131.98, Ar-C), (129.27, 
Ar-C), (128.60, Ar-C), (117.82, Ar-C), (109.65, Ar-Br), (106.20, Ar-C), (104.30, Ar-C), 
(99.50, Ar-C), (94.68, Ar-C). m/z = 351 [M+]. IR (neat, cm-1) ν = 3285 (O-H), 1652 (C=O), 
1480 (Ar C=C), 1250 (O-H), 1164 (C-O-C), 840 (C-F), 632 (C-Br). 
6.11.5 - 3-(5-bromo-2-chloro-benzoyl)-2-(5-bromo-2-chloro-phenyl)-5,7-
dihydroxy-chromen-4-one 
 
2’-Chloro-5’-bromobenzoic acid (2g, 8.5mM) was dissolved in DCM (80mL), the 
reaction flask was purged with nitrogen for 10 minutes and then oxalyl chloride 
(0.80mL, 9.3mmol) was added along with 2 drops of DMF. This was allowed to react 
and the progress was monitored by TLC over the period of an hour until completion. 
The product was isolated in vacuo to yield a viscous yellow oil (2g, 7.9mmol). 2’-
Hydroxy-4’,6’-dimethoxyacetophenone (1.5g, 7.6mmol) and 2’-chloro,5-
bromobenzoyl chloride (2g, 7.9mmol) was dissolved in DCM (50mL) along with 4-
DMAP (0.075g) and TEA (1.75mL) was added and the reaction was allowed to 
progress for 20 hours at room temperature until completion, however, a spot 
persisted with an rf value similar to that of 2’-chloro-5’-benzoyl chloride which 
persisted. The organic layer was separated and washed with distilled water 
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(2x25mL) and brine (30mL) and then dried (MgSO4). The remaining solution was 
isolated in vacuo leaving a pale brown crystalline solid behind (2.7g, 6.9mmol). NaH 
(0.28g, 6.9mmol) was added along with anhydrous THF (75mL) and this was heated 
to 66 °C for 23 hours. The reaction was then allowed to cool to room temperature 
and HCl (200mL) was added in 15mL aliquots, and the precipitate that had formed 
was collected through vacuum filtration (0.87g, 2.1mmol). The crude product was 
then dissolved in CH3COOH (60mL) and of H2SO4 (5 drops). This was heated to 
reflux at 118 °C for 6 hours. The flask was taken off heat and allowed to cool before 
being poured over an ice/water slurry (500mL) to yield a cream/brown precipitate 
which was collected through vacuum filtration (0.94g, 2.4mmol). HBr (50mL) was 
added along with CH3COOH (60mL) and this was heated to reflux at 122 °C for 30 
hours. The flask was then allowed to cool and then poured over an ice/water slurry 
(500mL) forming a pale brown precipitate to form, which was collected using vacuum 
filtration (0.51g, 0.9mmol). 
2-(5-bromo-2-chloro-phenyl)-5,7-dihydroxy-chromen-4-one (0.51g, 11.5%) Mp 
273-277°C. 1H NMR (300 MHz, DMSO-d6) δ 12.11 (s, 1H, O-H), 11.24 (s, 1H, O-H), 
7.85 (d, J = 2.5 Hz, 1H, Ar-H), 7.83 (d, J = 2.5 Hz, 1H, Ar-H), 7.73 (dd, J = 8.5, 2.5 Hz, 
1H, Ar-H), 7.68 (dd, J = 8.5, 2.5 Hz, 1H, Ar-H), 7.50 (d, J = 8.7 Hz, 1H, Ar-H), 7.40 (d, J 
= 8.7 Hz, 1H, Ar-H), 6.48 (d, J = 2.0 Hz, 1H, Ar-H), 6.32 (d, J = 2.0 Hz, 1H, Ar-H). 13C 
NMR (100.6 MHz, DMSO): δC (187.63, C=O), (178.52, C=O), (165.38, Ar-OH), (162.95, 
Ar-OH), (161.70, Ar-C), (157.21, Ar-C), (138.80, Ar-C), (135.68, Ar-C), (135.38, Ar-Cl), 
(132.54, Ar-C), (132.30, Ar-C), (132.05, Ar-C), (131.43, Ar-Cl), (130.11, Ar-C), (120.05, 
Ar-Br), (120.00, Ar-Br  ), (119.93, Ar-C), (103.71, Ar-C), (99.97, Ar-C ), (94.62, Ar-C) 
m/z = 584 [M+]. IR (neat, cm-1) ν = 3265 (O-H), 1610 (C=O), 1416 (Ar C=C), 1278 (O-
H), 1161 (C-O-C), 816 (C-F), 761 (C-Br). 
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6.11.6 Synthesis of 5,7-dihydroxy-2-(2-hydroxyphenyl)chromen-4-one 
 
2,4,6-Trimethoxybenzoic acid (1.1g, 5.2mmol), was dissolved in DCM (65mL), the reaction 
flask was purged with nitrogen for 10 minutes and then oxalyl chloride (0.50mL, 5.7 mmol) 
was added along with 2 drops of DMF. This was allowed to react and the progress was 
monitored by TLC over the period of an hour until completion. The product was isolated in 
vacuo to yield a viscous yellow oil (1.4g, 6mmol). 2’-Hydroxyacetophenone (0.66mL, 
5.5mmol) was added and dissolved in DCM (50mL), along with TEA (1.1mL) and 4-DMAP 
(0.070g) and the reaction was allowed to progress for 23 hours at room temperature, the 
presence of multiple spots on the TLC made the identification of the compound difficult and 
therefore the organic layer was extracted, washed with NaOH (2 x 25mL), followed by water 
(2 x 25mL), brine (30mL), this was then isolated in vacuo to yield a viscous yellow oil (1.8g, 
5.4mmol). The flask was purged with nitrogen for ten minutes followed by the addition of 
NaH (0.22g, 5.4mmol) along with anhydrous THF (50mL) and this was heated at 66 °C for 
20 hours. The solution was then acidified with HCl (250mL) to yield a pale yellow crystalline 
solid, which was collected using vacuum filtration (1.12g, 3.4mmol). Flash column 
chromatography was performed to isolate the desired product (0.8g (2.5mmol). H2SO4 (5ml) 
was added along with CH3COOH (60mL) and this was heated to reflux at 118 °C for 6 hours 
until completion, as determined by TLC. The solution was then poured over an ice/’water 
slurry to yield cream like crystals (0.2g 0.64mmol). Hydroiodic acid (5mL) was added along 
with phenol (3.21g) and this was heated to 122 °C for 2 hours. The solution was then poured 
over an ice/water slurry (300mL) to yield pale a pale-cream like crystalline powder (0.02g 
0.07mmol). 
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5,7-dihydroxy-2-(2-hydroxyphenyl)chromen-4-one (0.02g, 1.3%) Mp 260-262°C. 
1H NMR (300 MHz, DMSO-d6) δ 9.48 (m, 3H O-H), 8.04 (dd, 1.5 Hz, 1H, Ar-H), 7.77 
(ddt, J = 15, 7.5, 1.0 Hz, 1H Ar-H), 7.57 (d, J = 8.5 Hz, 1H, Ar-H), 7.53 – 7.43 (t, J = 
15.0, 7.2 Hz, 1H, Ar-H), 6.23 (s, 1H, Ar-H), 5.90 (d, J = 1.0 Hz, 2H, Ar-H). m/z = 271 
[M+]. IR (neat, cm-1) ν = 3102 (O-H), 1604 (C=O), 1458 (Ar C=C), 1266 (O-H), 1137 (C-
O-C), 870 (C-F), 743 (C-Br). 
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Chapter 7 – Conclusion 
Type II diabetes (T2D) mellitus is the most common form of diabetes and is seen in 
90-95% of those diagnosed. Current methods for treatment of T2D are inefficient, 
and lifestyle changes are often the first approach taken to manage the disease as 
serious improvements in health can be achieved. Regular physical activity helps the 
body cells take up glucose for metabolism and this in turn lowers hyperglycaemia. 
[18] There are currently many oral hypoglycaemic drugs used to control the disease; 
biguanides, such as metformin, sulphonylureas, such as chlorpropamide and 
Meglitinide. However, there are substantial side-effects associated with the current 
drugs including a risk of hypoglycaemia. Accordingly, there is a swift need for a new, 
effective treatment that has little to no side effect for those suffering from T2D. 
Inhibition of both the catalytic site and the caffeine binding site of glycogen 
phosphorylase are seen as an extremely attractive target for an effective treatment 
for T2D as this enzyme is responsible for the first step of the glycogenolysis pathway. 
Computational methods such as docking and post docking calculations were 
exploited in this project on a group of β-D-glucopyranosyl derivatives with different 
heterocyclic linkers which have potential to bind at the catalytic site of GP. Exploiting 
known co-crystallised complexes from the PDB database, two protein structures for 
calculations were generated whose orientations belong to the two different 
orientation/geometries that were observed in residues Asn282, Asp283, Asn284 and 
Phe285, additionally, three different solvation models were explored. Two of these 
solvation models belonged to the solved crystal structures of the two different 
orientation observed and another was generated which took into account all solved 
crystal structures irrespective of residue orientation. Computational simulations 
have yielded a number of ligands predicted to have low micromolar inhibition of GP 
(potentially nanomolar) and can now be taken forward for kinetic experiments. We, 
for the first time, have derived computational models of MMGBSA for the GPb 
catalytic site which have revealed excellent predictive potential based on a thorough 
statistical analysis. Using these models, correlations between predicted and 
experimental inhibitory potential as high as 0.95 – 0.97 were obtained for a training 
128 | P a g e  
set of ligands. These methods have substantial potential for discovery of new 
effective compounds in the treatment of T2D as thousands of potential ligands could 
in the future be screened. 
The second component of this thesis involved the synthesis of a number of 5’,7-
dihydroxy flavone derivatives with different substituents on the B-ring which was 
achieved using a generalised procedure involving the Baker-Venkataraman 
rearrangement followed by cyclisation and finally a de-protection step to yield the 
desired compound. Five compounds were synthesised with different substituents on 
the B-ring, para-bromo (4’-Br), meta-fluoro, (3’-F), meta-chloro, para-fluoro (3’-Cl,4’-
F), meta bromo, para fluoro (3’-bromo,4’-fluoro) and ortho-hydroxyl (2’-OH). 
However, method limitations were found for a small number of compounds 
containing o-chloro substituents where 3’-benzoylflavones were synthesised. The 
5’,7’-dihydroxy flavones synthesised have undertaken previous computational 
screening and have been predicted to show biological activity against GP. Further 
kinetic experiments of the compounds listed will give insight into the effectiveness 
of 5’,7’-dihydroxyflavones derivatives and which substituent combination is most 
ideal in its ability to inhibit GP.  
While this thesis has demonstrated the potential of efficiently predicting the inhibition 
constants of a group of compounds, many opportunities for extending the scope of 
this thesis remain; the effects of solvation modelling is controversial in computational 
drug design and a more detailed analysis of this using different cut-off points of the 
cluster-waters script would elaborate the effects that including more or less explicit 
water molecules may have on predicted binding energies. Method development of 
synthetic limitations could be explored in order to produce ortho-chloro 5’,7’-
dihydroxyflavone derivatives so that a wider library of compounds could be tested 
with kinetic experiments; adaptations to the current procedure, the use of a different 
synthetic procedure and other parameters could be then explored in an attempt to 
efficiently produce these compounds. This thesis has laid the groundwork for the 
future exploration of these areas. 
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Appendix 
2-(4-bromophenyl)-5,7-dihydroxy-chromen-4-one 
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2-(3-fluorophenyl)-5,7-dihydroxy-chromen-4-one 
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2-(3-chloro-4-fluoro-phenyl)-5,7-dihydroxy-chromen-4-one 
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2-(3-bromo-4-fluoro-phenyl)-5,7-dihydroxy-chromen-4-one. 
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2-(5-bromo-2-chloro-phenyl)-5,7-dihydroxy-chromen-4-one 
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5,7-dihydroxy-2-(2-hydroxyphenyl)chromen-4-one 
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Scripts. 
Protocol for running Prime-MMGBSA using multiple protein conformations generated 
from GOLD docking poses. 
Aim: Docking with GOLD generates… 
Generating Complexes from GOLD. 
gold_utils –write_complexes –conf <conf_filename> -o <output directory> -format 
<output_format> 
 
Splitting of the complex into receptor and ligand pose viewer 
$SCHRODINGER/run pv_convert.py –mode split_pv <filename> 
 
Deleting/Renaming files in a directory. 
rename ‘s/gold_complex_LigandsForGOLD_//’ gold_complex_LigandsForGOLD_* 
To replace text 
(to replace lig for instance)  
$SCHRODINGER\/prime_mmgbsa –prime_opt OPLS_VERSION\/OPLS3 –out_type COMPLEX - WAIT 
Making a command executable 
Chmod u+x    
(to run the command) ./file > file.out 
 
Running Prime 
$SCHRODINGER/prime_mmgbsa –prime_opt OPLS_VERSION/OPLS3 –out_type COMPLEX –WAIT 
<out_pv.mae> 
 
Deleting text from files 
:%s/<name>/ /g 
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Protocol for Generating Solvation of different residue orientations. 
Cluster Waters 
(with 0.5 Å cutoff distance) 
$SCHRODINGER/run cluster_waters.py –c 0.5 <protein1> <protein2> <output_file.pdb> 
(to keep only waters that superimpose across 100% of all proteins)  
grep 1.00100.00 <output_file.pdb> > <name.pdb>  
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